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Despite differences in epidemiology, pathology, and treatment, growing evidence 
suggests a bidirectional relationship between venous thromboembolism (VTE), a collective 
term for pulmonary embolism (PE) and deep vein thrombosis (DVT), and arterial 
cardiovascular diseases (CVD, i.e., myocardial infarction [MI] and ischemic stroke). The aim 
of this thesis was to investigate the impact of atherosclerosis, MI and ischemic stroke on the 
risk of incident VTE. Additionally, we aimed to investigate the effect of prothrombotic 
genotypes and ischemic stroke on the risk of VTE. 
We recruited study participants from the Tromsø Study, a population-based, 
prospective cohort study. In all four papers, we used participants from the fourth, fifth and 
six survey of the Tromsø Study. In paper I, the participants consisted of a subgroup from the 
Tromsø Study with a more extensive examination, including ultrasonography of the carotid 
artery. In paper IV, a subgroup of participants with extended genetic analysis was included. 
We found no association between the formation or progression of asymptomatic 
atherosclerosis and risk of VTE in time-varying analyses. However, MI and ischemic stroke 
were associated with a transient risk of VTE after adjusting for potential confounding factors. 
The study participants with MI had a particularly high risk of developing PE. After both MI 
and stroke, the risk was particularly high for provoked VTE events. The proportion of 
patients immobilized before the VTE event was substantially higher in those with compared 
in those without stroke. We also found a synergistic effect of ischemic stroke and 
prothrombotic genotypes on the risk of VTE. The risk increased gradually with the number of 
risk alleles.  
Our findings imply that incident MI and ischemic stroke are associated with an 
increased transient risk of VTE, and that genetic risk factors are important in the 
development of VTE after stroke. The transient nature of the VTE risk suggests that indirect 
(e.g., hospitalization, immobilization) or direct (e.g. activation of the coagulation system) 





Til tross for klare forskjeller i forekomst, sykdomsmekanisme og behandling, er det 
flere studier som indikerer en sammenheng mellom venøs tromboembolisme (VTE), et 
samlebegrep for lungeemboli (LE) og dyp venetrombose (DVT), og arterielle kardiovaskulære 
sykdommer som hjerteinfarkt og iskemisk hjerneslag. Målet med denne avhandlingen har 
vært å undersøke om aterosklerose, hjerteinfarkt og hjerneslag øker risikoen for VTE i den 
generelle befolkning. I tillegg har vi undersøkt om kombinasjonen av slag og trombotiske 
risikogener ga en samlet økt effekt på risikoen for VTE. 
Studiedeltakerne ble rekruttert fra Tromsøundersøkelsen, en stor prospektiv 
befolkningsbasert kohortestudie. I alle fire artiklene brukte vi deltakere fra den fjerde, femte 
og sjette Tromsøundersøkelsen. I artikkel I besto studiedeltakerne av en undergruppe som 
fikk en utvidet undersøkelse som inkluderte ultralydundersøkelse av halspulsåren. 
Deltakerne inkludert i artikkel IV bestod av en undergruppe som fikk utført genetiske 
analyser. 
Vi fant ingen sammenheng mellom nydannelse eller progresjon av aterosklerose og 
økt risiko for VTE. Derimot fant vi at både hjerteinfarkt og slag økte risikoen for VTE. For 
både hjerteinfarkt- og slagpasienter var risikoen for VTE høyest de første månedene etter 
den opprinnelige hendelsen. Særlig var risikoen for provosert VTE høy hos disse pasientene. 
Pasienter med hjerteinfarkt har særlig høy risiko for å utvikle LE. Slagpasientene hadde en 
høyere grad av immobilisering før VTE-hendelsen enn pasienter uten slag. Vi fant at 
kombinasjonen slag og risikogener ga en høyere risiko for VTE enn de isolerte faktorene. 
Risikoen ble høyere jo flere risikogener pasientene hadde. 
Våre funn tyder på at pasienter som får hjerteinfarkt eller hjerneslag har en større 
risiko for å få VTE, men at denne risikoen er begrenset til den første tiden etter hendelsen. 
Videre har slagpasienter med protrombotiske gener høyere risiko for VTE enn slagpasienter 
uten disse genene. Den forbigående risikoen for VTE tyder på at er indirekte eller direkte 
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Venous thromboembolism (VTE) is a collective term for deep vein thrombosis (DVT) 
and pulmonary embolism (PE). The first recorded description of VTE is found in the ancient 
Indian Ayurveda medical texts from 600-900 BC written by the physician Susruta Samhita (1). 
Samhita described an event of DVT similar as we will describe it today: “…the legs become 
extremely red, hot, soft and swollen … indescribable burning sensation” (2, 3). After this, VTE 
is not described in literature until the 13th century when a French illustrated manuscript 
describes a man with thrombophlebitis (1, 2, 4). The famous German physician and 
pathologist Rudolf Virchow first made the connection between DVT and PE in the late 19th 
century (1, 2, 4). Today, VTE is a common disease with potentially serious short- and long-
term complications, including the development of the post-thrombotic syndrome (PTS) after 
DVT, chronic thromboembolic pulmonary hypertension (CTEPH), and sudden death as a 
consequence of circulatory collapse secondary to PE (5-8). Despite the high disease burden, 
the public awareness of VTE is low, and increased knowledge and awareness about risk 
factors, symptoms and preventive treatment are needed (9).   
 
1.1  Epidemiology - Venous thromboembolism in the general population 
1.1.1 Incidence of venous thromboembolism 
VTE is the third most frequent cardiovascular disease (CVD) after myocardial 
infarction (MI) and stroke (10), with an estimated annual incidence rate from 10.4 to 18.3 
per 10 000 person-years (5, 7, 11-19). The incidence of DVT (4 to 12 per 10 000 person-
years) is higher than the incidence of PE (2.9 to 7.8 per 10 000 person-years) (7, 11, 13-16). 
Although VTE can occur in all ages, the risk of VTE increases with age and is mainly a disease 
of older age (12, 18). In childhood, the incidence is 1 in 100 000, while it rises to nearly 1 in 
100 in individuals over 85 years (20-23). The highest incidence exists in individuals of African-
American origin, followed by individuals of Caucasian origin (11, 12, 14, 15, 19). The variation 
between incidence rates in different studies may depend on population characteristics 
including age distribution, ethnicity, available data sources, case definition and validation 
procedures, and study design.  
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The incidence trend of VTE has been studied in different populations (18, 19, 24-26). 
In the Tromsø Study, a 27% overall age-adjusted increase in VTE incidence was observed in 
the period 1996 to 2012, from 16 per 10 000 person-years in 1996 to 20 per 10 000 in 2011. 
The increase was mainly caused by an increased incidence of PE with and without 
concurrent DVT, from 4.5 per 10 000 person-years in 1996/97 to 11 per 10 000 person-years 
in 2010/11. The incidence of isolated DVT slightly declined from 11 to 9 per 10 000 person-
years (19). Several other studies have reported a similar increase in VTE incidence, also 
predominantly due to an increase of PE (19, 24, 26, 27). In contrast, a study from Western 
France reported a 28% reduction from 1998 to 2013 (25). Notable, this study included both 
first and recurrent VTEs in their incidence calculations and the study was based on two 
cross-sectional measurements, which could make it more vulnerable to random fluctuations 
in the incidence rates (25).  
The observed increase in PE incidence may partly reflect a higher sensitivity of 
diagnostic methods, particularly computed tomography pulmonary angiogram (CTPA) and 
magnetic resonance imaging, detecting smaller emboli of unclear clinical significance. In the 
Tromsø study, the proportion of PE patients examined with CTPA increased from 23.1% in 
1999 to 76% in 2011 (19). Contrary, the incidence of ischemic stroke and MI have 
substantially decreased by 25-50% in the last decades despite the simultaneous 
development of high-sensitive diagnostics tools (28-30). The decrease in stroke and MI 
incidence is mainly attributed to the reduction of cardiovascular risk factors (28-30). Likely, 
improved diagnostic tools may only partly explain the increase in VTE incidence, and 
important risk factors are yet to be discovered. 
 
1.1.2 Recurrent venous thromboembolism 
VTE tends to recur, and patients with an incident VTE have a 50% higher risk of a 
recurrent VTE than individuals in the general population having a first VTE (11, 14, 31-37). 
The risk is highest shortly after the index VTE, despite that most patients receive 
anticoagulant therapy in this period. Nevertheless, the risk of recurrence never falls to 
baseline, and 30-40% of the VTE-patients experience a recurrent event within ten years (7, 
12, 32, 38). In the Tromsø Study (39), the 1-year cumulative recurrence rate (7.2%) was 
found to be lower than two comparable studies from the United States (11-13%) (35, 37). 
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However, in long-term follow up after more than ten years, the cumulative incidence of 
recurrence corresponded well with 28% (39) and 30% (35), in the Tromsø Study and the 
Rochester Epidemiology Project respectively. The lower 1-year cumulative recurrent rate in 
the Tromsø Study, the most recent study, may indicate an improvement of initial short-term 
treatment strategies. However, similar long-term rates may reflex a catch-up phenomenon 
after discontinuing the initial short-term thromboprophylaxis (32, 40, 41).  
Several factors, including male sex, high body mass index (BMI), and neurologic 
disease with leg paresis (19, 35, 42-47) increase the risk of recurrence. The highest 
recurrence rates are observed in patients with persisting provoking factors such as cancer, 
followed by patients with unprovoked VTE. Individuals with an unprovoked VTE have an 
estimated 11% risk of recurrence the first year after discontinuing treatment, while 
recurrence in individuals with persistent provoking factors depends on the presenting risk 
factor (33, 34, 48). Although a substantial risk factor for a first event, hereditary 
thrombophilia increases the risk of recurrence only 1.5-fold (47). Transient provoking risk 
factors (e.g., recent surgery and trauma, pregnancy, oral contraceptive and hormone 
therapy) present at the time of the VTE event, are associated with a lower risk of recurrence 
(16, 33, 35). The lowest recurrence risk is observed in VTE occurring after surgery with a 
0.7% risk per patient-year, while the patients with non-surgical risk factors have a risk of 
recurrence of around 3% per patient-year (49).  
 
1.1.3 Complications of venous thromboembolism  
Impaired thrombus resolution after VTE may result in PTS and CTEPH, both 
associated with high health care expenses and substantial morbidity (8). PTS is the most 
common complication to DVT and develops in 25-50% of the patients. Usually, PTS develops 
within 1-2 years after the thrombotic event (50-52). It typically presents with pain, persistent 
swelling, and heaviness of the affected extremity. Around ten percent develop venous leg 
ulcers, a resource-demanding condition, and PTS is associated with both reduced physical 
functioning and work-related disability (8, 33, 50, 53, 54). Women have a higher risk than 
men, and obese patients have a 50% increased risk of PTS. Other important risk factors for 
PTS include proximal DVT location, recurrent DVTs, and varicose veins. Cancer, surgery, 
plaster casts or inherited thrombophilias do not influence the risk of PTS (8, 50, 53). Elastic 
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compression stockings were earlier recommended to prevent PTS. However, a large 
multicenter randomized controlled trial (RCT) found that routine use of compression 
stockings did not reduce PTS and did significantly increase dermatological complications 
(50). Consequently, the newest American College of Chest Physicians (ACCP) guideline does 
not recommend routine use of graduated compression stocking (55).  
CTEPH is a rare, but serious complication after acute PE (8). Usually, all thrombotic 
material in the pulmonary vascular bed resolve. However, 2-4% of patients develop 
pulmonary vascular disease of the major pulmonary arteries after PE due to incomplete 
resolving in the pulmonary circulation (14, 56). If left untreated, CTEPH will cause increasing 
fibrotic occlusion of the pulmonary artery leading to increased pulmonary vascular 
resistance, progressive pulmonary hypertension and in the end, right ventricular dysfunction 
(14, 56). Although CTEPH is considered to be a chronic complication of VTE, classic 
thromboembolic risk factors are lacking (8). While antithrombin deficiency, protein C 
deficiency, protein S deficiency, factor V Leiden, and prothrombin G20210A mutation 
increase the risk of VTE, CTEPH patients do not commonly carry these thrombotic risk 
factors. Previous splenectomy, infected ventriculo-atrial shunts, indwelling venous catheters 
and leads, thyroid replacement therapy, cancer, and chronic inflammatory states have been 
identified as risk factors for both VTE and CTEPH (8). The low incidence after acute PE makes 
routine screening for CTEPH in asymptomatic patients after VTE unfeasible, resulting in a 
frequent delay of diagnosis (57). CTEPH should be considered in patients with a history of PE 
who develop persistent dyspnea and large persistent perfusion defects (> 15%) on 
ventilation/perfusion scans (8). The treatment of CTEPH is to remove the obstructive 
material from the pulmonary vasculature with pulmonary endarterectomy, relieving 
pulmonary hypertension, and significantly improving the prognosis (8). 
1.1.4 Mortality after venous thromboembolism 
Overall, epidemiological models estimate around 500 000 VTE-related deaths per 
year in Europe (17). In the United Kingdom, the annual number of deaths from VTE is 
fivefold higher than the combined number of deaths from breast cancer, AIDS, and road 
traffic incidents (58). The survival rates after an incident VTE vary, ranging from 77% to 97% 
at one week, and 61-75% at eight to ten years (33, 34, 59, 60). A recent study including 710 
study participants with an incident VTE from 1994 until 2012, reported an all-cause mortality 
15 
 
rate of 9% at 30 days and 24% at one year (39). The mortality rates are almost identical to 
those reported in a previous Norwegian study of 740 VTE patients recruited in the period 
1995-2001 (20). The occurrence of cancer may explain the high one-year mortality, as the 1-
year mortality rate is 60%-80% in patients with cancer-related VTE (20, 39, 61). 
Nevertheless, the overall mortality rates of VTE at 30-days and 1-year are higher than the 
respective 30-days and 1- year mortality rates of MI. For acute coronary syndrome (ACS) in 
total, the 30 days cumulative mortality rate is 2-5%, and the 1-year mortality rate is 9-15% 
(62, 63). For ST-elevation MI (STEMI) alone, the 30 days mortality rate is 2.5-10% (62). 
The survival after VTE varies with the location of the thrombus (20, 39). Almost one-
quarter of PE presents as sudden death (64), and PE is associated with more than a 3-fold 
increase in 30-day mortality compared to isolated DVT (7, 16, 20, 37, 64). However, the 
increased mortality of PE compared to DVT only persists for the first three months (16, 20, 
64, 65). Increasing age, male sex, lower BMI, in-hospital management, congestive heart 
failure, chronic lung disease, severe neurologic disease, and active cancer are all reported to 
be independent predictors of reduced survival after VTE (46, 64, 65). Patients with recurrent 
VTE does not have an increased 3-year mortality more than after an incident VTE (37). 
 
1.2  Pathophysiology of venous thromboembolism 
Hemostasis is the physiological process that stops bleeding after a vascular injury 
while maintaining normal blood flow elsewhere in the circulation. This is achieved by 
complex pro- and antithrombotic mechanisms. The bleeding is ceased by recruitment of 
circulating platelets that both form a temporary blockage by a platelet plug, and release 
chemicals (e.g., adenosine diphosphate, serotonin, von Willebrand factor (vWF), 
thromboxane A2, FV, FXI). The chemicals activate additional platelets and stimulate the 
coagulation system, which culminates in thrombin converting fibrinogen to fibrin to stabilize 
the platelet plug. The coagulation cascade consists of the intrinsic and the extrinsic pathway, 
leading to the adjoined common pathway (66-69). The extrinsic pathway is the primary 
physiological activator of the coagulation cascade and is initiated by formation of the tissue 
factor-FVIIa complex. Tissue factor (TF) is expressed on TF-bearing cells like stromal 
fibroblasts, leukocytes, and microparticles released from activated cells. The formation of 
the TF–FVIIa complex initiates a proteolytic cascade activating the coagulation factor FX to 
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FXa, and culminating in the FXa-FVa prothrombinase complex (66-70). Exposure of 
subendothelial collagen and activation of FXII to FXIIa initiate the intrinsic pathway. FXIIa 
catalyzes a cascade of FXI, FIX and FVIII activation, culminating in the FXa-FVa 
prothrombinase complex. The path from the prothrombinase complex to the thrombin and 
fibrin formation, the coagulation cascade is called the common pathway (66-70). While the 
extrinsic pathway is the primary physiological activator of the coagulation cascade, the 
intrinsic pathway has a minor role in the initiation of hemostasis as illustrated by the lack of 
bleeding disorders in patients and animals with deficiency of FXII (71, 72).  
In addition to fibrin formation, thrombin activates FVa and FVIIIa, regenerating the 
prothrombinase complex. As a consequence, the coagulation cascade self-perpetuates the 
fibrin formation, also after the inhabitation of the TF-FVIIa complex by the TF-pathway 
inhibitor (TFPI) (67). To confine this process, several crucial regulatory mechanisms exist. 
When pathologic processes overwhelm these mechanisms, increased quantities of thrombin 
is formed, initiating the development of pathological thrombi (67, 70). 
A venous thrombus is formed under low shear stress on the surface of a mostly intact 
endothelium (70, 73). This is contrary to arterial thrombosis that arises under high shear 
stress, typically after erosion, ulceration or complete rupture of an atherosclerotic plaque 
with the release of constituents of the plaque into the lumen of the blood vessel (74). An 
undamaged endothelium is vital in maintaining an antithrombotic state by expressing 
various anticoagulants, such as TFPI, thrombomodulin, endothelial protein C receptor, and 
heparin-like proteoglycans (75). A thrombus is classified depending on the relative amount 
of platelets and red blood cells. White thrombi are characterized by a predominance of 
platelets, while red thrombi are predominated of fibrin and trapped red blood cells. 
Thrombosis in the arterial circulation may lead to MI and ischemic stroke, and consists of 
white thrombi, while DVT and PE occur in the venous circulation system and consist of red 
thrombi (69, 70).  
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Simplified, VTE occurs as a result of one or more of the following three factors; 1) 
hypercoagulability, 2) altering of the blood flow (stasis), or 3) endothelial dysfunction or 
damage of the vessel wall (76). This 
pathophysiological basis for VTE is known as 
Virchow’s triad (figure 1), named after the 
famous pathologist and physician Rudolf 
Virchow, who proposed the triad in a lecture 
in 1855 (77). In VTE, hypercoagulability and 
increased stasis of the blood allow 
accumulation of procoagulant proteases, such 
as thrombin (66, 69, 70), while the direct 
damage of the vessel wall is less central. This 
is supported by a histological study with no evidence of endothelial damage in the majority 
of venous thrombi recovered from autopsies (78). However, endothelial damage in the 
understanding of dysfunction of the endothelium is probably as central as stasis and 
hypercoagulability in the initiation of thrombus formation (66). 
Most DVTs form in the valve pockets and soleal sinuses of the deep veins in the 
calves, as demonstrated by radiological and post-mortem studies (figure 2) (70, 76, 78-80). A 
declining oxygen gradient from the top to the bottom of the valve pocket after two hours of 
stasis has been demonstrated in dogs (81), indicating that hypoxia is a significant 
complication of stasis. Hypoxia promotes a subtle form of endothelial injury leading to 
alterations of protein expression and activation of the endothelium (82). Under this 
pathological condition, the endothelium is converted from an anticoagulant to a 
procoagulant surface (66, 82). An important mediator in the coagulation process is the 
relocation of P-selectin from an internal cell location to the surface of the activated 
endothelial cell. By P-selectin, the endothelial cells capture platelets, leukocytes, and 
leukocyte-derived TF-containing microvesicles (83). The leukocytes adhered to the 
endothelial surface become activated and express more TF. The local activation of the 
coagulation cascade overwhelms the protective anticoagulant pathways and triggers 
thrombosis (66, 70, 82). Additionally, recruited leukocytes release neutrophil extracellular 
traps (NETs), which is suggested to play a key role in inflammatory-mediated thrombosis 
Figure 1. Virchow's triad 
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(84). However, the underlying mechanisms between microvesicles, NETs, and VTE remain to 
be established.  
A direct correlation between DVT frequency and the number of valves exists (85). The 
location of the thrombi initiation have been attributed to hypoxic endothelial dysfunction 
and increased stasis followed by accumulation of coagulation factors, activation of 
endothelial cells, platelets and leukocytes (86). Usually, the skeletal muscle pump prevents 
DVT by moving blood past the venous valves and thereby inhibiting a high concentration of 
clotting factors in the valves pockets. Several mechanisms may overwhelm this system, 
including reduced mobility (e.g., bed-rest, neurological deficits or long-haul travel), 
hyperviscosity (e.g., polycythemia vera), congestive heart failure, and mechanic obstruction 
of the vessels (e.g., in pregnancy) (80, 87).  
Hypercoagulability 
is an abnormally increased 
tendency toward clotting 
and could be inherited or 
acquired. In vitro studies 
show that plasma 
hypercoagulability leads to 
increased thrombin 
generation (88), which 
increases the risk of VTE 
(89). Inherited 
hypercoagulability is caused 
by prothrombotic 
genotypes increasing the 
activity or quantity of proteins promoting coagulation (i.e., Factor V Leiden and prothrombin 
G20210A) or genotypes decreasing the quantity of proteins that inhibit coagulation (i.e., 
Protein C and Protein S) (69, 90). Major surgery, cancer, obesity, chronic inflammation, 
antiphospholipid syndrome, and use of oral contraception may all cause acquired 
hypercoagulability (91, 92). These conditions increase the amount of circulating TF and other 
procoagulant proteases leading to hypercoagulability. 
Figure 2. The venous valvular sinus as a predilection site for DVT initiation. Blood is 
trapped in a vortex of the valve pockets, and the resultant hypoxia activates the 
venous endothelium, leading to the recruitment and binding of leukocytes, especially 
monocytes (Mc), platelets (Plt) and TF-positive microparticles (MP). Consequently, TF 
from activated monocytes and microparticles may activate the coagulation cascade 
and initiate thrombosis formation. 
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PE has been considered as a complication of DVT that occurs if a part of the 
thrombus break away, travels to the lungs, and lodges in a pulmonary artery (69). However, 
studies demonstrate that the origin of the emboli remains undetected in half of the patients 
with PE (93-96). This could be due to a dislodging of the entire thrombus formation in the 
deep veins. However, recent studies support the concept that PE may arise from other sites 
in addition to the deep veins. Possible locations for thrombus formation include the right 
atrium and de novo formation in the pulmonary circulation (93, 97). Echocardiography and 
autopsy studies have displayed clots in the right atrium of patients with atrial fibrillation (AF) 
(98, 99). It is hypothesized that AF can cause right-sided cardiac thrombus formation, which 
could subsequently embolize, thereby leading to PE in a similar manner to systemic 
embolization leading to stroke (100). Supporting this hypothesis, patients diagnosed with 
atrial fibrillation are at a transient 6- to 10-fold increased risk of PE (97, 101). Additionally, 
20% of patients with PE have a known history of AF (97, 102).  
 
1.3 Risk factors for incident venous thromboembolism 
VTE is a complex, 
multifactorial disease, 
involving interactions 
between acquired or 
inherited predispositions to 
thrombosis and 
environmental exposures 
(90). The risk of VTE change 
with age and genetic and 
acquired risk factors 
interact dynamically. To 
explain why thrombosis 
occurs in one person at a 
specific time, Rosendaal described the thrombosis potential model in 1999 (90). The model 
demonstrates how the combination of risk factors are necessary to yield a thrombosis 
Figure 3. The thrombosis potential model. The blue line represents intrinsic 
factors that are stable over time such as inherited risk factors (e.g. Factor V 
Leiden [FVL]), and the green line represents the effect of a risk factor that 
increases over time, like age 
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potential (figure 3). When sufficient risk factors have accumulated, the thrombosis potential 
exceeds the ‘thrombosis threshold,’ and a thrombotic event occurs (47, 90).  
Some risk factors for VTE are modifiable, while others, like advancing age and 
inherited thrombophilia, are not. Further, it is important to discriminate between transient 
and persistent risk factors, as this influence the risk of recurrence, and, thus, decisions on 
treatment duration (55). Risk factors are classified as transient if they occur up to 3 months 
before a VTE event and are not persistent (87). Examples of transient risk factors are 
surgery, pregnancy, and hospitalization, while non-modifiable risk factors as age, 
prothrombotic genotypes, and untreatable cancer are important persistent risk factors (15, 
16, 87). Persistent risk factors are considered as clinical risk factors increasing the baseline 
risk of VTE. However, additionally to persistent risk factors, transient factors are often 
necessary to trigger a VTE event (87). VTE events are classified as unprovoked or provoked 
depending on the presence of provoking factors. An event is classified as unprovoked if they 
do not meet the criteria for provoked VTE-events (87). The amount of VTE events without 
provoking factors at the time of diagnosis ranges from 25 to 40% (14, 16, 103). 
The degree to which risk factors are associated with thrombosis varies from very 
weak to very strong (87). The Scientific and Standardization Committee (SSC) of the 
International Society of Thrombosis and Haemostasis (ISTH) recently stated two 
circumstances for when a transient risk factor should be considered major (87). First, more 
than half of the risk of recurrent VTE after ceasing anticoagulant therapy should be 
attributable to the risk factor. Secondly, the risk factor should be responsible for a 10-fold 
increase in the risk of a first VTE event (87). Transient risk factors are classified as minor (yet 
important) if it is associated with half the risk of recurrent VTE after stopping anticoagulant 
therapy (compared with if there was no transient risk factor), when the risk factor occurred 
up to 2 months before the VTE, or a 3 to 10-fold increase in the risk of having a first VTE (87). 
Major surgery is regarded as a major transient risk factor, whereas hospital admission for <3 
days with an acute medical illness, estrogen therapy, pregnancy/puerperium and leg injury 
associated with immobility for >3 days are examples of minor transient risk factors (87). A 
recent, prospective cohort study of 646 patients with incident VTE found no difference in the 
recurrence rate in patients with or without exposures to risk factors more than three 
months before the incident VTE (104). Consequently, patients with a remote VTE risk factor 
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should not be managed differently from patients with unprovoked VTE. In the following 
sections, acquired and genetic risk factors will be elaborated. 
1.3.1 Acquired risk factors 
The incidence of VTE increases with age. In childhood, the incidence is 1 in 100 000, 
while it rises to nearly 1 in 100 in individuals over 85 years (20-23). The observed increased 
risk could be attributed to age-specific risk factors of thrombosis (i.e., endothelial 
dysfunction, frailty, and reduced muscle strength in the calves) or conventional risk factors 
that are more prevalent in the elderly than in young and middle-aged, including increased 
immobilization, malignant disease, and presence of co-morbidities associated with VTE risk 
(23). Nevertheless, a cohort study using data from the Tromsø Study showed that the 
increased incidence of VTE in elderly is not caused by the higher incidence of cancer in the 
same age group (105). Genetic risk factors are associated with increased risk of thrombosis 
in the elderly, although a lower relative risk is reported compared with the younger 
population (23). 
Overweight is an important risk factor for VTE and BMI is a stronger predictor for VTE 
than for MI (10, 106). Results from previous prospective cohorts have consistently shown a 
2- to 3-fold increase in the risk of VTE in obese individuals (13, 107, 108). Heit and colleges 
found that obesity accounted for about one-third of the unprovoked VTE events (18). In 
addition to BMI, total body fat (108), waist and hip circumference (106, 108-110), and the 
waist-to-height ratio (106) independently increase the risk of VTE. Of these, increased waist 
circumference is the preferable anthropometric measure of obesity to identify individuals at 
risk and to predict the risk of future VTE (106, 109). Additionally, weight gain, independent 
of attained BMI, is a risk factor for VTE (111). The mechanisms behind the strong association 
between obesity and risk of VTE are not fully understood, but recent Mendelian 
randomization studies imply that there may exist a causal relationship between high BMI 
and risk of VTE (112, 113). Chronic low-grade inflammation (114) and increased levels of 
procoagulant and hypofibrinolytic agents such as FVIII, fibrinogen, and PAI-1 may further 
affect the association (115). However, studies assessing the role of chronic low-grade 
inflammation in VTE are not consistent (116-118). Another possible mechanism is obesity-
induced stasis caused by increased intra-abdominal pressure (119, 120). 
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Immobilization, whether in-hospital or in the community, increases the risk of VTE. 
Presumably, stasis of blood flow in the venous circulation is an important reason for the risk 
increase (15). In a meta-analysis including 43 observational studies of medical patients, a 
pooled odds ratio (OR) of more than two was reported for immobilized patients compared 
with non-immobilized patients (121). The most common definition of immobilization in the 
43 studies was confinement to bed or bed rest lasting more than three days. In the meta-
analysis, the risk of VTE was not adjusted for age. In a different study, bed rest up to 14 days 
was associated with an almost 6-fold risk increase of VTE in patients above 65 years (122). 
The risk of VTE is at its highest during the first weeks of bed-rest, but also long-term 
immobilization, which is most common in the elderly, increases the risk of VTE (23, 123). 
Even in healthy individuals, immobilization caused by for example injuries in the lower 
extremity treated with leg-cast or long-haul travels, may cause venous stasis and increase 
the risk of VTE (124, 125).  
The VTE incidence is five times higher in pregnant women compared with non-
pregnant women of similar age, and 20 times higher in the postpartum period. The risk 
peaks during the first six weeks postpartum and declines to rates approximating that of the 
general population by about 13 to 18 weeks (126, 127). The increased risk is mainly a result 
of hypercoagulability induced by hormonal changes present as early as the first trimester 
(128), increased venous stasis due to increased intra-abdominal pressure, and compression 
of the vena cava by the enlarging uterus (129).  
About 9% of women of reproductive age worldwide use oral contraceptives. In 
Norway, as many as 70-80% of reproductive women use oral contraceptives, the highest 
contraceptives prevalence in the world (130). Combined oral contraceptives increase the risk 
of VTE 3.5-fold, and the effect size depends both on the progestogen used and the dose of 
ethinylestradiol (synthetic estrogen derivate) (131). Oral contraceptives containing 
levonorgestrel and those that contain a low-dose estrogen are associated with lower risk 
than preparations containing other types of progestogens and greater estrogen dose (131).  
Patients in the hospital usually have several risk factors for VTE, and 40% to 60% of all 
cases of VTE are associated with hospitalization (132-135). The estimated incidence of VTE is 
1 to 3 cases per 100 admissions per year (136, 137). Accordingly, the age- and sex-adjusted 
incidence of VTE is more than 130 times greater among hospitalized patients than among 
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community residents (135). Up to 20% of patients admitted to medical service, and 40% of 
the patients admitted to a surgical department will develop VTE (15). At discharge from the 
hospital, 31% of patients are at risk of VTE (138). Furthermore, almost 10% of all deaths in 
hospital are related to PE, a diagnosis often not suspected before death (139).  
According to the Epidemiologic International Day for the Evaluation of Patients at 
Risk for Venous Thromboembolism in the Acute Hospital Care Setting (ENDORSE) study, less 
than 40% of at-risk hospitalized medical patients received the ACCP-recommended 
prophylaxis (140). Medical patients at-risk were less likely than surgical patients to receive 
appropriate prophylaxis (140). A recent study from the US showed an increase in the 
proportion of hospitalized patients receiving adequate VTE prophylaxis from 40% in 2005 to 
90% in 2010 (134). However, the annual age- and sex-adjusted hospitalization-related VTE 
attack rate did not change significantly during the 5-year study period. In the study, the 
median duration of hospitalization and in-hospital prophylaxes were three days and 70 
hours, respectively. Most VTE events (75%) occurred after hospital discharge, with an almost 
20-day median time to VTE (134). Despite these findings, the latest ACCP guidelines on 
prevention of VTE in nonsurgical patients from 2012, recommend not to extend the duration 
of thromboprophylaxis beyond the period of patient immobilization or acute hospital stay, 
mainly due to the risk of major bleeding (141). This was supported by the Extended 
Prophylaxis for Venous Thromboembolism in Acutely Ill Medical Patients With Prolonged 
Immobilization (EXCLAIM) study, were over 6000 hospitalized patients over 40 years were 
randomized to receive extended-duration enoxaparin for 38 days or placebo. The risk of 
major bleeding was significantly increased with extended-duration enoxaparin, and there 
were four intracranial bleeding events in the extended enoxaparin group compared with 
none in the placebo group (142).  
Three large trials comparing standard-duration (7-10 days) and extended-duration 
(25-35 days) thromboprophylaxis in acutely ill medical patients, showed that extended-
prophylaxis with enoxaparin (142) and rivaroxaban (143), reduced the risk of VTE compared 
with standard-duration of enoxaparin, while an extended-prophylaxis with apixaban was not 
superior to a shorter course of enoxaparin (144). Recently, the Food and Drug 
Administration of the United States of America approved the direct oral anticoagulation 
(DOAC) betrixaban as the first DOAC for the prevention of VTE in acutely ill medical patients. 
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The approval of betrixaban was a result of the large APEX trial consisting of more than 7500 
patients (145). In the trial, patients were randomized to either extended-duration treatment 
with betrixaban (35-42 days) or standard-duration treatment with enoxaparin (10±4 days). 
Betrixaban was superior in preventing VTE (symptomatic and asymptomatic) and major 
bleeding in the overall population (145, 146). These findings indicate that post-discharge 
prophylaxis may be more important than previously considered and that additional effort is 
needed to identify patients at high risk of VTE who will benefit from extended-duration 
prophylaxis. The recently published MARINER trial assessed post-discharge extended VTE 
prophylaxis with rivaroxaban in selected high-risk medical patients investigating the rate of 
symptomatic VTE (147). However, the trial failed to meet its primary endpoint to reduce the 
risk of a composite of symptomatic VTE or VTE-related death. Because the trial failed to 
meet its primary endpoint, any looks at secondary endpoints should be considered 
exploratory. Nonetheless, the authors observed lower rates of symptomatic nonfatal VTE 
and a composite of symptomatic VTE or all-cause death in the rivaroxaban arm (147). After 
the Mariner trial, the usefulness of extended thromboprophylaxis remains uncertain. The 
authors of the study, states that future studies should more accurately identify deaths 
caused by thrombotic mechanisms and focus on the patients who are at highest risk and 
who may benefit from anticoagulant prophylaxis (147). 
There are numerous risk factors for VTE in surgical patients (e.g., type and extent of 
surgery or trauma, duration of hospital stay, and surgical complications), and up to 40% of 
the patients admitted to a surgical department will develop an asymptomatic VTE (15, 148). 
The incidence of fatal PE without proper thromboprophylaxis is around 0.1-0.8% in patients 
undergoing elective general surgery, 2-3% in patients having an elective total hip 
replacement, and 4-7% of patients undergoing surgery for a fractured hip (149). In the 
Million Women Study, 1 in 140 women undergoing inpatient surgery and 1 in 815 women 
undergoing outpatient surgery were admitted with VTE during the first 12-week after 
surgery compared to only 1 in 6200 women not undergoing surgery (150). 
Patients with medical illness often have multiple comorbidities, and the VTE risk 
factors are diverse and probably less commonly identified than risk factors among surgical 
patients. PE has been recorded as the cause of death in over 5% of patients with medical 
illness using postmortem reports (151). Of patients with fatal PE, 80% occurred in patients 
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who had not received recent surgery. In more than 50% of the cases, an acute medical 
illness was reported within the last six weeks before death (151). Several medical conditions 
are associated with increased risk of VTE including cancer, infectious disease, renal 
impairment, acute respiratory disease (including exacerbation of chronic obstructive 
pulmonary disease [COPD]), heart failure, and arterial CVD. In addition, all patients admitted 
to intensive care units are at increased risk of VTE, even after routine anticoagulation (152).  
Cancer is strongly associated with VTE (153). Already in 1861, the French physician 
Armand Trousseau described how thrombosis could predict occult cancer (154). A 
hypercoagulable state probably mediates the risk of VTE in cancer patients. The 
hypercoagulability is caused by the release of inflammatory cytokines and activation of the 
coagulation cascade (155). The high risk of VTE in cancer patients is visible as 20-25% of all 
VTE cases occur in cancer patients. Additionally, around 20% of all cancer patients develop 
VTE during the course of the disease (155, 156). Overall, cancer is associated with a 4-7-fold 
increased risk of VTE (156, 157). The risk of VTE is highest during the first year after the 
cancer diagnosis (153) and is dependent on tumor type, age, stage of cancer and cancer-
treatment (158).  
Several different infectious diseases are associated with an increased risk of VTE 
(159-161). Virus infections with human immunodeficiency virus and cytomegalovirus 
increase the risk of VTE with 30% and 70%, respectively (161). Bacterial pneumonia and 
urinary tract infections increase the risk of VTE considerably, with a higher risk of PE than 
DVT (160, 162-164). 
Patients with end-stage renal disease have a higher incidence of VTE compared with 
the general population (165, 166). Stage 3 to 4 chronic renal disease is associated with an 
almost 2-fold risk of VTE compared with patients with normal renal function (165). Patients 
in dialysis are further predisposed to VTE (167). Respiratory failure and exacerbation of 
COPD are recognized as risk factors for VTE (168). Both temporary immobilization and 
localized hypoxia may increase the release of procoagulant factors and predispose for VTE 
during exacerbations. However, also patients without exacerbation with severe COPD have 
an increased risk of VTE compared with the general population, mainly caused by increased 
incidence of provoked VTE. Thus, immobilization and infections possibly increase the risk of 
VTE in patients with stable, severe COPD (169).  
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Heart failure increases the risk of DVT and PE 1.2- and 2-fold respectively (170). All 
three factors of Virchow’s triad could explain the association between heart failure and VTE 
(171). First, reduced myocardial contractility, dilated cardiac chambers, and low cardiac 
output could all cause abnormal blood flow and stasis in the venous system. Second, heart 
failure increases the activity of the hemostatic system and platelets, inducing a 
hypercoagulable state. Third, heart failure stretches and injure the vessel wall creating 
endothelial dysfunction. The risk of VTE is highest in patients with right heart failure, 
indicating that increased stasis is of high importance in the pathogenesis (171).  
 
1.3.2 Genetic risk factors 
VTE is a highly heritable disease, and 50 to 70% of the variance in VTE incidence could 
be attributed to genetic risk factors (172-177). Hereditary thrombophilia follows a 
multifactorial, non-Mendelian inheritance model, where multiple genetic risk factors 
contribute to the increased risk (178, 179). Overall, the incidence of a first time VTE is 0.8% 
per year in carriers of a prothrombotic defect compared with 0.1% per year in non-carriers 
(174). However, there are considerable differences in the risk of VTE among individuals with 
different types of hereditary thrombophilia (174). To date, 20 to 30 genetic VTE risk factors 
have been identified (178, 180).  
The genetic risk factors could be categorized as loss-of-function mutations and gain-
of-function mutations (181). In gain-of-functions mutations, there is a gain of function of 
procoagulant factors, while there is a loss of function of endogenous anticoagulation in loss-
of-function mutations. Gain-of-function mutations can result in the increased synthesis of a 
normal protein (i.e., prothrombin G20210A), impaired breakdown or down-regulation of a 
normal protein (i.e., Factor V Leiden), or rarely, synthesis of a functionally hyperactive 
protein (i.e., factor IX Padua). Loss-of-function mutations are in general rarer than gain-of-
function mutations and tend to be associated with higher risk estimates for VTE.   
 
Loss-of-function mutations 
Inherited risk of VTE was first recognized by the Norwegian hematologist Olav 
Egeberg when he discovered a family with an increased risk of VTE due to antithrombin 
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deficiency (182). Antithrombin is a potent inhibitor of the coagulation cascade and 
mutations in the SERPINC1 cause antithrombin deficiency. Antithrombin deficiency is rare in 
the general population (0.02%) and is associated with a 10- to 50-fold increase in the risk of 
VTE (183, 184).  
Heterozygous deficiencies of protein C and protein S are other causes of loss-of-
function mutations increasing the risk of VTE (185, 186). Protein C is a natural plasma 
anticoagulant that, when activated, inactivates FVa and FVIIIa to down-regulate the 
thrombin generation. Protein S assist in the downregulation of thrombin formation by 
serving as a co-factor of both activated Protein C and TFPI (184, 187). Both deficiencies of 
protein C and protein S increase the risk of VTE by approximately 8-fold (184, 188, 189). 
However, deficiencies of protein C and protein S are rare, occurring in less than 1% of the 
general population (178, 184, 190). 
 
Gain-of-function mutation 
The most frequent prothrombotic genotype variant is non-O blood type, which is 
present in 60 to 70% of the population (191). Individuals with B and A1 blood groups are at a 
1.5 to 2.0-fold higher risk of VTE compared with individuals with O and A2 blood groups, 
respectively (184, 191-194). The association could be caused by levels of FVIII and vWF in 
blood as individuals with O blood type have 25% lower levels of these factors than 
individuals with non-O blood (195). However, non-O blood type has been found to increase 
the risk of VTE independent of levels of FVIII (184, 195). Due to the high frequency of non-O 
blood type in the general population, over 30% of the VTE events could be partly explained 
by the presence of non-O blood type despite the modest relative risk increase (192). 
Additionally, non-O blood type has an additive effect on the risk of VTE combined with both 
factor V Leiden and the prothrombin mutation (193). 
Activated protein C (APC) resistance was discovered in 1993 (196). One year later, 
Bertina et al. from the Leiden University Medical Center in the Netherlands, published a 
paper in Nature describing the Factor V Leiden (FVL) mutation, also known as rs6025. FVL 
causes the majority of the cases with APC resistance. The condition is caused by a single 
point mutation in the factor V gene, which predicts substitution of arginine at position 506 
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with glutamine (197). This substitution interferes with the normal APC cleavage site of factor 
V. In addition to APC-resistance, FVL is thought to be prothrombotic by the abnormal 
breakdown of FVIII by APC (198). In the Caucasian general population, FVL is found in 3 to 
8%, while in Asian, African and indigenous Australian populations, the mutation is extremely 
rare (178, 198). Heterozygous carriers have a 2- to 5-fold increase in the risk of VTE 
compared with the general population, while homozygous carriers are under a 10- to 80-fold 
risk (178, 183, 184, 197-202).  
In 1996, a mutation of the prothrombin gene, prothrombin 20210A (rs1799963), was 
discovered (203). The mutation causes an overproduction of prothrombin increasing the risk 
of VTE, and is present in 1-2% of the population (178, 181, 184). Carriers of the prothrombin 
20210A allele have a 2- to 3-fold increased risk of VTE (183, 184, 203, 204). Factor V Leiden 
and the prothrombin 20210A mutations are relatively common and their coinheritance with 
other thrombophilias increase the risk of VTE (183, 193). The Fibrinogen gamma chain (FGG) 
gene encodes the fibrinogen γ chain, which is one of the three polypeptides composing the 
fibrinogen molecule. Fibrinogen γ is important for the antithrombin activity that develops 
during fibrin formation. The allele of the rs2066865 polymorphism, with frequency around 
0.25, was found to reduce fibrinogen γ plasma levels and to increase the risk of VTE around 
1.5-fold (205, 206). 
The last decade new genotypes related to increased risk of VTE have been discovered 
through genome-wide association studies (GWAS). This method searches the genome for 
small variations called single nucleotide polymorphisms (SNPs) that occur more frequently in 
people with a particular disease than in people without the disease. GWAS may identify 
SNPs associated with VTE without a prespecified hypothesis, opposite to previous 
investigations of clustering of VTEs in families (182) and the candidate-gene approaches of 
genes coding molecules of the coagulation/fibrinolysis pathways (180) used to identify the 
previously mentioned risk variants. Using GWAS, tests of large samples of VTE patients may 
discover unknown SNPs more frequently present in VTE patients than controls (207). High 
plasma levels of Factor XI (FXI) are associated with elevated risk of VTE (180, 184, 208), and 
several SNPs at the FXI locus are found to be associated with a 1.3-fold increase in the risk of 
VTE through modulation of FXI plasma levels (190, 202, 209, 210). Recently, more SNPs 
associated with VTE have been identified. However, the majority of SNPs identified through 
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GWAS have a modest effect on VTE risk with ORs ranging from 1.10 to 1.35, and single SNPs 
may only have limited clinical utility in prediction and diagnostics of VTE (184). 
In the future, new and more extensive studies are warranted to identify 
undiscovered genetic variants associated with VTE (211). To identify new genetic variants, 
the INVENT consortium has been created to combine several genetic studies worldwide to 
increase the sample size. One large meta-analysis from the INVENT consortium has already 
identified nine new genetic variables increasing the risk of VTE. Of these, two of the new loci 
identified, TSPAN15 and SLC44A2, do not belong to conventional pathways for thrombosis or 
have previously been associated with CVD (211). These findings suggest that unexpected 
actors of VTE etiology exists, and a meta-analysis of exome-wide association studies by the 
INVENT consortium are currently ongoing to discover new, rare genetic variants associated 
with VTE (178). 
 
1.3.3 Cardiovascular risk factors, atherosclerosis, and venous thromboembolism 
Atherosclerosis is a condition in which the lumen of an artery narrows as a result of a 
localized buildup of inflammatory cells, cholesterol and other lipids, connective tissue, and 
calcium deposits in the tunica intima zone of the arterial vessel wall (212). The development 
of atherosclerosis begins with injury to the endothelial cells lining the surface of the interior 
vessel wall (212, 213). Endothelial dysfunction is a consequence of many interfering factors, 
including hypertension, hemodynamics, hyperlipidemia, oxidative stress, and inflammation. 
None of them are compulsory for disease development, but all increase the risk of 
endothelial dysfunction. The endothelial injury eventually causes chronic endothelial 
dysfunction, and in turn, increased permeability through the junctions between the 
endothelial cells. As a consequence, low-density lipoprotein (LDL) in blood plasma invade the 
endothelium. Increased oxidative stress causes oxidation of the LDL, and oxidized LDL (ox-
LDL) affects the migration of monocytes and lymphocytes into the subendothelial space. 
Once within the intima, monocytes transform into macrophages that devour lipoproteins, 
like ox-LDL. This process converts the macrophages into lipid-laden foam cells. The activation 
of these macrophages also leads to cytokine production, which recruits additional 
inflammatory cells and stimulates the adhesion of more monocytes and lymphocytes (212, 
214). The next step on the path to a developed atherosclerotic plaque is proliferation and 
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migration of vascular smooth muscle cells and deposition of extracellular matrix (e.g., 
collagen). The final stage of the plaque consists of a raised lesion with a soft, yellow core of 
lipid covered by a firm, white fibrous cap (212, 215-218). 
The atherosclerotic plaque may be asymptomatic for decades or could erode or 
rupture (219, 220). Plaque rupture exposes prothrombotic material from the core of the 
plaque, including tissue factor, collagen, phospholipids, and platelet-adhesive molecules, to 
the blood. The exposure of the prothrombotic material to the bloodstream activating the 
clotting cascade resulting in the generation of thrombin. Contact with collagen in the 
plaque’s extracellular matrix can trigger platelet activation, and circulating platelets adhere 
to the damaged site, aggregate, activate, and release secondary aggregators like 
thromboxane A2, adenosine diphosphate, and serotonin. Consequently, the formation of a 
thrombus can occlude the lumen of the coronary vessel, causing MI, or an intracerebral 
artery, causing an ischemic stroke (74, 218-221). Several factors increase the risk of the 
development of atherosclerosis, including age, obesity, smoking, diabetes mellitus, 
hypertension, reduced physical activity, and hyperlipidemia. Additionally, family history of 
MI (FHMI) is closely associated with atherosclerotic disease (222-228).  
Traditionally, arterial CVD and VTE have been classified as two separate diseases due 
to different epidemiology, pathophysiology, risk factors and treatment (13, 69, 229). 
However, in the last decade, data from studies suggests that arterial and venous thrombosis 
have more similarities than previously believed. In 2003, Prandoni et al. published a study in 
the New England Journal of Medicine where patients with unprovoked VTE had a higher 
prevalence of atherosclerotic plaque (230). Subsequently, several studies have investigated 
whether shared risk factors or causal mechanisms could explain the association between 
arterial and venous thrombosis. In the next section, the association between atherosclerotic 
diseases, traditional cardiovascular risk factors, and future risk of VTE will be discussed. 
Smoking is one of the most influential risk factors for arterial CVD (231), and several 
studies have investigated the impact of tobacco smoking on the risk of with VTE. In 2013, a 
meta-analysis summarizing all published prospective and case-control studies to date 
regarding the risk of VTE in smokers found that both former and current smoking increased 
the risk of VTE slightly (232). However, the study did not differentiate between provoked 
and unprovoked VTE events. Data from the Tromsø study, one of the studies included in the 
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meta-analysis, observed that heavy smoking was a risk factor for provoked VTE in analyses 
with VTE as the only outcome. When participants were censored at the occurrence of cancer 
or MI, there was no observed association between smoking and VTE (233). In the Iowa 
Women’s Health Study, only the incidence of secondary-, and particularly cancer-related VTE 
events, was higher among smoking- than never-smoking-participants (234). Recently, 
Mahmoodi et al. performed an individual level random-effect meta-analysis including nine 
prospective studies with measured baseline cardiovascular risk factors and validated VTE 
events (235). Different from previous meta-analyses, only prospective cohort studies with 
information about possible confounding factors and validated VTE events were included to 
reduce the risk of bias. Similar to prior findings, an association was only observed between 
cigarette smoking and provoked VTE (235). These findings suggest that smoking-attributable 
diseases (e.g., cancer, ischemic stroke or MI) or other predisposing factors are essential for 
smoking to convey a risk of VTE (233).  
Ageno et al. found a positive association between hypertension and increased VTE 
incidence in a meta-analysis from 2008 (236). However, the authors did not adjust for 
confounding factors such as age and BMI, both strongly associated with hypertension as well 
as VTE. Further, the meta-analysis consisted mainly of retrospective, case-control studies 
(236). Most prospective cohort studies have shown no association between hypertension 
and VTE after adjusting for age, sex and obesity (13, 109, 237). In the meta-analysis by 
Mahmoodi et al. (235), an association was found between hypertension and VTE in the 
unadjusted model. The association disappeared after adjustment for age, sex, and BMI, and 
when modeled continuously, an inverse association was observed for systolic blood pressure 
(235).  
Previous studies are inconsistent regarding the association between diabetes 
mellitus (DM) and risk of VTE. One prospective cohort study showed a 50% increased risk of 
VTE in diabetic patients (13), and two large meta-analyses identified DM as a risk factor for 
VTE (236, 238). However, most prospective cohort studies and the recent meta-analysis 
from Mahmoodi et al., did not observe an independent association between DM and VTE 
after adjusting for relevant confounding factors such as obesity, hospitalization, major 
surgery, and nursing home recidency (109, 110, 235, 239, 240). These findings suggest that 
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the association between DM and VTE could be caused by obesity and the other 
comorbidities associated with DM.  
Physical activity has been found to be associated with both lower risk (237, 241, 
242), and no effect on the risk of VTE (13, 110, 243) after adjustment for BMI. More 
surprisingly, some studies indicate that hard physical activity may increase the risk of VTE in 
vulnerable groups such as obese and elderly (241, 243). In elderly, this could be triggered by 
microtrauma activating the coagulation system.  
Regarding hyperlipidemia, previous studies are more consistent. Despite some 
studies finding the levels of lipids in the bloodstream to be associated with VTE incidence 
(110, 237), most studies indicate that hyperlipidemia, including high levels of cholesterol and 
triglycerides, is not associated with risk of VTE (13, 109, 117, 235, 244). Opposite, FHMI is 
not only a significant risk factor for MI (245), but also an independent risk factor for VTE 
(117, 246-249).  
To summarize, recent studies indicate that traditional cardiovascular risk factors, 
excluding age, obesity, and FHMI, are not associated with an increased risk of VTE. Smoking 
does increase the risk of provoked VTE, but this could be attributed to smoking-associated 
conditions independently increase the risk of VTE (e.g., cancer, MI or stroke).  
 
Atherosclerosis 
Atherosclerosis is a condition affecting the tunica intima zone of the arterial vessel 
walls (212). As the development of atherosclerosis is vital in the pathogenesis of CVD, the 
risk of VTE in these patients could be caused by the presence or progression of 
atherosclerosis. As previously mentioned, in a case-control study conducted by Prandoni et 
al., patients with unprovoked VTE had twice the prevalence of atherosclerotic plaque 
measured by carotid intima-media thickness (IMT), compared with age- and sex-matched 
hospitalized controls (230). Similar results were reported in two other case-control studies. 
Hong et al. reported a higher prevalence of coronary artery calcification in patients with 
unprovoked VTE compared with controls (250), and Jezovnik et al. reported a significantly 
thicker IMT and higher prevalence of atherosclerotic plaques (251). However, both the two 
latter studies and the landmark study from Prandoni have some important limitations. Most 
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notably, the measurement of IMT and coronary artery calcium was performed after the VTE 
events. Thus, the temporal relation of the association observed in the papers was not clear.  
Succeeding Prandoni et al., two population-based cohort studies, using the 
Atherosclerosis Risk in Communities (ARIC) (250) and the Cardiovascular Health Study (252), 
investigated the association between atherosclerosis and risk of VTE. In both studies, 
measurements of IMT were done at baseline. In the ARIC study, increased carotid IMT or 
presence of carotid plaque was not associated with an increased incidence of VTE after 
adjusting for relevant confounding factors such as age and sex (253). In the Cardiovascular 
Health Study, an inverse association between high-risk carotid plaques and VTE was 
observed (252). These findings suggest that subclinical atherosclerosis in itself is not a risk 
factor for VTE.  
IMT measured only at baseline may introduce potential bias. First, the measurement 
of atherosclerosis was often performed years before the VTE event. Second, both studies 
were unable to provide any information about the progression or prevalence of 
atherosclerosis later in the follow-up (253). Thus, as Prandoni himself proclaim in a review 
paper regarding the association between atherosclerosis and VTE, the only conclusion we 
may draw from the existing studies is that subclinical parameters of atherosclerosis are 
unlikely to predict future VTE (254). In the Tromsø study, competing risk analyses were used 
to eliminate the development of MI as an intermediate factor affecting the risk of VTE. In the 
prospective cohort, carotid atherosclerosis was associated with risk of future MI, but not VTE 
(252, 253).  
The findings from the three large, prospective cohort studies suggest that 
asymptomatic atherosclerosis is unlikely to be associated with an increased risk of VTE. 
However, as atherosclerotic plaque progress over time, it is difficult to determine the actual 
association with only one measurement of plaque. The long follow-up may introduce 





1.3.4 Arterial cardiovascular diseases and risk of venous thromboembolism 
Myocardial infarction: 
Symptomatic atherosclerotic events, such as MI and ischemic stroke have been found 
to increase the risk of VTE in several studies. In a meta-analysis published in 1996, reviewing 
clinical effects of anticoagulant therapy in suspected MI, 4% of patients with MI had 
symptomatic PE within two weeks after hospitalization (256). Contrary, in a study of almost 
24 000 autopsies, an increased risk of VTE was found in patients with ischemic stroke and 
peripheral artery thrombosis, but not in patients with MI. In fact, these patients had a 
reduced risk of VTE in comparison with the overall population (257). A high mortality rate 
(91%) among the patients with coronary thrombosis could explain the reduced risk. In the 
time setting with fewer therapeutic modalities for acute MI available than today, many of 
these patients did not survive long enough to be at risk of developing VTE (257). The possible 
association between MI and VTE was supported by a cross-sectional study where an 
association between coronary artery disease and PE was found in patients aged 60 years or 
older (258). However, the cross-sectional study design has several limitations, and 
prospective studies are necessary to investigate the association between MI and VTE.  
In the ARIC study, no association between atherosclerosis and VTE was found (253). 
However, both patients with MI and patients with stroke had an increased risk of VTE (253). 
Similar results were found in the General Practice Research Database from the United 
Kingdom, using a nested case-control analysis. In this study, 6 000 VTE patients were 
compared with a random sample of 10 000 age- and sex-matched controls. The results 
showed that MI increased the risk of PE, but not DVT (259). Two large registry-based, case-
control studies from Denmark showed that patients with MI and other heart diseases had an 
increased risk of VTE (260, 261). The earliest of the two studies, published in 2009, 
investigated the association between MI and VTE using almost 6 000 cases of VTE compared 
with 60 000 age- and sex-matched controls. In this study, MI was associated with a more 
than 4-fold increase in the risk of VTE the first three months after the incident event. 
However, after more than three months, MI was no longer significantly associated with VTE 
risk. The risk did not vary between provoked and unprovoked events. Similar to previous 
studies, the risk was higher for PE than DVT (260). The second study, using the entire 
population of Denmark, investigated whether heart disease increased the risk of incident PE 
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without apparent DVT (261). In the study, 45 000 patients had PE alone, 5000 had PE and 
DVT, and 60 000 had DVT alone. The control group consisted of 540 000 age- and sex-
matched controls from the general population. Sørensen et al. found that MI and heart 
failure in the preceding three months increased the risk of isolated PE more than 40-fold, 
and the combined risk of PE and DVT 20-fold. The risk more than three months after the 
incident MI was lower, but the long-term risk was persistently increased for isolated PE 
compared with the general population (261). Right-sided valvular disease was associated 
with a higher risk than left-sided valvular disease (OR 75 vs. OR 13.5) (261). Also, the 
Rochester Epidemiology Project observed an association between MI and subsequent VTE 
using a case-control study. However, in this study, the association between MI and VTE was 
markedly attenuated after adjusting for hospitalization and nursing home confinement 
(262).  
Ischemic stroke: 
The increased risk of VTE in patients with ischemic stroke are well known. Already in 
1972, Warlow et al. studied 30 patients with ischemic stroke causing weakness of one leg 
and showed that the frequency of DVT was 60% within the first ten days, detected by I-125 
fibrinogen scanning (263). Of these, four patients developed PE. The study was limited by 
the study size and the lack of a control group. Subsequent studies have shown a high 
incidence of DVT in stroke patients (264-273), with DVT incidence varying from 3% (272) to 
75% after stroke (264). However, the majority of these studies have actively searched for 
asymptomatic DVT. The incidence is, in general, lower in studies using venography and 
Doppler ultrasound instead of I-125 fibrinogen screening (274). Most studies report rates of 
asymptomatic DVT in around 30-40% of stroke patients (267-269, 273), while symptomatic 
DVT occurs in 1-10% of stroke patients (273, 275-279). The incidence of PE varies in studies 
from 1-5% of clinical PE (275, 280, 281), to around 10% in studies were the great majority of 
cases were asymptomatic (273). The frequency of both DVT and PE might have declined the 
recent years due to more intensive use of thromboprophylaxis (282). 
DVT develops early after the ischemic stroke (265, 283), with a peak incidence of 
asymptomatic events during the first ten days (277, 284). The incidence of VTE ranges from 
6% to 30% the first 14 days after stroke (270, 277, 284-286). In the large The Clots in Legs Or 
sTockings after Stroke (CLOTS) trial, DVT was detected within 30 days in 15% of immobile 
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patients with acute stroke using duplex ultrasound (277). Despite the incidence peak shortly 
after the stroke, the incidence of DVT and PE continue to be increased during the 
rehabilitation phase (287-289). Around 4% of patients entering a rehabilitation unit may 
develop PE (289), and bilateral venography revealed DVT in 33% of patients nine weeks after 
an incident stroke (287). PE events are observed as much as 4 months after the stroke (288).  
In both the acute and the rehabilitation phase, the risk of DVT varies with the degree 
of immobilization, leg paralysis and stroke severity (269, 273, 279, 287, 290-294). Increasing 
age, dehydration, and pre-stroke disability are other important risk factors for VTE in stroke 
patients (279, 295, 296). The majority of DVTs are detected in the paretic leg (277). 
However, bilateral DVTs occur in 15% to 20% of the patients (269, 283). 
VTE counts for a significant share of deaths after stroke (281). Stroke patients with PE 
had higher rates of in-hospital death and disability at 30 days and one year than stroke 
patients without PE (297, 298). In older studies of patients not receiving 
thromboprophylaxis, PE counted for up to one-quarter of early deaths after stroke (297, 
298). For stroke patients with incident DVT without concurrent PE, there is not observed an 
increased risk of mortality (279). Fatal PE may occur as early as the first week (288). 
However, fatal PE-events occur most often between the second and fourth week after the 
stroke, and in these weeks, PE is the most common cause of death in stroke patients (298-
300).  
Most studies regarding the incidence of VTE after stroke are based on clinical trials 
with preselection of patients. Participants included in these studies have in general lower 
rate of comorbidities, lower age and higher motivation for rehabilitation (301). Further, the 
clinical trials consist solely of stroke patients. Consequently, limited data exist regarding the 
association between ischemic stroke and risk of VTE in the general population. A registry-
based, case-control study revealed that patients with a history of stroke had a 50% overall 
increased risk of VTE, driven by a short-term 4.4-fold increase in risk the first three months 
after stroke (260). The overall risk corresponded well with an autopsy study from Sweden 
where cervico-cranial arterial thrombosis increased the risk of VTE with 50% after 
adjustment for sex, age and other possible confounding factors (257). Nevertheless, similar 




2. Aims of the thesis 
 
The aims of the thesis were: 
• To investigate the association between the presence, formation, and progression of 
carotid atherosclerosis and risk of venous thromboembolism using a large 
prospective cohort with repeated measurements of intima-media thickness and total 
plaque area. 
 
• To explore the association between myocardial infarction and future risk of venous 
thromboembolism in a population-based cohort study with validated information on 
exposure, endpoint, and potential confounders. 
 
 
• To study the time-dependent risk of venous thromboembolism by ischemic stroke in 
a population-based cohort with validated information on exposure, endpoint, and 
potential confounders. 
 
• To investigate the combined effect of ischemic stroke and the most influential 
thrombosis-associated SNPs on the risk of future venous thromboembolism using a 






3. Study population and methods 
1.4  The Tromsø Study 
In 1974, the newly established University of Tromsø conducted the first Tromsø 
survey due to a rapid increase of cardiovascular mortality in the Northern-Norway after 1950 
(302, 303). In this first survey, only young and middle-aged men were targeted. Since then, 
six more surveys have been conducted, including both sexes from the age of 20-89 years. In 
total, more than 50 000 inhabitants of Tromsø have participated in one or more of the six 
surveys (302-304). As time went by, more information was obtained, including more 
clinically oriented examinations in large subgroups. From Tromsø 4, the protocols comprised 
questionnaires, anthropometric and blood pressure measurements, as well as laboratory 
analyses of blood lipids, blood glucose, renal and liver function, hematology, hormones, and 
genetics (302-304).  
In this thesis, we have used data from Tromsø 4, Tromsø 5 and Tromsø 6. In Tromsø 
4, all inhabitants 25 years and older were invited, and 27 158 participated (77% of the 
eligible population). In Tromsø 5 and Tromsø 6, selected subgroups were invited, and 10 353 
(79% of the invited), and 19 762 (66% of the invited) participated, respectively. In paper 1, all 
inhabitants in Tromsø 4 aged 55–74 years and a random 5– 10% sample in the other age 
groups > 24 years, were invited to a second, more extensive examination, including 
ultrasonography of the carotid artery (305). Study participants who attended the second 
visit of Tromsø 4, in addition to random samples within different age groups, were eligible 
for the second visit of Tromsø 5 and Tromsø 6. Participants attending for the ultrasound 
examination were excluded if they had missing information on the measures of carotid 
atherosclerosis. In total, 10 426 participants attended for ultrasound examination of the 
right carotid artery in Tromsø 4, Tromsø 5, and Tromsø 6. The participants were followed 
until the follow-up (December 2012) or until a censoring event (i.e., migration, death). In 
paper 2 and paper 3, participants from all three surveys were followed from the date of 
enrollment until the outcome event occurred, the participant died or moved from the 
municipality of Tromsø or until the end of the study period December 31, 2010. The study 
population in paper 4 consisted of a subgroup of study participants from the three surveys 
with extended genetic analysis. In the subgroup, 692 first time VTE events from 1994 until 
39 
 
the end of follow-up on December 31, 2012, were included together with a subcohort 
consisting of 2016 age- and sex-weighted participants. 
 
1.5  Baseline measurements 
Information about study participants was collected by physical examination, blood 
samples and self-administrated questionnaires at each survey. Height and weight were 
measured with participants wearing light clothes and no shoes. BMI was calculated as 
weight in kilograms divided by the square of height in meters (kg/m2). Obesity (BMI of ≥ 30 
kg m2) was classified according to the World Health Organization (WHO) definition (306). 
Systolic and diastolic blood pressures were measured three times at 1-minute intervals with 
an automatic device (Dinamap Vital Signs Monitor, 1846; Critikon, Tampa, FL, USA) with the 
participant in a sitting position after 2 min of rest, and defined as the mean of the last two 
readings. Hypertension was classified as a mean systolic blood pressure of ≥ 140 mmHg, a 
mean diastolic blood pressure of ≥ 90 mmHg, or self-reported use of blood pressure-
lowering drugs. Non-fasting blood samples were collected from an antecubital vein and 
analyzed at the Department of Clinical Chemistry, the University Hospital of North Norway 
(UNN), Tromsø, Norway. Hypercholesterolemia was classified as a total serum cholesterol 
level of ≥ 6.5 mmol L-1 or self-reported use of lipid-lowering drugs.  
Information on smoking status, family history of MI, diabetes mellitus, physical 
activity and education level was collected from a self-administered questionnaire. Smoking 
status was measured by self-reported daily smoking (yes/no). Physical activity and education 
were assessed as ≥ 1 hour of moderate or hard physical activity per week (yes/no), and more 
than ten years of education (yes/no). 
 
1.6  Exposure and outcome measurements 
1.6.1 Carotid atherosclerosis 
Ultrasound examination of the right carotid artery was performed for assessment of 
total plaque area (TPA) and carotid intima-media thickness (IMT). High-resolution B-mode 
and color/pulsed-wave Doppler ultrasonography of the right carotid artery were performed 
in the extensive screenings in Tromsø 4, Tromsø 5 and Tromsø 6 by experienced examiners 
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who had completed a two-month pre-study training protocol to ensure similar and 
standardized examination techniques and measurement procedures (305, 307, 308). The 
right carotid artery was scanned longitudinally from the level of the clavicle, through the 
carotid bulb (bifurcation segment) and the proximal internal carotid segment as far 
downstream as possible. A plaque was defined as a localized protrusion of the vessel wall 
into the lumen of at least 50% compared to the adjacent IMT. For each plaque, a still image 
was recorded and digitized using the Matrix Meteor II frame-grabber and Matrox Intellicam. 
Adobe Photoshop 7.0 was subsequently used to measure plaque areas by outlining the 
perimeter of each plaque with a cursor, and the plaque area was calculated as pixel values. 
For the resolution used in paper 1 of this thesis, a plaque area of 167 pixels corresponded to 
one mm2. In participants with more than one plaque, TPA was calculated as the sum of all 
plaque areas. IMT was defined as the average of the mean IMT values of the near and far 
wall of the common carotid artery and far wall of the bifurcation. Novel plaque formation 
was defined as development of new plaques at the second ultrasound in vessels without 
plaques at the first ultrasound. Plaque progression was defined as an increase in TPA 
between the first and second ultrasound. 
 
1.6.2 Myocardial infarction 
All first-time events of MI were identified by linkage to the hospital discharge 
diagnosis registry at UNN, by searching for International Classification of Diseases (ICD)-9 
Revision codes 410-414, and 430-438 in the period 1994–1998, and after that ICD-10 
Revision codes I20-I25 and I60-I69. The unique national 11-digit identification number in 
Norway allowed linkage to national and local diagnosis registries. Linkage to the National 
Causes of Death Registry at Statistics Norway allowed the identification of fatal incident MI 
cases that occurred as out-of-hospital deaths. The death certificates were used to collect 
relevant information on the MI events from additional sources, such as autopsy reports and 
records from nursing homes, ambulance services, and general practitioners.  
An independent endpoint committee, using modified WHO MONICA/MORGAM 
criteria for MI, validated all possible hospitalized and out-of-hospital MI events. MI was 
defined by one of the following sets of conditions: a) typical, atypical or inadequately 
described symptoms + a definite new infarction in ECG recordings, b) typical symptoms + 
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significantly higher myocardial enzyme and/or troponin levels, c) atypical or inadequately 
described symptoms + significantly higher myocardial enzyme and/or troponin levels + a 
probable new infarction in ECG recordings, and d) post-mortem evidence of recent MI or 
thrombosis (309). 
1.6.3 Ischemic stroke 
Ischemic stroke was defined according to the WHO definition when computed 
tomography or magnetic resonance imaging scans or autopsy had ruled out brain 
hemorrhage (310). An independent end-point committee performed validation of 
hospitalized and out-of-hospital events of ischemic stroke based on data from hospital and 
out-of-hospital journals, autopsy records, and death certificates. The Norwegian national 11-
digit identification number allowed linkage to national and local diagnosis registries. Cases of 
possible incident ischemic stroke were identified by linkage to the hospital discharge 
diagnosis registry at UNN with a broad search for the International Classification of Diseases 
(ICD), 9th Revision codes 430 to 438 in the period 1994 to 1998, and after ICD, 10th Revision 
codes I60 to I69. Linkage to the National Causes of Death Registry allowed the identification 
of fatal ischemic strokes that occurred as out-of-hospital deaths. 
 
1.6.4 Venous thromboembolism 
All incident VTE events during follow-up were identified by searching the hospital 
discharge diagnosis registry, the autopsy registry, and the radiology procedure registry of 
UNN. All hospital care and relevant diagnostic radiology in the Tromsø municipality are 
provided exclusively by this hospital. The relevant discharge codes were ICD-9 codes 325, 
415.1, 451, 452, 453, 671.3, 671.4, and 671.9 for the period 1994–1998 and ICD-10 codes 
I26, I80, I81, I82, 167.2, O22.5, O87.1 and O87.3 for the period 1999–2012. Trained 
personnel, blinded for the baseline variables, reviewed all medical records for each VTE case. 
Possible cases of VTE were confirmed and registered as a validated VTE event when all 4 of 
the following conditions were satisfied: 1) objectively confirmed by diagnostic procedures 
including compression ultrasonography, venography, spiral computed tomography, 
perfusion-ventilation scan, pulmonary angiography, or autopsy; 2) the medical record 
indicated that a trained physician had diagnosed DVT or PE; 3) presence of signs and 
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symptoms consistent with DVT or PE; and 4) the patients underwent treatment with 
anticoagulants (heparin, warfarin, or direct oral anticoagulation), thrombolytic therapy, or 
vascular surgery, unless contraindications were specified. For patients derived from the 
autopsy registry, a VTE-event was recorded when the autopsy record indicated PE as the 
cause of death or as a significant condition contributing to death.  
A VTE event was classified as either a DVT or PE. When these events occurred 
concurrently, the event was classified as a PE. VTE events were further classified as provoked 
or unprovoked according to the presence of provoking risk factors at the time of diagnosis. 
Provoking factors included recent surgery or trauma within the previous eight weeks, active 
cancer, immobilization (i.e., bed rest for > 3 days, or long-distance travel exceeding 4 hours 
within the 14 days prior to the event), or any other factor described by a physician in the 
medical record (e.g., intravascular catheter). If none of these factors were present at the 
time of diagnosis, the event was classified as unprovoked. 
In paper 4 in this thesis, the five SNPs included in the genetic risk score proposed by 
de Haan et al. (311) were investigated. Genotyping of the SNPs rs6025 (F5, FVL), rs1799963 
(prothrombin G20210A), rs8176719 (ABO, non-O blood type), and rs2036914 (F11) was done 
using the Sequenom platform and rs2066865 (fibrinogen gamma chain [FGG]) by the 
TaqMan platform. Sequenom uses single-base extension followed by mass spectrometry to 
measure the molecular mass of the extended primers. Samples were genotyped using the 
Sequenom iPlex Gold Assay according to the recommended protocol, using an initial input of 
10-20 ng DNA and were analyzed using the MassARRAY Analyzer 4. We only used genotypes 
with a high-quality score of “A. Conservative” or “B. Moderate.” When multiple attempts 
were made to genotype an individual, one of the highest quality genotypes across all 
attempts was chosen for each SNP. For TaqMan, we used an initial input of 100 ng of DNA. 
Samples were genotyped using the Applied Biosystems 7900HT according to the 
recommended protocol, processed using SDS 2.4 (Thermo Fisher). Genotypes passing a 
quality value threshold of 95 were used. Participants were considered carriers of the 
prothrombotic risk gene if one or two risk alleles were present. We did not differentiate in 
hetero- and homozygote due to few homozygous study participants.
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4. Main results 
1.7  Paper 1: Repeated Measurements of Carotid Atherosclerosis and Future Risk of 
Venous Thromboembolism. The Tromsø Study 
The relationship between atherosclerosis and VTE is controversial, and previous 
prospective cohort studies have failed to find any association. However, these studies were 
based on a single measurement of intima-media thickness (IMT) and total plaque area (TPA). 
Therefore, we aimed to investigate the association between carotid atherosclerosis and VTE 
using repeated measurements of IMT and TPA in participants recruited from the fourth 
(1994-1995), fifth (2001-2002) and sixth (2007-2008) surveys of the Tromsø study. 
Measurements of IMT and TPA and potential confounders were updated at each available 
survey for the 10 426 participants attended. Time-varying Cox-regression models were used 
to calculate hazard ratios (HR) of VTE across various levels of TPA and carotid IMT adjusted 
for age, sex, and BMI. During a median follow-up of 10.8 years, 368 participants developed 
an incident VTE event. Participants with increasing carotid IMT were on average older and 
had a less favorable cardiovascular risk profile. There was no association between TPA as a 
continuous variable and VTE (HR per standard deviation [SD] increase 0.99, 95% confidence 
interval [CI] 0.90-1.11), and we found no linear trend of increased risk of VTE across 
increasing tertiles of TPA. Carotid IMT was not associated with risk of VTE (HR per SD 
increase 0.96, 95% CI 0.86-1.07) and the P for trend across increasing quartiles of IMT was 
0.5. Additional adjustment for total cholesterol, high-density lipoprotein cholesterol, 
smoking, diabetes mellitus and diastolic blood pressure had a negligible effect on the risk 
estimates. Further, plaque formation and plaque progression showed no increased risk of 
VTE with HR 1.00 (95% CI 0.98-1.02) and HR 0.96 (95% CI 0.84-1.11), respectively. These 
findings imply that the presence of atherosclerosis and plaque progression are not 
associated with increased risk of VTE, even in repeated measure analysis taking regression 




1.8  Paper 2: Impact of incident myocardial infarction on the risk of venous 
thromboembolism. The Tromsø Study 
Previous studies have demonstrated an association between MI and VTE. However, 
the association has not been investigated using a prospective, population-based study with 
adjustment for traditional cardiovascular risk factors and validation of exposure, outcome 
and potential confounding factors. In total, 29 506 participants were recruited from three 
surveys of the Tromsø Study. During a median follow-up of 15.7 years, 1898 participants 
experienced a first-time MI and 699 experienced an incident VTE. In participants without MI, 
652 VTE events were identified with an incidence rate of 1.8 per 1000 person-years, whereas 
there were 47 VTE events in participants exposed to MI with an incidence rate of 6.7 per 
1000 person-years. The proportion of PEs was higher among VTE events occurring after MI 
compared to VTE events appearing in the absence of MI (53% versus 41%). Overall, MI was 
associated with a 51% increased risk of total VTE (HR 1.51; 95% CI 1.08-2.10) and a 72% 
increased risk of PE (HR 1.72; 95% CI 1.07-2.75). The risk of isolated DVT was not significantly 
increased (HR 1.36; 95% CI 0.86-2.15). Regarding both VTE and PE events, the risk estimates 
were higher for provoked than unprovoked events. Incidence rates and HRs of VTE were 
high immediately after the incident MI and declined rapidly thereafter. The highest risk 
estimates for PE were observed during the first six months after the MI (HR 8.49; 95% CI 
4.00-18.77), and the risk was no longer increased after the first year (HR 1.45; 95% CI 0.53–
3.91). MI explained 6.2% of the PEs in the population (population attributable risk) and 
78.5% of the PE risk in MI patients (attributable risk). Our findings indicate that MI is 
associated with a transient increased risk of VTE, independently of traditional cardiovascular 
risk factors. The risk estimates were particularly high for PE. 
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1.9  Paper 3: Ischemic Stroke and Risk of Venous Thromboembolism in the General 
Population: The Tromsø Study 
Clinical data supports a relation between ischemic stroke and VTE, but the strength 
and time dependence of the association remains to be settled at the population level. The 
purpose of this study was to investigate the association between ischemic stroke and VTE in 
a prospective population-based cohort adjusting for cardiovascular risk factors. Using three 
surveys of the Tromsø study, 30 002 participants were recruited and followed through 2010. 
Information about cardiovascular risk factors (age, sex, BMI, blood pressure, blood lipids, 
diabetes, smoking, and education) was collected at baseline, and all incident events of 
ischemic stroke and VTE during follow-up were recorded. In a median follow-up time of 15.7 
years, 1360 participants developed ischemic stroke, and 722 participants developed incident 
VTE. In total, 57 of the 722 VTEs occurred in patients with ischemic stroke. VTE events in 
stroke patients had a higher proportion of provoked events compared to VTE events in 
participants without stroke. The proportion of patients immobilized before the VTE event 
was substantially higher in those with stroke compared in those without (44% versus 16%). 
The cumulative incidence of VTE was 15% during the first three months in individuals with 
ischemic stroke, compared with 0.2% in the general population during the same period. The 
incidence curves for VTE remained substantially parallel in the period more than six months 
after the event. The risk of VTE was highest the first month, and from one to three months 
after the incident stroke (HR 19.7 [95% CI 10.1-38.5] and HR 10.6 [95% CI 5.0-22.5], 
respectively), but declined rapidly thereafter. The risk estimates were essential for DVT (HR 
19.1; 95% CI, 7.8-38.5), and PE (HR 20.2; 95% CI, 7.4-55.1). Stroke was associated with a 
higher risk of provoked (HR 22.6; 95% CI, 12.5-40.9) than unprovoked VTE (HR 7.4; 95% CI, 
2.7-20.1) the first three months. Our findings suggest that additional predisposing factors, 
such as immobilization, potentiate the transient VTE risk in patients with ischemic stroke. 
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1.10  Paper 4: Effect of prothrombotic genetic variants on the risk of venous 
thromboembolism in patients with ischemic stroke. The Tromsø Study 
Prothrombotic genotypes may augment the VTE risk under conditions of high 
thrombosis risk related to stroke (e.g., hospitalization, immobilization, and infections). To 
investigate the effect of prothrombotic genotypes in patients with ischemic stroke on the 
risk of VTE, we performed a case-cohort study with 660 incident VTE and a randomly 
selected age-weighted subcohort consisting of 1803 participants recruited from the general 
population. All participants were genotyped for the five SNPs in the genetic risk score 
proposed by de Haan et al. (311), including ABO (rs8176719), F5 (rs6025), F2 (rs1799963), 
FGG (rs2066865) and F11 (rs2036914). Cox regression models were used to calculate hazard 
ratios (HR) for incident VTE according to individual SNPs and categories of risk alleles (the 5-
SNP score; 0-1, 2, 3-4 and ≥5) in participants with and without ischemic stroke. In total, 263 
patients had an incident stroke, of whom 60 developed subsequent VTE. The proportion of 
provoked VTE was higher in patients with ischemic stroke (75%) than in those without stroke 
(48%). For all SNPs, the joint exposure of stroke and risk alleles was associated with 
increased risk of VTE compared with stroke-free study participants with zero risk alleles. The 
risk of VTE increased 24% (HR 1.24, 95% CI 1.05-1.46) per increase of genetic risk category in 
participants without stroke, and 54% (HR 1.54, 95% CI 1.34-1.75) among those with stroke. 
Stroke patients with ≥5 risk alleles had a 12-fold (HR 11.77, 95% CI 4.17-33.25) higher risk of 
VTE than study participants without stroke and 0-1 risk alleles. Estimation of the attributable 
proportion due to interaction revealed that 84% of the total VTE events in study participants 
with stroke and ≥5 risk alleles were due to the interaction between the two exposures. 
When the 5-SNP score was applied in patients with stroke, the risk estimates for VTE across 
categories of risk alleles in the 5-SNP score were higher for provoked than for unprovoked 
events. The risk of provoked events increased by almost 80% per increase of risk category 
(HR 1.76, 95% CI 1.41-2.06). These findings imply that prothrombotic genotypes increases 




5. General discussion 
1.11  Methodological considerations 
1.11.1 Study design 
The results in the present thesis are based on data from a population-based cohort 
study, the Tromsø Study. In paper I-III we used the cohort study design. The cohort study 
design is along with the case-control study design the most commonly used observational 
design in clinical medicine (312). Cohort studies follow one group exposed to a risk factor or 
intervention of interest and another non-exposed group to determine the occurrence of the 
outcome of interest. They are designed to examine multiple outcomes of a single exposure 
and are useful for estimating the absolute and relative risk of diseases. In a cohort with a 
large number of participants from the general population, like the Tromsø Study, there will 
be a high degree of generalization, increasing the external validity of the study (313-315). 
The temporal sequence of the exposure and outcome avoids the debate as to which comes 
first. Additionally, collecting information in advance of the censoring event minimize the 
possibility of recall bias (313-315). The epidemiological challenges in cohort studies include 
loss-to-follow-up, change in risk of disease during follow-up, bias and confounding (316-
318). Further, the design is time-consuming and require a large study population, and may 
be inefficient to investigate outcomes with a low incidence (315). Even though our study was 
derived from a large cohort, the number of VTE events was low in certain subgroups. 
Consequently, a potential limitation in the thesis is low statistical power. 
Case-control studies compare the proportion of individuals with disease (i.e., cases) 
with specific exposure to the proportion of controls with the same exposure. As the cases 
are intentionally chosen based on the desired outcome, the case-control design is more 
cost-efficient than the cohort design as a smaller sample size is sufficient to generate 
adequate information. Case-control studies are particularly useful to investigate rare 
outcomes. There are some limitations to the case-control study design. Selection bias may 
occur with improper selection of cases and control. This is mainly due to problems selecting 
the controls as they should be representative of the population at risk of becoming cases. 
Further, the exposures of controls should be measured with similar accuracy as the 
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exposures of the cases. These principles are often impossible to satisfy as controls often are 
selected either from the general population, without comparable assessment of exposure, 
or from hospitalized patients with other diseases that may be unrepresentative of the study 
population. Controls recruited from the general population may also generate recall bias as 
cases with diseases are more likely to remember particular events or exaggerate or minimize 
what they consider to be risk factors compared with healthy controls. In the present thesis 
exploring the association between CVD and VTE, the case-control design is not suitable to 
confirm the direction of association due to the undetermined temporal sequence of 
exposure and outcome (254, 315, 317, 319). 
Randomized controlled trials (RCTs) were first introduced to clinical medicine 
evaluating the treatment of tuberculosis (320), and have been presumed to be the most 
reliable methods of determining the effects of treatment and causal relationships (301, 312, 
321-324). In large RCTs, participants are randomized and distributed evenly between the 
control and intervention groups, reducing the risk of potential of known and unknown 
confounders. The randomization minimizes allocation and selection bias, and it is easy to 
compare the two groups directly (301, 312, 325). Despite the many strengths, there are 
essential limitations of RCTs. Lack of external validity and generalizability is the most 
frequent criticism of RCT, as most trials include a selective group of participants, often 
younger and healthier than the general population. RCT is also resource-intensive regarding 
both costs and time, and impractical for urgent situations and rare diseases. Compared to 
RCTs, the cohort and case-control studies are ethically safe and more accessible to conduct 
due to the non-experimental design (321, 324-326).   
In Paper IV, we used a case-cohort design with study participants recruited from 
Tromsø 4, Tromsø 5, and Tromsø 6. The case-cohort design includes all individuals 
developing VTE in the full cohort plus a randomly sampled subcohort from the entire cohort 
independent of disease status. In our study, 660 VTE cases were included, and an age-
weighted subcohort was randomly selected from the same population. The subcohort is 
meant to reflect the occurrence of the exposure in the original cohort population (319, 327, 
328). Similar to cohort studies, the case-cohort study has a definite temporal sequence of 
exposure and outcome, reducing the risk of recall bias. As the cases and controls are 
sampled from the same population, and exposures are assessed with investigators blinded 
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to the case status, there is a low degree of differential misclassification. Compared with 
cohort studies, the case-cohort study design is favorable for studying rare exposures as the 
full covariate data is only required for cases and controls in the subcohort. With appropriate 
sampling and analysis, the HR estimates are similar in the case-cohort as in the full-cohort 
(319, 327, 328). We chose the case-cohort design to limit the costs and time required for 
genotyping. There are some limitations to be aware of regarding the case-cohort study 
design. The cases in a case-cohort are often overrepresented in the sample (327). However, 
as the control-cohort included a large sample of study participants, there are limited risk of 
overrepresentation of cases. Additionally, if many participants are censored, the subcohort 
may be limited and not representative of the full cohort (328). In our study, participants 
were only censored at VTE-events, migration, or death, which should limit the introduction 
of bias.  
 
1.11.2 Causality 
Causality is derived from the Latin word causa and means cause or reason. Causal 
factors are in medicine often called risk factors and are the producer of an effect, results or 
consequence (229). A risk factor may induce an effect either directly or indirectly, and it is 
postulated that if the risk factor is removed, the disease will no longer occur (229). 
Epidemiological studies investigate the association between exposures and outcomes. In 
observational studies, positive associations are theoretical measures suggesting that a given 
exposure may cause the outcome of interest. However, a correlation or association between 
two phenomena does not necessarily equal the presence of causality (229, 329).  
To evaluate a possible causality between smoking and lung cancer, Sir Austin 
Bradford Hill defined nine criteria during a talk to the Section of Occupational Medicine of 
the Royal Society of Medicine in 1965 (330). The nine criteria were 1) strength of the 
association, 2) consistency (reproducibility of the findings in different places with different 
samples), 3) specificity (when a single putative cause produces a specific effect), 4) 
temporality, 5) biological gradient (greater exposure should generally lead to higher 
incidence of the effect), 6) plausibility (association agrees with currently accepted 
understanding of pathological processes), 7) coherence (association should be compatible 
50 
 
with existing theory and knowledge), 8) experiment and 9) analogy (existence of other 
cause-effect relationships analogous to the one under study) (331). These criteria were 
meant as a guideline of issues that should be addressed when evaluating causality of an 
observed association. Of the nine criteria, the temporality criterion is the only absolute 
(331). Thus, failure to satisfy some of these criteria does not disprove a causal association, 
and causal inference should not be based on these criteria alone (329, 332, 333).  
In our cohort study, several of the given criteria are fulfilled regarding a causal 
association between CVD and VTE. First, our study design assures temporality as all 
participants with previous VTE were excluded, and those developing VTE during follow-up 
were censored at the time. Further, both the strength of the observed association and the 
consistency with previous studies indicate that there might exist causation. Additionally, 
there are several plausible mechanisms after MI and ischemic stroke that may increase the 
risk of VTE. However, biological causality may not be declared, as experimental evidence is 
not available. The possible mechanisms behind the increased risk of VTE in patients with 
CVD are further discussed in the section discussion of the main results (page 62 and 64). 
 Mendelian randomization is an epidemiological method to assess causality within 
observational studies. The method was first described in a study more than 30 years ago, 
and the use of Mendelian randomization has increased simultaneously with increasing 
genetic information (334). Using Mendelian randomization studies, it is possible to assess 
the contribution of a risk factor to a disease by investigating the association between the 
disease and a genetic variant influencing the risk factor. This is possible due to the random 
assorting of alleles at conception, creating nature’s own RCT (334). Thus, confounding by 
other factors than those related to the genetic variant are eliminated. As the genetic 
makeup exists from conception, a temporal sequence must necessarily exist. Some 
Mendelian randomization studies are performed investigating the risk of VTE, including 
studies implying a causal relationship between high BMI (113), and taller height (335) and 
VTE. Several genotypes are known to increase the risk of arterial CVD, including some of the 
prothrombotic genotypes collected in the Tromsø Study (336). However, the genetic variant 
in Mendelian randomization studies should only affect the outcome through the effect on 
the exposure, and not directly affect the outcome. As the genotypes we used in paper IV 




All epidemiological studies attempt to generalize the results in the study population 
to a defined reference population (i.e., internal validity) and other populations (i.e., external 
validity). Results from RCTs are applied for clinical care of large populations. However, as 
most RCTs have strict criteria for participants included in the trial, the external validation, or 
the generalizability, is often questioned (326). Cohort studies with proper inclusion and 
exclusion criteria may have higher generalizability, as participants from a broader specter of 
groups are included. Nevertheless, selection bias may limit the generalizability of 
population-based cohort studies. High participation rate and minimal loss to follow up are 
indications of possible high external validity (313).  
The participation rate in the Tromsø Study is high compared with other prospective 
cohort studies, with a total overall attendance rate in Tromsø 4, Tromsø 5 and Tromsø 6 
exceeding 70%. The largest survey, Tromsø 4, had an attendance rate of 77% (303). In two 
comparable cohort studies, the Norwegian HUNT 2-study and the Danish Diet, Cancer, and 
Health study, the participation rates were 70% and 35%, respectively (337, 338). All 
inhabitants aged 25 years or older living in Tromsø were invited in Tromsø 4, ensuring a 
broad specter of age groups. Further, the incidence and prevalence of CVD, cardiovascular 
risk factors, and VTE reported in our studies are comparable to similar populations (20, 24). 
We assume that our results have high generalizability to other Western populations. 
In a cohort study, non-responders tend to have lower socioeconomic status and 
higher mortality then attendees (339). This is likely due to the increased health-interest, and 
high attendance rates, in groups with higher socioeconomic status. Consequently, an 
underestimation of the actual risk may occur, as the participants in a cohort study may be 
healthier than the general population (339, 340). Additionally, participation in most cohort 
studies require physical attendance at the study site, and this may cause selection bias due 
to lower attendance rate of severely ill or disable participants. In the Tromsø study, there is 
a relatively low attendance rate in the age groups under 40 years and over 80 years, and 
men have a lower attendance rate than women (303). This is important to be aware of, since 
it may affect the generalizability in these age groups. Nevertheless, the bias between survey 
attendees and non-attendees is mainly theoretical, and it is not likely that it has a substantial 
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effect on our results. As we mainly report relative risk estimates rather than absolute risks, 
this type of bias should not considerably affect our results. 
In Paper IV, we used genotyping information for the five SNPs rs8176719 (non-O 
blood type) in ABO, rs6025 (factor V Leiden) in F5, rs1799963 (prothrombin G20210A) in F2, 
rs2066865 in FGG, and rs2036914 in F11. The distribution of SNPs may vary from other as 
there are large global variations in the human genome (341). However,  the allele 
frequencies for the SNPs in our study population is coherent with other western reference 
populations, with 0.32 and 0.30 for ABO, 0.04 and 0.05 for FVL, 0.01 and 0.02 for 
prothrombin G20210A, 0.23 and 0.25 for FGG, and 0.41 and 0.52 for F11, in our and the 
western reference population respectively (190). 
 
1.11.4 Confounding 
In cohort studies, the baseline characteristics of the exposed and unexposed 
participants may differ. If these differences have independent effects on the outcome, they 
may affect the incidence of outcome (i.e., VTE) in the different groups separately from those 
related to the investigated exposure (i.e., atherosclerosis, MI and ischemic stroke). This 
effect is known as confounding. A confounder is defined in epidemiology as a factor related 
to both the exposure and the outcome, unevenly distributed among the compared exposure 
groups (318). Any factor that represents a step in the causal chain between exposure and 
disease should not be treated as a confounding factor but requires special treatment as an 
intermediate factor (318, 342). Confounding may strengthen or weaken a true association, 
and may lead both to type I and type II errors. In RCTs, all potential confounders are 
expected to be evenly distributed among the groups being compared and not affect the risk 
estimates (342). Cohort studies have no similar protection against confounding factors and 
are particularly vulnerable to residual confounding. Thus, all observed associations in a 
cohort study must be assessed for possible confounders. The comparison groups in a cohort 
should be as identical as possible only separated by the exposure variable of interest to 
reduce the risk of confounding (316, 342, 343).  
A practical approach to reducing confounding is to include only similar study 
participants (344). For example, in a study with only women, sex cannot be a confounding 
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factor. However, such analyses will reduce the external validity of the study. An analytic 
strategy to keep a high degree of external validity and reduce confounding is stratification. 
The advantage of stratification is more similar subgroups than the entire diverse population, 
which is suitable to eliminate interaction between variables. An important limitation of 
stratification is the possible reduction of statistical power due to the reduced number of 
participants in each stratum (344). Another strategy to decrease confounding is using 
regression models (344). Regression models use data to estimate how confounders are 
related to the outcome and are used to limit the effect of confounding on the risk estimates 
(314). There are different types of regression analysis, including linear-, logistic- and Cox 
regression. With regression analysis, it is possible to simultaneously examine all exposure 
variables and estimate the true effect of every single exposure. The main advantage of 
regression compared with stratification is that data from all participants are used, and the 
statistical power in the study is not reduced (314).  
In our studies, we used regression models to limit possible confounding. We used 
multivariable regression analysis where potential confounders were included as covariates. 
A large meta-analysis showed that high BMI and advancing age are associated with both CVD 
and venous thromboembolism (235). It is important to adjust for these factors as they may 
confound the association between CVD and VTE. Further, we adjusted for several 
cardiovascular risk factors despite that many of these are presumably not associated with 
VTE (235). As the presence of cardiovascular risk factors obviously was distinctly different 
between those with and without CVD, we chose to adjust for these factors to minimize the 
difference between the exposed and unexposed groups. Further, participants with 
cardiovascular risk factors are less healthy compared to the general population, which may 
indicate an increased rate of comorbidities confounding the risk estimates for VTE. In paper 
I-III we performed regression models only adjusted for age, sex and BMI and models 
adjusted for blood pressure, diabetes mellitus, cholesterol, smoking, physical activity, and 
education level in addition to age, sex and BMI. We observed only small differences in risk 
estimates between the models, underscoring that cardiovascular risk factors do not affect 
the risk of VTE.  
The observed associations between MI, and ischemic stroke and VTE remained 
statistically significant after adjustments of potential confounding factors. This indicates that 
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shared risk factors alone cannot fully explain the observed relation between CVD and VTE. 
However, there may exist residual or unmeasured confounders that affect the risk estimate. 
Residual confounding factors could be unknown risk factors affecting both CVD and VTE. 
Unmeasured confounding is risk factors we know affect the outcome, but where we lack 
information about the variable. Possible unmeasured confounding factors in our study 
include genetic risk factors and the use of antithrombotic treatment and statins. Concerning 
unknown residual confounders, we assume that it is unlikely for them to have a substantial, 
independent effect on the outcome of interest. Thus, residual confounding should not 
generate considerable bias, despite a possible uneven distribution (342). 
 Statistical interaction describes a situation where two or more risk factors modify the 
effect of each other with regard to the occurrence of a given outcome (314). This 
phenomenon is also known as effect modification. Effect modification occurs when an 
exposure has a different effect among different subgroups (314). A risk factor only increases 
the risk of disease in female is an example of effect modification. When effect modification 
is present, it can be approached by stratifying the data on the effect modifying variable 
(314). In paper I-III, we tested statistical interactions by including cross-product terms in the 
proportional hazards models. No interactions were found between sex and the main 
exposures. 
 
1.11.5 Information bias and misclassification 
Bias is a systematic error in a study’s design or procedures and may result in incorrect 
assessments of the association between an exposure and outcome (345). Bias may be 
introduced through the selection of the study participants (i.e. selection bias), 
measurements and classification of exposure or outcomes (i.e. information bias), and the 
presence of confounding factors (314). Selection bias occurs when the exposure or outcome 
status of an individual influence the probability of participating in the study. This is primarily 
a problem in case-control studies and rarely lead to erroneous associations in prospective 
studies (313, 317). However, as mentioned previously, participants in cohort studies are 
more likely to be healthier than the general population (339, 340).  
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Information bias occurs when study participants are placed in the wrong exposure- or 
outcome category. In prospective cohort studies, information bias is a more frequent 
problem than selection bias and is important to consider. Information bias may induce 
misclassification, which occurs when a positive outcome is classified as negative or vice 
versa, or when participants are placed in the wrong exposure group. There are two main 
types of misclassification, non-differential misclassification, and differential misclassification 
(318). Non-differential misclassification occurs when a variable is misclassified 
independently of the outcome or the exposure. In non-differential misclassification, all 
groups have the same error rate or probability of being misclassified. In differential 
misclassification, the variable misclassified is dependent on the outcome or the exposure. As 
a result, one of the groups is more often misclassified than the comparison group and this 
may introduce bias (314). In this thesis, participants are included before the exposure and 
the outcome assessment, and differential misclassification is unlikely.  
Non-differential misclassification is more common in cohorts and may occur in this 
thesis due to incomplete medical records or questionnaires. For example, study participants 
may have difficulties to remember past exposure during interviews or when completing 
questionnaires. Physical examination may also lead to misclassification due to technical 
errors, errors from the examination or random errors. A normotensive study participant 
with stress-induced high blood pressure at examination will be misclassified as hypertensive. 
Self-administrated questionnaires increase the risk of misclassification as questions could be 
misunderstood or skipped. An example is diabetes mellitus, which is defined based on self-
reporting in the Tromsø Study. This may explain why the prevalence of diabetes mellitus 
type 2 is markedly reduced in the Tromsø Study compared with the general population 
(346). The reduced prevalence may generate an underestimation of the true impact of 
diabetes on diseases. However, misclassification in a cohort study is usually non-differential.  
An equal distribution of misclassification in participants with and without the exposure will 
not largely affect the risk estimate in the study. Self-administered questionnaires are also 
less expensive and time-consuming than most other methods, and self-reported 
questionnaires are reported to have high validity and accuracy (347). For collecting data on 
sensitive topics (e.g., mental health, sexuality, and alcohol use), a self-administered 
questionnaire is showed to be more accurate compared to interviewer-administered 
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questionnaires (348). The repeated measurements of several study participants allowed us 
to update information concerning cardiovascular risk factors during follow up and correct 
any misclassification in the previous survey. 
To ensure the correctness of the classification of exposure and outcome variables, we 
validated the known effect of specific exposure variables on outcomes. In our data material, 
traditional cardiovascular risk factors increased the risk of both MI and stroke as expected. 
An independent end-point committee validated both exposures (i.e., atherosclerosis, 
myocardial infarction and ischemic stroke) and outcome (i.e., VTE) in all the papers in the 
thesis. For VTE, all possible cases were confirmed as a validated VTE event when four criteria 
were satisfied. The criteria included radiological evidence, symptoms, clinical diagnosis and 
treatment of DVT or PE. WHO criteria were used to validated stroke and MI events, while 
trained personal assessed presence and degree of atherosclerotic plaque in the carotid 
artery. We therefore assume that there is limited misclassification concerning the most 
important variables, and information bias should not profoundly influence our risk 
estimates.  
 
1.11.6 Regression dilution bias and modifiable risk factors 
Regression dilution bias is a phenomenon that results in an underestimation of the 
true association between exposure and outcome due to measurement errors, temporary 
fluctuations, and changes in variables over time (349-352). In most cohort studies, 
information about risk factors is collected at inclusion. As the majority of cardiovascular risk 
factors are modifiable, changes during follow-up may influence the risk estimates of CVD 
and VTE (352). When the risk profile of study participants changes during follow-up, the 
possibility of type I errors (an observed association when there is none) decrease, whereas 
the risk of type II errors (no observed association when there is a true association) increases 
(351).  
The median follow-up time in the four papers in the thesis varied between 10.8 and 
15.7 years. Changes in baseline variables during the long follow-up time may lead to an 
underestimation of the true association. In paper I, the awareness of possible regression 
dilution bias is especially important. As the exposure (i.e., atherosclerosis) may develop over 
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time, a long follow-up with several years between the baseline measurement and the 
outcome (i.e., VTE) could introduce regression dilution bias. Thus, a small effect of 
atherosclerosis on the risk of VTE could be masked in traditional cohort studies with single 
measurements and long-term follow-up (254). Using time-varying analyses with repeated 
measures of carotid atherosclerosis, we reduced the possibility of regression dilution bias. 
Our findings suggest that the discrepancy in case-control and cohort studies regarding 
atherosclerosis and VTE are most likely not explained by formation or progression of 
atherosclerosis during the long follow-up (230, 250, 252, 253, 353). Other possible 
explanations for the differences between case-control and cohort studies include selection 
bias and reverse causation as the exposure is measured after the outcome in case-control 
studies (354). 
In paper II and III, the exposure variable (i.e., MI and ischemic stroke, respectively) 
was included as a time-dependent covariate and updated during follow-up. Further, as the 
exposure of CVD does not change during the follow-up after the incident event, the risk of 
regression dilution bias is limited. However, most other covariates of interest, including BMI, 
smoking, blood pressure, and cholesterol, are modifiable. Misclassification of confounding 
factors may over- or underestimate the association between exposures and outcome. 
However, as several study participants participated in more than one of the surveys in the 
Tromsø Study, information on cardiovascular risk factors was obtained at different time 
points during the follow-up. In the time-varying analysis, each participant contributed with 
observation periods from the time of inclusion to the date of an incident diagnosis of VTE, 
the date the participant died or moved from Tromsø, or until the end of the study period, 
whichever came first. Information on possible confounding risk factors was updated at each 
survey in those who participated in several surveys to avoid misclassification. We performed 
time-varying Cox proportional hazards regression analysis to limit the influence of changes in 
confounders during follow-up. Thus, this should not affect our risk estimates.  
We did not perform time-varying analysis in paper IV, and regression dilution may 
influence confounding factors affecting the risk estimates of VTE in patients with ischemic 
stroke and prothrombotic genotypes. However, in a recent paper from Småbrekke et al. 
(352), risk estimates of MI and VTE based on a single measurement of cardiovascular risk 
factors in time-fixed analysis corresponded well with risk estimates based on repeated 
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measurements of the same risk factors in time-varying analyses (352). Of traditional 
cardiovascular risk factors, only BMI and age was associated with VTE in both time-fixed and 
time-varying analyses, suggesting that underestimation of risks due to regression dilution 
bias may not explain the lack of association between cardiovascular risk factors and VTE as 
reported in most prospective cohorts (235, 352). Thus, regarding traditional cardiovascular 
risk factors, risk estimates based on a single measurement are generally reliable in cohort 
studies with long follow-up (352). 
1.11.7 Missing data 
In nearly all epidemiological studies, there are some missing data observations (355-
357). Missing values may occur due to malfunction of equipment, inadequate responding to 
questionnaires, loss of laboratory samples, and loss to follow-up before the end of the study. 
There are three main types of missing data; missing completely at random (MCAR), missing 
at random (MAR) and not missing at random (NMAR) (355-357). MCAR rarely exist, while 
MAR occurs when the missing data is related to a particular variable, but it is not related to 
the value of the variable. An example of MAR is a study participant who accidentally forgets 
to answer a question in a questionnaire. NMAR is data missing for a specific reason and 
could occur if a particular group of participants does not answer a specific question in a 
questionnaire. For example, older study participants may not be aware of family history of 
disease and, therefore, not answer questions concerning hereditary (355, 356, 358).  
A large amount of missing data is a major threat to the integrity of a study as the 
available data could be biased. There are several methods available to handle missing data 
and reduce the risk of bias (355, 357). First, both variables with a large number of missing 
values and individuals with incomplete data can be omitted. Omitting individuals from the 
study who do not have complete data is termed list-wise deletion or complete case analysis 
(355). When only a few observations are missing, the risk of introducing bias is minor when 
excluding all participants with missing values for the variables of interest. However, 
exclusion of participants may both reduce the statistical power and introduce selection bias, 
unless the data are missing completely at random. Omitting whole variables may introduce 
confounding, and valuable variables could be removed from the statistical analyses. Another 
option to reduce missing data is pair-wise deletion or available case analysis (357). In pair-
wise deletion, only the variable with missing value is omitted from the analysis, while other 
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non-missing variables in the same study participants are included in the analysis (357). Some 
disadvantages of using pair-wise deletion exist. As for list-wise deletion, the results are 
unbiased only if the data are missing at random. Additionally, pair-wise deletion may lead to 
mathematical problems in computing estimates of some parameters (355, 357). Imputation 
is a statistical method used to replace missing values by estimating the most probable values 
(355). Simple imputation is based on the assumption that the missing values are MAR or 
MCAR, and there is not given that the estimate is the correct value of the missing variable 
(355-357). 
In our study population, we have few missing values in the relevant variables. The 
total amount of missing data across all variables is only 1-2% in the Tromsø Study, (303, 
304). The prospective study design, collecting of information at baseline, and the thoughtful 
validation of events are important for reducing the amount of missing in our cohort. In the 
present thesis, missing data regarding exposure (i.e., carotid atherosclerosis, MI, ischemic 
stroke, and genetic variables) and outcome (i.e., VTE) were handled by excluding all 
participants with missing variables (i.e., list-wise deletion). Due to the small number of 
missing and a large number of participants, we assume that the statistical power was not 
largely reduced by using list-wise deletion and censoring participants with missing values. 
Still, removing study participants may introduce selection bias if the characteristics of those 
with missing values differ from the rest of the study population (355). In our study, most 
missing is likely due to MAR, and the number of missing values are probably similar between 
exposed and unexposed participants. Besides, the municipality of Tromsø is served by a 
single hospital, minimizing the chance of loss to follow-up and missing data regarding the 
exposing events. For missing values of possible confounding factors used in the multivariable 
Cox regression, we used pair-wise deletion. By using pair-wise deletion, the power in our 





1.12 Discussion of main results  
1.12.1 Atherosclerosis and risk of venous thromboembolism 
In accordance with previous cohort studies (252, 253, 353), we found no association 
between atherosclerosis and VTE in paper 1. In the ARIC study, 13 081 participants aged 45- 
65 years underwent carotid ultrasonography to measure IMT and TPA, and no association 
was found during a mean follow-up of 12.5 years (253). In the Cardiovascular Health Study, 
an inverse association was found when investigating more than 4100 participants over 65 
years over a follow-up period of 12 years. Atherosclerosis was surprisingly found to protect 
against unprovoked VTE (RR 0.60, CI, 0-39-0.91) (252). A previous study from the Tromsø 
Study, including more than 6200 participants with a follow-up time of 15 years, found that 
atherosclerosis was associated with MI, but not VTE (353). In contrast, three different case-
control studies have demonstrated that atherosclerosis is more prevalent in patients with 
VTE than age- and sex-matched control, suggesting that atherosclerosis could be a shared 
risk factor for CVD and VTE (230, 250, 251).  
Several factors could explain the discrepancies between cohort and case-control 
studies. First, to establish causation, temporality between the exposure and the outcome is 
necessary (330). Due to the undetermined temporal sequence between exposure and 
outcome, case-control studies are not designed to reveal the direction of an association. 
Further, two of the three case-control studies selected controls among hospitalized patients 
without VTE or atherosclerosis (230, 250), and recruitment of controls that are not 
representative of the source population may result in overestimation of the real effect. 
The previous cohort studies were based on a single measurement of TPA, and carotid 
IMT obtained at the beginning of long follow-up periods. Potentially, carotid 
ultrasonography was performed several years prior to VTE events, which could mask a small 
effect of atherosclerosis on VTE-risk due to regression dilution bias (254, 255). In Paper I of 
this thesis, the risk status of the participants was updated during follow-up using time-
varying analysis with repeated measurements of TPA and IMT. This allowed us to obtain a 
better estimation of an individual’s atherosclerotic status closer to the VTE event. Still, we 
did not reveal any association between carotid atherosclerosis and VTE, and neither plaque 
formation nor plaque progression between two different surveys was associated with 
increased risk of VTE. 
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Our study supports previous findings that atherosclerosis is unlikely to be an 
intermediate for the association between CVD and VTE. However, it has been suggested that 
cardiovascular risk factors may confound the association by increasing the risk not only for 
the formation of atherosclerosis but also for VTE (254). Previous studies have thoroughly 
investigated the associations between known cardiovascular risk factors and risk of VTE. 
Cohort studies using cause-specific analyses have revealed age and obesity as shared risk 
factors for CVD and VTE, while other traditional cardiovascular risk factors are not likely to 
increase the risk of VTE (235, 244, 359). According to previous studies, our findings indicate 
that shared cardiovascular risk factors do not affect the observed association between 
atherosclerosis, CVD, and VTE. Adjustments for traditional cardiovascular risk factors would 
substantially attenuate the association if the risk factors were actual confounders. We found 
that adjusting for cardiovascular risk factors had a negligible effect on the risk estimates. As 
many cardiovascular risk factors are modifiable, the risk profile to the participants may 
change during follow-up, increasing the risk of regression dilution bias and an 
underestimation of the associations. In paper I to III, we performed repeated measurements 
of the cardiovascular risk factors during follow-up. Using time-varying analysis with updated 
information, we could more appropriately explore the real effect of cardiovascular risk 
factors on VTE during follow-up. Further, as the appearance of risk factors most commonly 
increases with time, shared risk factors are expected to induce a permanent or progressive 
risk of VTE. Conversely, we observed a transient VTE risk after MI and stroke.  
 
1.12.2 Myocardial infarction and risk of venous thromboembolism 
In paper II, we found that MI was associated with an increased risk of VTE in the 
general population. The risk was particularly increased for developing PE and provoked VTE-
events. Our findings are in line with previous studies (253, 256, 258, 260, 261). In the two 
largest studies, Sørensen et al. found that the risk of VTE was higher in the first months 
immediately after an MI compared to the VTE risk in the general population (260, 261). As in 
our study, the authors demonstrated a higher risk of PE than DVT after hospitalization for 
MI. However, the exposure, outcome, and provoking factors for VTE were all based on 
information from hospital registries, and the information was not validated (260, 261, 360). 
Thus, results from these registry-based studies should be interpreted with caution. 
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Use of antiplatelet treatment and statins are standard to prevent new MI-events, 
incident strokes and death (361). In our study, treatment with antiplatelet agents and statins 
in patients with MI could affect the association between MI and VTE. A recent study, 
investigating antiplatelet therapy of ischemic events in stable patients with symptomatic 
atherosclerosis, found that more intensive antiplatelet therapy reduced the risk of VTE 
(362). The findings support previous data, showing that aspirin and statins reduce the risk of 
both incident (363, 364) and recurrent (365, 366) VTE events. The effect on VTE by statins is 
probably mediated by decreasing levels of FVIII, as showed in a recent RCT (367). A 
systematic review and meta-analysis including 13 cohort studies and 23 RCTs of statins 
versus placebo or no treatment suggested a beneficial effect of statin use on VTE, with up to 
25% reduced risk (364). Unfortunately, we do not have information regarding antiplatelet 
agents and statins in our study, and an underestimation of the true impact of MI on the risk 
of VTE may exist. 
The mechanisms causing the observed association between MI and VTE are not 
established (229), but as discussed, shared risk factors are unlikely to play an essential role. 
One possible mechanism could be a transient factor related to the MI, increasing the risk of 
VTE (229). We found the risk of VTE to be highest the initial six months following an incident 
MI and declined rapidly thereafter. Similarly, the association between MI and VTE has been 
reported to diminish (261) or disappear (260) after more than three months in previous 
studies. In a study of more than 2500 postmenopausal women with coronary heart disease, 
the risk of VTE increased particularly the first three months after an MI diagnosis (368). The 
transient increase in VTE risk after MI points towards mechanisms related to the MI-event 
itself. Both hospitalization and temporal immobilization are common after MI and are strong 
predisposing factors for VTE (132). Previous studies have suggested that hospitalization after 
MI could partly explain the observed association between MI and VTE (260-262). The 
attenuation of VTE risk if the hospitalization for MI was within three months before the 
index admission, but not during the same hospitalization as for VTE, supports the substantial 
impact of hospitalization (261). This finding indicates that MI is indirectly associated with 
VTE through hospitalization. Further, in a study of more than 1300 patients with incident 
VTE events, MI was no longer associated with VTE after adjusting for hospitalization for 
surgery or acute medical illness, and nursing home confinement (262). Contrary to our 
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findings, the risk in the large Danish registry-based studies was similar for provoked and 
unprovoked events (260). This could be caused by limited information regarding 
immobilization prior to the VTE event, which may introduce misclassification of the event as 
unprovoked (260). The transient risk of provoked VTE in our study suggest that indirect 
causal factors, such as hospitalization and subsequent immobilization as well as coronary 
artery bypass surgery or endovascular procedures after MI, may contribute substantially to 
the observed association between MI and VTE. 
A direct causal relationship between MI and PE may contribute to the increased VTE 
risk in MI patients, and is biological plausible. First, we found a higher risk of PE than DVT 
after MI. DVT can be identified in only 50% of patients with PE (369), which supports the 
concept that pulmonary thrombi may form de novo in the lungs or originate from other 
sources of emboli, such as in the right ventricle after MI (97). The formation of de novo 
thrombi in the lungs may occur secondary to left ventricular dysfunction. Abnormal flow due 
to low cardiac output, dilated cardiac chambers, and poor contractility occurs in patients 
with reduced left ventricular ejection fraction, and may cause stasis in the pulmonary 
circulation due to backward failure (171). Second, atrial fibrillation is a frequent complication 
after MI with an estimated prevalence of 5-20%, with the highest risk the first two months 
after the incident event (370, 371). Our group observed that atrial fibrillation is associated 
with an increase in the risk of VTE, particularly for PE. Of all the PE events in the general 
population, one study from the Tromsø Study suggests that 15-20% could be attributed to 
atrial fibrillation (97). This supports the theory that isolated PE in atrial fibrillation patients 
may originate from right-side intracardiac thrombi, which have been identified as the only 
source of emboli in 4% of all patients with PE (372). Third, the other components in 
Virchow’s triad may be responsible for the observed association in addition to stasis due to 
left ventricular dysfunction and atrial fibrillation. Both injury of the vascular endothelium 
(171, 373), and activation of the coagulation system during the acute phase of MI (171, 374, 
375) may increase the risk of PE. Patients with both unstable angina and acute MI exhibit 
increased coagulation activity in the acute phase, which persists long after clinical 
stabilization (374, 375).  
Considering the transient nature of VTE risk and the particularly high risk of PE 
observed in our study, it is likely to assume that direct causal mechanism(s) secondary to 
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local disturbances in the cardiopulmonary circulation or electro-mechanical activity (e.g., 
atrial fibrillation) may convey parts of the VTE risk after MI. However, the high risk of PE 
rather than DVT after MI may also partly be explained by surveillance bias, as patients with 
previous MI are more likely to undergo further examinations for chest pain.  
 
1.12.3 Ischemic stroke and risk of venous thromboembolism 
In the third paper of this thesis, we found that patients with ischemic stroke had a 
distinct increased risk of VTE compared with the general population. The incidence rate and 
relative risk were especially high during the first three months after the stroke diagnosis and 
declined rapidly thereafter. Moreover, the analysis displayed a higher risk of provoked than 
unprovoked events. Our findings are consistent with data from clinical trials of stroke 
patients, showing a high risk of VTE after stroke (273-275, 284, 376). Most data regarding 
ischemic stroke and risk of VTE are from randomized trials, and limited data exist concerning 
the association in the general population. Our findings are similar to the findings in two 
observational studies using a medical database including approximately 20% of the total 
Danish population (260) and the Danish National Patient Registry (360). In a sizeable case-
control by Sørensen et al. revealed that patients with a history of stroke had a 4.4-fold 
increased risk of VTE the first three months after the incident stroke (260). More recently, 
Corraini et al. found a 5-fold increase in the VTE rates the first three-months after the stroke, 
which remained increased compared to the general population during the follow-up period 
(360). However, both studies are registry-based studies where exposure, outcome, and 
provoking factors for VTE were based on non-validated information from hospital registries 
and the Danish National Patients Registry (260, 360).  
The explanations for the observed association between ischemic stroke and future 
risk of VTE are yet unknown but may include shared risk factors, indirect risk factors, or a 
direct relationship (229). The transient and short-term risk of VTE after ischemic stroke 
indicates that mechanism(s) or conditions related to the ischemic stroke itself partly explain 
the association. Hospitalization accompanied by periods of immobilization due to bed-rest or 
neurological deficits of affected limbs are frequent in stroke patients (272). The predilection 
for VTE in the paralyzed leg is probably explained by a combination of loss of the calf muscle 
pump and repeated minor trauma (267). Indeed, measures of stroke severity have been 
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shown to be strongly associated with the risk of VTE (273). Presumably, these patients are 
more susceptible to thrombus formation secondary to venous stasis in the affected leg (229, 
286). Medical complications, including infections, frequently occur among hospitalized 
stroke patients (282, 377-379). The risk of DVT and PE are more than two-fold increased the 
two first weeks after infection of either pneumonia or urinary tract infections (162, 164). 
Infections after stroke may either contribute to the increased VTE risk directly due to 
inflammation or via prolongation of the hospital stay, or both (132). The combination of 
immobilization and infection have a synergetic effect on the risk of VTE (160). In our study, 
stratified analyses displayed a higher risk of provoked compared with unprovoked VTE, with 
a particular preponderance of immobilization as a predisposing factor for VTE among stroke 
patients. Similarly, data from the Worcester VTE study displayed a higher frequency of 
comorbid conditions and immobilization in patients with stroke-related VTE compared to 
VTE patients without stroke (291). However, Corraini et al. showed that the risk of VTE 
within three-months after stroke remained slightly elevated even in the absence of 
prolonged immobilization (360).  
Direct causal mechanisms may explain some of the observed association. Studies 
have shown an activation of the coagulation system during the acute phase of ischemic 
stroke. The coagulation activation could also be secondary to medical conditions occurring 
after the stroke (380-383). Additionally, the sudden tissue damage after ischemic stroke may 
induce a temporary inflammation, which may induce systemic hypercoagulability (384). 
Thus, our findings suggest that transient indirect risk factors occurring in relation to ischemic 
stroke, possibly combined with enhanced activity in the coagulation system, are important 
contributors to the transient risk of VTE after ischemic stroke. 
Our risk estimates are probably an underestimation of the actual risk of VTE after 
stroke as current guidelines recommend initiation of anticoagulation within 48 hours after 
ischemic stroke with duration of treatment throughout the hospital stay or until the patient 
regains mobility (385). Unfortunately, we do not have information on the use of prophylactic 
anticoagulant treatment during the study period, but the consensus at UNN and Norwegian 
National Guidelines (386) corresponds well with international practice (385). Despite this 
potential underestimation of the VTE risk in stroke patients, we observed an absolute risk 
increase of 48.1 per 1000 patients for DVT and 32.0 per 1000 patients for PE during the first 
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month after the ischemic stroke compared to individuals in the general population. Corraini 
et al. found that 15-30% of VTE events could potentially be avoided with successful VTE 
prophylaxis in stroke patients with moderate or high comorbidity rate (360). Although some 
of the preventive effects may already be incorporated in our results, clinical trials imply that 
preventive treatment with low-molecular-weight heparin (LMWH) or unfractionated heparin 
has the potential to reduce the incidence of symptomatic DVT by 70% and the incidence of 
fatal and nonfatal PE by 30% (385). In subanalyses of the randomized controlled EXCLAIM 
trial, involving almost 400 patients with acute ischemic stroke, extended-duration 
prophylaxis with LMWH for 35-40 days was associated with a reduction in the incidence of 
VTE. However, an increase in major bleeding was reported (387). Our results support that 
VTE prophylaxis in stroke patients may be inadequate. Future studies are warranted to 
identify clinical triggers mediating the effect of stroke on VTE risk to improve the 
identification of high-risk patients. 
 
1.12.4 Effect of prothrombotic genetic variants on the risk of venous thromboembolism in 
patients with ischemic stroke  
In paper IV, we found a synergistic effect of ischemic stroke and prothrombotic 
genotypes on the risk of VTE. The combined exposure to ischemic stroke and each of the 
individual SNPs (i.e., factor V Leiden, prothrombin G20210A, or variations in FGG or F11) 
resulted in an effect on VTE risk that exceeded the sum of the separate effects. When a 
genetic risk score was applied (the 5-SNP score (311)), the number of prothrombotic risk 
alleles displayed a dose-response relationship with VTE risk in both participants with and 
without ischemic stroke. The dose-response was particularly pronounced in stroke patients. 
Stroke patients with ≥5 risk alleles were almost 12 times more likely to develop an incident 
VTE compared with stroke-free individuals with one or no risk allele. By assessing the 
interaction between ischemic stroke and the high-risk category of the genetic score, we 
found that more than 80% of the VTE events appeared to be attributable to the interaction 
between those two risk factors. 
Several mechanisms could explain the higher risk of VTE after stroke observed in 
patients with prothrombotic genotypes. As the risk of both stroke and VTE are reported to 
increase with the presence of prothrombotic genotypes (336, 388-391), shared genetic risk 
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factors may confound the estimates. A potential association between prothrombotic 
genotypes and severity of the stroke may lead to more pronounced or prolonged 
immobilization after acute stroke in these patients. However, whether the prothrombotic 
genotypes investigated in this study influence the outcome of ischemic stroke is yet unclear 
(392-394). The activation of the coagulation system in the inflammatory acute-phase after 
the ischemic stroke (380, 381) may be enhanced by the hypercoagulable state associated 
with prothrombotic genotypes. 
Our risk estimates correspond well with the findings in paper III, as there consistently 
was a higher risk of provoked VTE events in participants jointly exposed to stroke and 
prothrombotic genotypes. The high risk of provoked VTE events indicates that stroke-related 
factors are the main contributor to the development of thrombotic events. This is consistent 
with previous findings where stroke severity, infections, immobilization, and hospitalization 
are suggested as potential reasons for the increased VTE risk after stroke (260, 273, 293, 
360). Both prolonged immobilization (395, 396) and pneumonia (162) are found to increase 
the risk of VTE in carriers of prothrombotic genotypes that exceeds the sum of their separate 
effects. To the best of our knowledge, no other study has explored the joint effect of 
ischemic stroke and prothrombotic genotypes on the VTE risk.  
The international guidelines for VTE prevention are mainly based on the CLOTS trial, 
in which no information regarding the prevalence of prothrombotic genotypes in the study 
population was provided (376). Despite the recommendation of anticoagulant treatment 
with LMWH in patients with acute ischemic stroke and restricted mobility, the high incidence 
of VTE observed after stroke indicates that VTE prophylaxis in stroke patients is inadequate 
(278). Indeed, data from clinical practice have shown that less than 50% of ischemic stroke 
patients at risk of VTE receive any form of thromboprophylaxis (278, 397, 398). Additionally, 
only 6% receives prophylaxis in the outpatient settings (278). This may be due to poor 
compliance in following guidelines, or uncertainty on how to assess patients at increased risk 
of developing VTE. Several risk assessment models (RAMs) exist to assess patients with acute 
medical conditions at increased risk of VTE, including the Padua Prediction Score (399), the 
Geneva Risk Score (400) and the IMPROVE-RAM (401), which are all prospectively designed 
and externally validated (402). In all three RAMs, known thrombophilic conditions, and 
ischemic stroke (399, 400) or paralysis of the lower extremity (401) is integrated to assess 
68 
 
the risk of VTE in patients with acute medical diseases. However, the existing RAMs do not 
differentiate between the numbers of risk alleles (399-401). 
Despite that stroke have been established as a strong independent risk factor of VTE 
in previous studies (260), we found that the risk of VTE in stroke patients with one or zero 
prothrombotic risk allele was not increased as compared with participants without stroke. 
Our findings suggest that genetic risk factors play an important role in the development of 




6. Conclusions  
• We found that the formation and progression of carotid atherosclerosis, as assessed 
by TPA and IMT, was not associated with future risk of VTE in time-varying analyses. 
Our findings support previous studies reporting that atherosclerosis is not an 
intermediate for the association between arterial CVD and VTE. 
 
• MI was associated with an increased risk of VTE after adjusting for potential 
confounding factors. The risk was particularly high for PE. The risk of VTE was limited 
to the first months after the MI diagnosis. The transient risk of VTE indicates that 
indirect or direct mechanisms related to the MI event itself are primarily responsible 
for the observed association. 
 
• Ischemic stroke was associated with a transient increased risk of VTE independent of 
traditional cardiovascular risk factors. Our results displayed a higher risk of provoked 
than unprovoked events. This suggests that transient indirect risk factors, occurring 
in relation to the ischemic stroke, possibly together with enhanced activity in the 
coagulation system, are important contributors to the transient risk of VTE after 
ischemic stroke. 
 
• Prothrombotic genotypes increased the risk of VTE in stroke patients, and the risk 
increased with increasing number of risk alleles. The risk estimates were highest for 
provoked VTE events. Our findings suggest that genetic risk factors play an important 
role in the development of VTE after stroke.  
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7. Final remarks and future perspectives 
Based on previous findings in cohort studies and the findings reported in this thesis, 
the suggested association between atherosclerosis and VTE do not appear to exist. 
Nevertheless, we found that symptomatic CVD (i.e., MI and ischemic stroke) induce a 
transient increased risk of VTE. The transient risk is probably caused by temporary risk 
factors related to the MI or the stroke itself. Current guidelines recommend 
thromboprophylaxis during the period of immobilization or hospitalization (141, 385). 
However, the risk of VTE extends beyond hospital discharge (134, 360, 403).  
The high incidence of VTE after MI and ischemic stroke implies that extended 
anticoagulation may be necessary for a selection of high-risk patients based on 
comorbidities, risk factors for VTE and risk of bleeding. Several trials have shown that 
extended-duration prophylaxis reduces the risk of VTE compared with standard-duration 
treatment (142, 143, 145). However, current knowledge on risk factors and triggers of VTE in 
MI and stroke patients, particularly in the first months after the event, is scarce. To achieve a 
reduction in the risk of VTE without increasing the risk of bleeding, further studies are 
warranted to identify patients at high risk of VTE. Although there exist RAMs for VTE in 
patients with acute medical conditions, these are of limited clinical use, mainly due to the 
diversity of patients hospitalized for acute medical illness (136, 402). In existing RAMs, 
patients with ischemic stroke and known thrombophilic conditions are automatically placed 
in the high-risk category (399, 400). Thus, the RAMs are not suitable to differentiate 
between high- and low-risk patients among stroke patients with prothrombotic genotypes. 
Development of new RAMs for VTE evaluating only patients with ischemic stroke or MI may 
better identify patients with a favorable benefit-to-harm ratio for thromboprophylaxis (136, 
402).  
Our finding of a dose-dependent increased risk of VTE with increasing number of risk 
alleles suggests that genetic risk factors play an important role in the development of VTE 
after stroke. This may imply that the number of prothrombotic risk alleles could be 
considered when assessing the VTE risk in patients with ischemic stroke. A RAM for VTE 
based on clinical risk factors, biomarkers, and genetic risk factors would allow the 
implementation of more efficient thromboprophylaxis, which may reduce the incidence of 




1. Hume M. Pulmonary Embolism. Historical Aspects. Arch Surg 1963; 87: 709-714.  
2. Goodman LR. In search of venous thromboembolism: the first 2913 years. Am J 
Roentgenol 2013; 201: W576-581.  
3. Bhishagratna KKL. An English translation of the Sushruta Samhita based on original 
Sanskrit text. Published 1907. University of Toronto Gerstein Science Information 
Centre website. https://archive.org/details/englishtranslati00susruoft Accessed 
February 01, 2017. 
4. Dexter L. The chair and venous thrombosis. Trans Am Clin Climatol Assoc 1973; 84: 1-
15.  
5. Heit JA. Venous thromboembolism: disease burden, outcomes and risk factors. J 
Thromb Haemost 2005; 3: 1611-1617.  
6. Vazquez SR, Kahn SR. Advances in the diagnosis and management of postthrombotic 
syndrome. Best Pract Res Clin Haematol 2012; 25: 391-402.  
7. Heit JA. Epidemiology of venous thromboembolism. Nat Rev Cardiol 2015; 12: 464-
474.  
8. Winter MP, Schernthaner GH, Lang IM. Chronic complications of venous 
thromboembolism. J Thromb Haemost 2017; 15: 1531-1540.  
9. Wendelboe AM, McCumber M, Hylek EM, et al. Global public awareness of venous 
thromboembolism. J Thromb Haemost 2015; 13: 1365-1371.  
10. Glynn RJ, Rosner B. Comparison of risk factors for the competing risks of coronary 
heart disease, stroke, and venous thromboembolism. Am J Epidemiol 2005; 162: 975-
982.  
11. Spencer FA, Emery C, Lessard D, et al. The Worcester Venous Thromboembolism 
study: a population-based study of the clinical epidemiology of venous 
thromboembolism. J Gen Intern Med 2006; 21: 722-727.  
12. Silverstein MD, Heit JA, Mohr DN, et al. Trends in the incidence of deep vein 
thrombosis and pulmonary embolism: a 25-year population-based study. Arch Intern 
Med 1998; 158: 585-593.  
13. Tsai AW, Cushman M, Rosamond WD, et al. Cardiovascular risk factors and venous 
thromboembolism incidence: the longitudinal investigation of thromboembolism 
etiology. Arch Intern Med 2002; 162: 1182-1189.  
14. White RH. The epidemiology of venous thromboembolism. Circulation 2003; 107: I4-
8.  
15. Cushman M. Epidemiology and risk factors for venous thrombosis. Semin Hematol 
2007; 44: 62-69.  
16. Heit JA, Spencer FA, White RH. The epidemiology of venous thromboembolism. J 
Thromb Thrombolysis 2016; 41: 3-14.  
17. Cohen AT, Agnelli G, Anderson FA, et al. Venous thromboembolism (VTE) in Europe. 
The number of VTE events and associated morbidity and mortality. Thromb Haemost 
2007; 98: 756-764.  
18. Heit JA, Ashrani A, Crusan DJ, et al. Reasons for the persistent incidence of venous 
thromboembolism. Thromb Haemost 2017; 117: 390-400.  
19. Arshad N, Isaksen T, Hansen JB, et al. Time trends in incidence rates of venous 
thromboembolism in a large cohort recruited from the general population. Eur J 
Epidemiol 2017; 32: 299-305.  
72 
 
20. Naess IA, Christiansen SC, Romundstad P, et al. Incidence and mortality of venous 
thrombosis: a population-based study. J Thromb Haemost 2007; 5: 692-699.  
21. Oger E. Incidence of venous thromboembolism: a community-based study in Western 
France. EPI-GETBP Study Group. Groupe d'Etude de la Thrombose de Bretagne 
Occidentale. Thromb Haemost 2000; 83: 657-660.  
22. Rosendaal FR. Thrombosis in the young: epidemiology and risk factors. A focus on 
venous thrombosis. Thromb Haemost 1997; 78: 1-6.  
23. Engbers MJ, van Hylckama Vlieg A, Rosendaal FR. Venous thrombosis in the elderly: 
incidence, risk factors and risk groups. J Thromb Haemost 2010; 8: 2105-2112.  
24. Huang W, Goldberg RJ, Anderson FA, et al. Secular trends in occurrence of acute 
venous thromboembolism: the Worcester VTE study (1985-2009). Am J Med 2014; 
127: 829-839 e825.  
25. Delluc A, Tromeur C, Le Ven F, et al. Current incidence of venous thromboembolism 
and comparison with 1998: a community-based study in Western France. Thromb 
Haemost 2016; 116: 967-974.  
26. Wiener RS, Schwartz LM, Woloshin S. Time trends in pulmonary embolism in the 
United States: evidence of overdiagnosis. Arch Intern Med 2011; 171: 831-837.  
27. Deitelzweig SB, Johnson BH, Lin J, et al. Prevalence of clinical venous 
thromboembolism in the USA: current trends and future projections. Am J Hematol 
2011; 86: 217-220.  
28. Mannsverk J, Wilsgaard T, Mathiesen EB, et al. Trends in Modifiable Risk Factors Are 
Associated With Declining Incidence of Hospitalized and Nonhospitalized Acute 
Coronary Heart Disease in a Population. Circulation 2016; 133: 74-81.  
29. Vangen-Lonne AM, Wilsgaard T, Johnsen SH, et al. Time trends in incidence and case 
fatality of ischemic stroke: the tromso study 1977-2010. Stroke 2015; 46: 1173-1179.  
30. Schmidt M, Jacobsen JB, Lash TL, et al. 25 year trends in first time hospitalisation for 
acute myocardial infarction, subsequent short and long term mortality, and the 
prognostic impact of sex and comorbidity: a Danish nationwide cohort study. BMJ 
2012; 344: e356.  
31. Becattini C, Agnelli G. Treatment of Venous Thromboembolism With New 
Anticoagulant Agents. J Am Coll Cardiol 2016; 67: 1941-1955.  
32. Hansson PO, Sorbo J, Eriksson H. Recurrent venous thromboembolism after deep 
vein thrombosis: incidence and risk factors. Arch Intern Med 2000; 160: 769-774.  
33. Prandoni P, Lensing AW, Cogo A, et al. The long-term clinical course of acute deep 
venous thrombosis. Ann Intern Med 1996; 125: 1-7.  
34. Prandoni P, Noventa F, Ghirarduzzi A, et al. The risk of recurrent venous 
thromboembolism after discontinuing anticoagulation in patients with acute 
proximal deep vein thrombosis or pulmonary embolism. A prospective cohort study 
in 1,626 patients. Haematologica 2007; 92: 199-205.  
35. Heit JA, Mohr DN, Silverstein MD, et al. Predictors of recurrence after deep vein 
thrombosis and pulmonary embolism: a population-based cohort study. Arch Intern 
Med 2000; 160: 761-768.  
36. Huang W, Goldberg RJ, Cohen AT, et al. Declining Long-term Risk of Adverse Events 
after First-time Community-presenting Venous Thromboembolism: The Population-
based Worcester VTE Study (1999 to 2009). Thromb Res 2015; 135: 1100-1106.  
73 
 
37. Spencer FA, Gore JM, Lessard D, et al. Patient outcomes after deep vein thrombosis 
and pulmonary embolism: the Worcester Venous Thromboembolism Study. Arch 
Intern Med 2008; 168: 425-430.  
38. Zhu T, Martinez I, Emmerich J. Venous thromboembolism: risk factors for recurrence. 
Arterioscler Thromb Vasc Biol 2009; 29: 298-310.  
39. Arshad N, Bjori E, Hindberg K, et al. Recurrence and mortality after first venous 
thromboembolism in a large population-based cohort. J Thromb Haemost 2017; 15: 
295-303.  
40. Baglin T, Luddington R, Brown K, et al. Incidence of recurrent venous 
thromboembolism in relation to clinical and thrombophilic risk factors: prospective 
cohort study. Lancet 2003; 362: 523-526.  
41. Eikelboom JW, Ginsberg JS, Hirsh J. Anticoagulation for venous thromboembolism. 
BMJ 2007; 334: 645.  
42. Streiff MB. Predicting the risk of recurrent venous thromboembolism (VTE). J Thromb 
Thrombolysis 2015; 39: 353-366.  
43. Nichele I, Tosetto A. Scoring Systems for Estimating the Risk of Recurrent Venous 
Thromboembolism. Semin Thromb Hemost 2017; 43: 493-499.  
44. Kyrle PA, Minar E, Bialonczyk C, et al. The risk of recurrent venous thromboembolism 
in men and women. N Engl J Med 2004; 350: 2558-2563.  
45. Roach RE, Cannegieter SC, Lijfering WM. Differential risks in men and women for first 
and recurrent venous thrombosis: the role of genes and environment. J Thromb 
Haemost 2014; 12: 1593-1600.  
46. Verso M, Agnelli G, Ageno W, et al. Long-term death and recurrence in patients with 
acute venous thromboembolism: the MASTER registry. Thromb Res 2012; 130: 369-
373.  
47. Cannegieter SC, van Hylckama Vlieg A. Venous thrombosis: understanding the 
paradoxes of recurrence. J Thromb Haemost 2013; 11 Suppl 1: 161-169.  
48. Agnelli G, Prandoni P, Santamaria MG, et al. Three months versus one year of oral 
anticoagulant therapy for idiopathic deep venous thrombosis. Warfarin Optimal 
Duration Italian Trial Investigators. N Engl J Med 2001; 345: 165-169.  
49. Iorio A, Kearon C, Filippucci E, et al. Risk of recurrence after a first episode of 
symptomatic venous thromboembolism provoked by a transient risk factor: a 
systematic review. Arch Intern Med 2010; 170: 1710-1716.  
50. Kahn SR, Shapiro S, Wells PS, et al. Compression stockings to prevent post-
thrombotic syndrome: a randomised placebo-controlled trial. Lancet 2014; 383: 880-
888.  
51. Prandoni P, Lensing AW, Prins MH, et al. Below-knee elastic compression stockings to 
prevent the post-thrombotic syndrome: a randomized, controlled trial. Ann Intern 
Med 2004; 141: 249-256.  
52. Tick LW, Kramer MH, Rosendaal FR, et al. Risk factors for post-thrombotic syndrome 
in patients with a first deep venous thrombosis. J Thromb Haemost 2008; 6: 2075-
2081.  
53. Labropoulos N, Waggoner T, Sammis W, et al. The effect of venous thrombus location 
and extent on the development of post-thrombotic signs and symptoms. J Vasc Surg 
2008; 48: 407-412.  
74 
 
54. Braekkan SK, Grosse SD, Okoroh EM, et al. Venous thromboembolism and 
subsequent permanent work-related disability. J Thromb Haemost 2016; 14: 1978-
1987.  
55. Kearon C, Akl EA, Ornelas J, et al. Antithrombotic Therapy for VTE Disease: CHEST 
Guideline and Expert Panel Report. Chest 2016; 149: 315-352.  
56. Piazza G, Goldhaber SZ. Chronic thromboembolic pulmonary hypertension. N Engl J 
Med 2011; 364: 351-360.  
57. Lang IM, Madani M. Update on chronic thromboembolic pulmonary hypertension. 
Circulation 2014; 130: 508-518.  
58. Fitzmaurice DA, Murray E. Thromboprophylaxis for adults in hospital. BMJ 2007; 334: 
1017-1018.  
59. Anderson FA, Jr., Wheeler HB, Goldberg RJ, et al. A population-based perspective of 
the hospital incidence and case-fatality rates of deep vein thrombosis and pulmonary 
embolism. The Worcester DVT Study. Arch Intern Med 1991; 151: 933-938.  
60. Prandoni P, Villalta S, Bagatella P, et al. The clinical course of deep-vein thrombosis. 
Prospective long-term follow-up of 528 symptomatic patients. Haematologica 1997; 
82: 423-428.  
61. Sorensen HT, Mellemkjaer L, Olsen JH, et al. Prognosis of cancers associated with 
venous thromboembolism. N Engl J Med 2000; 343: 1846-1850.  
62. Roe MT, Messenger JC, Weintraub WS, et al. Treatments, trends, and outcomes of 
acute myocardial infarction and percutaneous coronary intervention. J Am Coll 
Cardiol 2010; 56: 254-263.  
63. Montalescot G, Dallongeville J, Van Belle E, et al. STEMI and NSTEMI: are they so 
different? 1 year outcomes in acute myocardial infarction as defined by the ESC/ACC 
definition (the OPERA registry). Eur Heart J 2007; 28: 1409-1417.  
64. Heit JA, Silverstein MD, Mohr DN, et al. Predictors of survival after deep vein 
thrombosis and pulmonary embolism: a population-based, cohort study. Arch Intern 
Med 1999; 159: 445-453.  
65. Goldhaber SZ, Visani L, De Rosa M. Acute pulmonary embolism: clinical outcomes in 
the International Cooperative Pulmonary Embolism Registry (ICOPER). Lancet 1999; 
353: 1386-1389.  
66. Wolberg AS, Rosendaal FR, Weitz JI, et al. Venous thrombosis. Nat Rev Dis Primers 
2015; 1: 15006.  
67. Furie B, Furie BC. Mechanisms of thrombus formation. N Engl J Med 2008; 359: 938-
949.  
68. Mackman N, Tilley RE, Key NS. Role of the extrinsic pathway of blood coagulation in 
hemostasis and thrombosis. Arterioscler Thromb Vasc Biol 2007; 27: 1687-1693.  
69. Mackman N. Triggers, targets and treatments for thrombosis. Nature 2008; 451: 914-
918.  
70. Mackman N. New insights into the mechanisms of venous thrombosis. J Clin Invest 
2012; 122: 2331-2336.  
71. Renne T, Pozgajova M, Gruner S, et al. Defective thrombus formation in mice lacking 
coagulation factor XII. J Exp Med 2005; 202: 271-281.  
72. Kenne E, Renne T. Factor XII: a drug target for safe interference with thrombosis and 
inflammation. Drug Discov Today 2014; 19: 1459-1464.  
73. Wakefield TW, Myers DD, Henke PK. Mechanisms of venous thrombosis and 
resolution. Arterioscler Thromb Vasc Biol 2008; 28: 387-391.  
75 
 
74. Lippi G, Franchini M, Targher G. Arterial thrombus formation in cardiovascular 
disease. Nat Rev Cardiol 2011; 8: 502-512.  
75. Esmon CT, Esmon NL. The link between vascular features and thrombosis. Annu Rev 
Physiol 2011; 73: 503-514.  
76. Esmon CT. Basic mechanisms and pathogenesis of venous thrombosis. Blood Rev 
2009; 23: 225-229.  
77. Virchow R. Gesammelte abhandlungen zur wissenschaftlichen medicin: Meidinger; 
1856. 
78. Sevitt S. The structure and growth of valve-pocket thrombi in femoral veins. J Clin 
Pathol 1974; 27: 517-528.  
79. Bovill EG, van der Vliet A. Venous valvular stasis-associated hypoxia and thrombosis: 
what is the link? Annu Rev Physiol 2011; 73: 527-545.  
80. Kearon C. Natural history of venous thromboembolism. Circulation 2003; 107: I22-30.  
81. Hamer JD, Malone PC, Silver IA. The PO2 in venous valve pockets: its possible bearing 
on thrombogenesis. Br J Surg 1981; 68: 166-170.  
82. Zhou J, May L, Liao P, et al. Inferior vena cava ligation rapidly induces tissue factor 
expression and venous thrombosis in rats. Arterioscler Thromb Vasc Biol 2009; 29: 
863-869.  
83. Michiels C, Arnould T, Remacle J. Endothelial cell responses to hypoxia: initiation of a 
cascade of cellular interactions. Biochim Biophys Acta 2000; 1497: 1-10.  
84. Geddings JE, Mackman N. New players in haemostasis and thrombosis. Thromb 
Haemost 2014; 111: 570-574.  
85. Liu GC, Ferris EJ, Reifsteck JR, et al. Effect of anatomic variations on deep venous 
thrombosis of the lower extremity. AJR Am J Roentgenol 1986; 146: 845-848.  
86. McLachlin AD, McLachlin JA, Jory TA, et al. Venous stasis in the lower extremities. 
Ann Surg 1960; 152: 678-685.  
87. Kearon C, Ageno W, Cannegieter SC, et al. Categorization of patients as having 
provoked or unprovoked venous thromboembolism: guidance from the SSC of ISTH. J 
Thromb Haemost 2016; 14: 1480-1483.  
88. Allen GA, Wolberg AS, Oliver JA, et al. Impact of procoagulant concentration on rate, 
peak and total thrombin generation in a model system. J Thromb Haemost 2004; 2: 
402-413.  
89. Tripodi A, Martinelli I, Chantarangkul V, et al. The endogenous thrombin potential 
and the risk of venous thromboembolism. Thromb Res 2007; 121: 353-359.  
90. Rosendaal FR. Venous thrombosis: a multicausal disease. Lancet 1999; 353: 1167-
1173.  
91. Polgar J, Matuskova J, Wagner DD. The P-selectin, tissue factor, coagulation triad. J 
Thromb Haemost 2005; 3: 1590-1596.  
92. Tesselaar ME, Romijn FP, Van Der Linden IK, et al. Microparticle-associated tissue 
factor activity: a link between cancer and thrombosis? J Thromb Haemost 2007; 5: 
520-527.  
93. van Langevelde K, Sramek A, Vincken PW, et al. Finding the origin of pulmonary 
emboli with a total-body magnetic resonance direct thrombus imaging technique. 
Haematologica 2013; 98: 309-315.  
94. Yamaki T, Nozaki M, Sakurai H, et al. Presence of lower limb deep vein thrombosis 
and prognosis in patients with symptomatic pulmonary embolism: preliminary 
report. Eur J Vasc Endovasc Surg 2009; 37: 225-231.  
76 
 
95. Girard P, Sanchez O, Leroyer C, et al. Deep venous thrombosis in patients with acute 
pulmonary embolism: prevalence, risk factors, and clinical significance. Chest 2005; 
128: 1593-1600.  
96. Jimenez D, Aujesky D, Diaz G, et al. Prognostic significance of deep vein thrombosis in 
patients presenting with acute symptomatic pulmonary embolism. Am J Respir Crit 
Care Med 2010; 181: 983-991.  
97. Enga KF, Rye-Holmboe I, Hald EM, et al. Atrial fibrillation and future risk of venous 
thromboembolism:the Tromso study. J Thromb Haemost 2015; 13: 10-16.  
98. DeGeorgia MA, Chimowitz MI, Hepner A, et al. Right atrial spontaneous contrast: 
echocardiographic and clinical features. Int J Card Imaging 1994; 10: 227-232.  
99. Aberg H. Atrial fibrillation. I. A study of atrial thrombosis and systemic embolism in a 
necropsy material. Acta Med Scand 1969; 185: 373-379.  
100. Bikdeli B, Abou Ziki MD, Lip GYH. Pulmonary Embolism and Atrial Fibrillation: Two 
Sides of the Same Coin? A Systematic Review. Semin Thromb Hemost 2017; 43: 849-
863.  
101. Lutsey PL, Norby FL, Alonso A, et al. Atrial fibrillation and venous thromboembolism: 
evidence of bidirectionality in the Atherosclerosis Risk in Communities Study. Journal 
of Thrombosis and Haemostasis 2018; 16: 670-679.  
102. Barra SN, Paiva LV, Providencia R, et al. Atrial fibrillation in acute pulmonary 
embolism: prognostic considerations. Emerg Med J 2014; 31: 308-312.  
103. Heit JA, O'Fallon WM, Petterson TM, et al. Relative impact of risk factors for deep 
vein thrombosis and pulmonary embolism: a population-based study. Arch Intern 
Med 2002; 162: 1245-1248.  
104. Farren-Dai L, Carrier M, Kovacs J, et al. Association between remote major venous 
thromboembolism risk factors and the risk of recurrence after a first unprovoked 
episode. J Thromb Haemost 2017; 15: 1977-1980.  
105. Blix K, Braekkan SK, le Cessie S, et al. The increased risk of venous thromboembolism 
by advancing age cannot be attributed to the higher incidence of cancer in the 
elderly: the Tromso study. Eur J Epidemiol 2014; 29: 277-284.  
106. Horvei LD, Braekkan SK, Mathiesen EB, et al. Obesity measures and risk of venous 
thromboembolism and myocardial infarction. Eur J Epidemiol 2014; 29: 821-830.  
107. Hansson PO, Eriksson H, Welin L, et al. Smoking and abdominal obesity: risk factors 
for venous thromboembolism among middle-aged men: "the study of men born in 
1913". Arch Intern Med 1999; 159: 1886-1890.  
108. Severinsen MT, Kristensen SR, Johnsen SP, et al. Anthropometry, body fat, and 
venous thromboembolism: a Danish follow-up study. Circulation 2009; 120: 1850-
1857.  
109. Borch KH, Braekkan SK, Mathiesen EB, et al. Abdominal obesity is essential for the 
risk of venous thromboembolism in the metabolic syndrome: the Tromso study. J 
Thromb Haemost 2009; 7: 739-745.  
110. Holst AG, Jensen G, Prescott E. Risk factors for venous thromboembolism: results 
from the Copenhagen City Heart Study. Circulation 2010; 121: 1896-1903.  
111. Horvei LD, Braekkan SK, Hansen JB. Weight Change and Risk of Venous 
Thromboembolism: The Tromso Study. PLoS One 2016; 11: e0168878.  
112. Lindstrom S, Germain M, Crous-Bou M, et al. Assessing the causal relationship 
between obesity and venous thromboembolism through a Mendelian Randomization 
study. Hum Genet 2017; 136: 897-902.  
77 
 
113. Klovaite J, Benn M, Nordestgaard BG. Obesity as a causal risk factor for deep venous 
thrombosis: a Mendelian randomization study. J Intern Med 2015; 277: 573-584.  
114. Gregor MF, Hotamisligil GS. Inflammatory mechanisms in obesity. Annu Rev Immunol 
2011; 29: 415-445.  
115. Braekkan SK, Siegerink B, Lijfering WM, et al. Role of obesity in the etiology of deep 
vein thrombosis and pulmonary embolism: current epidemiological insights. Semin 
Thromb Hemost 2013; 39: 533-540.  
116. Grimnes G, Horvei LD, Tichelaar V, et al. Neutrophil to lymphocyte ratio and future 
risk of venous thromboembolism and mortality: the Tromso Study. Haematologica 
2016; 101: e401-e404.  
117. Quist-Paulsen P, Naess IA, Cannegieter SC, et al. Arterial cardiovascular risk factors 
and venous thrombosis: results from a population-based, prospective study (the 
HUNT 2). Haematologica 2010; 95: 119-125.  
118. Hald EM, Braekkan SK, Mathiesen EB, et al. High-sensitivity C-reactive protein is not a 
risk factor for venous thromboembolism: the Tromso study. Haematologica 2011; 96: 
1189-1194.  
119. Willenberg T, Schumacher A, Amann-Vesti B, et al. Impact of obesity on venous 
hemodynamics of the lower limbs. J Vasc Surg 2010; 52: 664-668.  
120. Willenberg T, Clemens R, Haegeli LM, et al. The influence of abdominal pressure on 
lower extremity venous pressure and hemodynamics: a human in-vivo model 
simulating the effect of abdominal obesity. Eur J Vasc Endovasc Surg 2011; 41: 849-
855.  
121. Pottier P, Hardouin JB, Lejeune S, et al. Immobilization and the risk of venous 
thromboembolism. A meta-analysis on epidemiological studies. Thromb Res 2009; 
124: 468-476.  
122. Weill-Engerer S, Meaume S, Lahlou A, et al. Risk factors for deep vein thrombosis in 
inpatients aged 65 and older: a case-control multicenter study. J Am Geriatr Soc 
2004; 52: 1299-1304.  
123. Gaber TA. Significant reduction of the risk of venous thromboembolism in all long-
term immobile patients a few months after the onset of immobility. Med Hypotheses 
2005; 64: 1173-1176.  
124. van Stralen KJ, Rosendaal FR, Doggen CJ. Minor injuries as a risk factor for venous 
thrombosis. Arch Intern Med 2008; 168: 21-26.  
125. Lapostolle F, Surget V, Borron SW, et al. Severe pulmonary embolism associated with 
air travel. N Engl J Med 2001; 345: 779-783.  
126. Toglia MR, Weg JG. Venous thromboembolism during pregnancy. N Engl J Med 1996; 
335: 108-114.  
127. Heit JA, Kobbervig CE, James AH, et al. Trends in the incidence of venous 
thromboembolism during pregnancy or postpartum: a 30-year population-based 
study. Ann Intern Med 2005; 143: 697-706.  
128. James AH. Pregnancy and thrombotic risk. Crit Care Med 2010; 38: S57-63.  
129. Chunilal SD, Bates SM. Venous thromboembolism in pregnancy: diagnosis, 
management and prevention. Thromb Haemost 2009; 101: 428-438.  
130. United Nations. Department of Economic and Social Affairs. World contraceptive 
patterns 2013., 2013. 
78 
 
131. Stegeman BH, de Bastos M, Rosendaal FR, et al. Different combined oral 
contraceptives and the risk of venous thrombosis: systematic review and network 
meta-analysis. BMJ 2013; 347: f5298.  
132. Heit JA, Silverstein MD, Mohr DN, et al. Risk factors for deep vein thrombosis and 
pulmonary embolism: a population-based case-control study. Arch Intern Med 2000; 
160: 809-815.  
133. Francis CW. Clinical practice. Prophylaxis for thromboembolism in hospitalized 
medical patients. N Engl J Med 2007; 356: 1438-1444.  
134. Heit JA, Crusan DJ, Ashrani AA, et al. Effect of a near-universal hospitalization-based 
prophylaxis regimen on annual number of venous thromboembolism events in the 
US. Blood 2017; 130: 109-114.  
135. Heit JA, Melton LJ, 3rd, Lohse CM, et al. Incidence of venous thromboembolism in 
hospitalized patients vs community residents. Mayo Clin Proc 2001; 76: 1102-1110.  
136. Greene MT, Spyropoulos AC, Chopra V, et al. Validation of Risk Assessment Models of 
Venous Thromboembolism in Hospitalized Medical Patients. Am J Med 2016; 129: 
1001 e1009-1001 e1018.  
137. Harrington R, Gold A, Daaboul Y, et al. The IMPROVEDD VTE Risk Score: Incorporation 
of D-Dimer into the IMPROVE Score to Improve Venous Thromboembolism Risk 
Stratification. TH Open 2017; 01: e56-e65.  
138. Anderson FA, Jr., Zayaruzny M, Heit JA, et al. Estimated annual numbers of US acute-
care hospital patients at risk for venous thromboembolism. Am J Hematol 2007; 82: 
777-782.  
139. Baglin TP, White K, Charles A. Fatal pulmonary embolism in hospitalised medical 
patients. J Clin Pathol 1997; 50: 609-610.  
140. Cohen AT, Tapson VF, Bergmann JF, et al. Venous thromboembolism risk and 
prophylaxis in the acute hospital care setting (ENDORSE study): a multinational cross-
sectional study. Lancet 2008; 371: 387-394.  
141. Kahn SR, Lim W, Dunn AS, et al. Prevention of VTE in nonsurgical patients: 
Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of 
Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012; 141: e195S-
e226S.  
142. Hull RD, Schellong SM, Tapson VF, et al. Extended-duration venous 
thromboembolism prophylaxis in acutely ill medical patients with recently reduced 
mobility: a randomized trial. Ann Intern Med 2010; 153: 8-18.  
143. Cohen AT, Spiro TE, Buller HR, et al. Rivaroxaban for thromboprophylaxis in acutely ill 
medical patients. N Engl J Med 2013; 368: 513-523.  
144. Goldhaber SZ, Leizorovicz A, Kakkar AK, et al. Apixaban versus enoxaparin for 
thromboprophylaxis in medically ill patients. N Engl J Med 2011; 365: 2167-2177.  
145. Cohen AT, Harrington RA, Goldhaber SZ, et al. Extended Thromboprophylaxis with 
Betrixaban in Acutely Ill Medical Patients. N Engl J Med 2016; 375: 534-544.  
146. Chi G, Goldhaber SZ, Kittelson JM, et al. Effect of extended-duration 
thromboprophylaxis on venous thromboembolism and major bleeding among 
acutely ill hospitalized medical patients: a bivariate analysis. J Thromb Haemost 2017; 
15: 1913-1922.  
147. Spyropoulos AC, Ageno W, Albers GW, et al. Rivaroxaban for Thromboprophylaxis 
after Hospitalization for Medical Illness. N Engl J Med 2018; 0: null.  
79 
 
148. Geerts WH, Bergqvist D, Pineo GF, et al. Prevention of venous thromboembolism: 
American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th 
Edition). Chest 2008; 133: 381S-453S.  
149. Geerts WH, Pineo GF, Heit JA, et al. Prevention of venous thromboembolism: the 
Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 2004; 
126: 338S-400S.  
150. Sweetland S, Green J, Liu B, et al. Duration and magnitude of the postoperative risk 
of venous thromboembolism in middle aged women: prospective cohort study. BMJ 
2009; 339: b4583.  
151. Alikhan R, Peters F, Wilmott R, et al. Fatal pulmonary embolism in hospitalised 
patients: a necropsy review. J Clin Pathol 2004; 57: 1254-1257.  
152. Khouli H, Shapiro J, Pham VP, et al. Efficacy of deep venous thrombosis prophylaxis in 
the medical intensive care unit. J Intensive Care Med 2006; 21: 352-358.  
153. Blom JW, Doggen CJ, Osanto S, et al. Malignancies, prothrombotic mutations, and the 
risk of venous thrombosis. JAMA 2005; 293: 715-722.  
154. Trousseau A. Phlegmasia Alba Dolens; Clinique Médicale de l'Hôtel-Dieude Paris Vol 
3. Paris: J. B. Balliére et fils.  1865.  
155. Lyman GH. Venous thromboembolism in the patient with cancer: focus on burden of 
disease and benefits of thromboprophylaxis. Cancer 2011; 117: 1334-1349.  
156. Ay C, Pabinger I, Cohen AT. Cancer-associated venous thromboembolism: Burden, 
mechanisms, and management. Thromb Haemost 2017; 117: 219-230.  
157. Horsted F, West J, Grainge MJ. Risk of venous thromboembolism in patients with 
cancer: a systematic review and meta-analysis. PLoS Med 2012; 9: e1001275.  
158. Timp JF, Braekkan SK, Versteeg HH, et al. Epidemiology of cancer-associated venous 
thrombosis. Blood 2013; 122: 1712-1723.  
159. Cohoon KP, Ashrani AA, Crusan DJ, et al. Is Infection an Independent Risk Factor for 
Venous Thromboembolism? A Population-Based, Case-Control Study. Am J Med 
2017.  
160. Grimnes G, Isaksen T, Tichelaar YIGV, et al. Acute infection as a trigger for incident 
venous thromboembolism: Results from a population-based case-crossover study. 
Research and Practice in Thrombosis and Haemostasis 2018; 2: 85-92.  
161. Tichelaar YI, Kluin-Nelemans HJ, Meijer K. Infections and inflammatory diseases as 
risk factors for venous thrombosis. A systematic review. Thromb Haemost 2012; 107: 
827-837.  
162. Ribeiro DD, Lijfering WM, Van Hylckama Vlieg A, et al. Pneumonia and risk of venous 
thrombosis: results from the MEGA study. J Thromb Haemost 2012; 10: 1179-1182.  
163. Gangireddy C, Rectenwald JR, Upchurch GR, et al. Risk factors and clinical impact of 
postoperative symptomatic venous thromboembolism. J Vasc Surg 2007; 45: 335-
341; discussion 341-332.  
164. Smeeth L, Cook C, Thomas S, et al. Risk of deep vein thrombosis and pulmonary 
embolism after acute infection in a community setting. Lancet 2006; 367: 1075-1079.  
165. Wattanakit K, Cushman M, Stehman-Breen C, et al. Chronic kidney disease increases 
risk for venous thromboembolism. J Am Soc Nephrol 2008; 19: 135-140.  
166. Kumar G, Sakhuja A, Taneja A, et al. Pulmonary embolism in patients with CKD and 
ESRD. Clin J Am Soc Nephrol 2012; 7: 1584-1590.  
167. Tveit DP, Hypolite IO, Hshieh P, et al. Chronic dialysis patients have high risk for 
pulmonary embolism. Am J Kidney Dis 2002; 39: 1011-1017.  
80 
 
168. Fraisse F, Holzapfel L, Couland JM, et al. Nadroparin in the prevention of deep vein 
thrombosis in acute decompensated COPD. The Association of Non-University 
Affiliated Intensive Care Specialist Physicians of France. Am J Respir Crit Care Med 
2000; 161: 1109-1114.  
169. Borvik T, Braekkan SK, Enga K, et al. COPD and risk of venous thromboembolism and 
mortality in a general population. Eur Respir J 2016; 47: 473-481.  
170. Beemath A, Stein PD, Skaf E, et al. Risk of venous thromboembolism in patients 
hospitalized with heart failure. Am J Cardiol 2006; 98: 793-795.  
171. Lip GY, Gibbs CR. Does heart failure confer a hypercoagulable state? Virchow's triad 
revisited. J Am Coll Cardiol 1999; 33: 1424-1426.  
172. Heit JA, Phelps MA, Ward SA, et al. Familial segregation of venous thromboembolism. 
J Thromb Haemost 2004; 2: 731-736.  
173. Souto JC, Almasy L, Borrell M, et al. Genetic susceptibility to thrombosis and its 
relationship to physiological risk factors: the GAIT study. Genetic Analysis of 
Idiopathic Thrombophilia. Am J Hum Genet 2000; 67: 1452-1459.  
174. Vossen CY, Conard J, Fontcuberta J, et al. Risk of a first venous thrombotic event in 
carriers of a familial thrombophilic defect. The European Prospective Cohort on 
Thrombophilia (EPCOT). J Thromb Haemost 2005; 3: 459-464.  
175. Vossen CY, Conard J, Fontcuberta J, et al. Familial thrombophilia and lifetime risk of 
venous thrombosis. J Thromb Haemost 2004; 2: 1526-1532.  
176. Larsen TB, Sorensen HT, Skytthe A, et al. Major genetic susceptibility for venous 
thromboembolism in men: a study of Danish twins. Epidemiology 2003; 14: 328-332.  
177. Martin-Fernandez L, Ziyatdinov A, Carrasco M, et al. Genetic Determinants of 
Thrombin Generation and Their Relation to Venous Thrombosis: Results from the 
GAIT-2 Project. PLoS One 2016; 11: e0146922.  
178. Crous-Bou M, Harrington LB, Kabrhel C. Environmental and Genetic Risk Factors 
Associated with Venous Thromboembolism. Semin Thromb Hemost 2016; 42: 808-
820.  
179. Rosendaal FR, Reitsma PH. Genetics of venous thrombosis. J Thromb Haemost 2009; 
7 Suppl 1: 301-304.  
180. Tregouet DA, Morange PE. What is currently known about the genetics of venous 
thromboembolism at the dawn of next generation sequencing technologies. Br J 
Haematol 2017: n/a-n/a.  
181. Martinelli I, De Stefano V, Mannucci PM. Inherited risk factors for venous 
thromboembolism. Nat Rev Cardiol 2014; 11: 140-156.  
182. Egeberg O. Inherited Antithrombin Deficiency Causing Thrombophilia. Thromb Diath 
Haemorrh 1965; 13: 516-530.  
183. Seligsohn U, Lubetsky A. Genetic susceptibility to venous thrombosis. N Engl J Med 
2001; 344: 1222-1231.  
184. Morange PE, Tregouet DA. Current knowledge on the genetics of incident venous 
thrombosis. J Thromb Haemost 2013; 11 Suppl 1: 111-121.  
185. Griffin JH, Evatt B, Zimmerman TS, et al. Deficiency of protein C in congenital 
thrombotic disease. J Clin Invest 1981; 68: 1370-1373.  
186. Comp PC, Esmon CT. Recurrent venous thromboembolism in patients with a partial 
deficiency of protein S. N Engl J Med 1984; 311: 1525-1528.  
187. Esmon CT. The protein C pathway. Chest 2003; 124: 26S-32S.  
81 
 
188. Koster T, Rosendaal FR, Briet E, et al. Protein C deficiency in a controlled series of 
unselected outpatients: an infrequent but clear risk factor for venous thrombosis 
(Leiden Thrombophilia Study). Blood 1995; 85: 2756-2761.  
189. Martinelli I, Mannucci PM, De Stefano V, et al. Different risks of thrombosis in four 
coagulation defects associated with inherited thrombophilia: a study of 150 families. 
Blood 1998; 92: 2353-2358.  
190. Morange PE, Tregouet DA. Lessons from genome-wide association studies in venous 
thrombosis. J Thromb Haemost 2011; 9 Suppl 1: 258-264.  
191. Dentali F, Sironi AP, Ageno W, et al. Non-O blood type is the commonest genetic risk 
factor for VTE: results from a meta-analysis of the literature. Semin Thromb Hemost 
2012; 38: 535-548.  
192. Vasan SK, Rostgaard K, Majeed A, et al. ABO Blood Group and Risk of 
Thromboembolic and Arterial Disease: A Study of 1.5 Million Blood Donors. 
Circulation 2016; 133: 1449-1457; discussion 1457.  
193. Sode BF, Allin KH, Dahl M, et al. Risk of venous thromboembolism and myocardial 
infarction associated with factor V Leiden and prothrombin mutations and blood 
type. CMAJ 2013; 185: E229-237.  
194. Wu O, Bayoumi N, Vickers MA, et al. ABO(H) blood groups and vascular disease: a 
systematic review and meta-analysis. J Thromb Haemost 2008; 6: 62-69.  
195. Ohira T, Cushman M, Tsai MY, et al. ABO blood group, other risk factors and 
incidence of venous thromboembolism: the Longitudinal Investigation of 
Thromboembolism Etiology (LITE). J Thromb Haemost 2007; 5: 1455-1461.  
196. Dahlback B, Carlsson M, Svensson PJ. Familial thrombophilia due to a previously 
unrecognized mechanism characterized by poor anticoagulant response to activated 
protein C: prediction of a cofactor to activated protein C. Proc Natl Acad Sci U S A 
1993; 90: 1004-1008.  
197. Bertina RM, Koeleman BP, Koster T, et al. Mutation in blood coagulation factor V 
associated with resistance to activated protein C. Nature 1994; 369: 64-67.  
198. Kujovich JL. Factor V Leiden thrombophilia. Genet Med 2011; 13: 1-16.  
199. Emmerich J, Rosendaal FR, Cattaneo M, et al. Combined effect of factor V Leiden and 
prothrombin 20210A on the risk of venous thromboembolism--pooled analysis of 8 
case-control studies including 2310 cases and 3204 controls. Study Group for Pooled-
Analysis in Venous Thromboembolism. Thromb Haemost 2001; 86: 809-816.  
200. Heit JA, Sobell JL, Li H, et al. The incidence of venous thromboembolism among 
Factor V Leiden carriers: a community-based cohort study. J Thromb Haemost 2005; 
3: 305-311.  
201. Ridker PM, Hennekens CH, Lindpaintner K, et al. Mutation in the gene coding for 
coagulation factor V and the risk of myocardial infarction, stroke, and venous 
thrombosis in apparently healthy men. N Engl J Med 1995; 332: 912-917.  
202. Bezemer ID, Bare LA, Doggen CJ, et al. Gene variants associated with deep vein 
thrombosis. JAMA 2008; 299: 1306-1314.  
203. Poort SR, Rosendaal FR, Reitsma PH, et al. A common genetic variation in the 3'-
untranslated region of the prothrombin gene is associated with elevated plasma 




204. Margaglione M, Brancaccio V, Giuliani N, et al. Increased risk for venous thrombosis 
in carriers of the prothrombin G-->A20210 gene variant. Ann Intern Med 1998; 129: 
89-93.  
205. Uitte de Willige S, de Visser MC, Houwing-Duistermaat JJ, et al. Genetic variation in 
the fibrinogen gamma gene increases the risk for deep venous thrombosis by 
reducing plasma fibrinogen gamma' levels. Blood 2005; 106: 4176-4183.  
206. Morange PE, Suchon P, Tregouet DA. Genetics of Venous Thrombosis: update in 
2015. Thromb Haemost 2015; 114: 910-919.  
207. Hirschhorn JN, Daly MJ. Genome-wide association studies for common diseases and 
complex traits. Nat Rev Genet 2005; 6: 95-108.  
208. Meijers JC, Tekelenburg WL, Bouma BN, et al. High levels of coagulation factor XI as a 
risk factor for venous thrombosis. N Engl J Med 2000; 342: 696-701.  
209. Smith NL, Wiggins KL, Reiner AP, et al. Replication of findings on the association of 
genetic variation in 24 hemostasis genes and risk of incident venous thrombosis. J 
Thromb Haemost 2009; 7: 1743-1746.  
210. Tang W, Teichert M, Chasman DI, et al. A genome-wide association study for venous 
thromboembolism: the extended cohorts for heart and aging research in genomic 
epidemiology (CHARGE) consortium. Genet Epidemiol 2013; 37: 512-521.  
211. Germain M, Chasman DI, de Haan H, et al. Meta-analysis of 65,734 individuals 
identifies TSPAN15 and SLC44A2 as two susceptibility loci for venous 
thromboembolism. Am J Hum Genet 2015; 96: 532-542.  
212. Ross R. Atherosclerosis--an inflammatory disease. N Engl J Med 1999; 340: 115-126.  
213. Ross R. The pathogenesis of atherosclerosis: a perspective for the 1990s. Nature 
1993; 362: 801-809.  
214. Gerrity RG. The role of the monocyte in atherogenesis: II. Migration of foam cells 
from atherosclerotic lesions. Am J Pathol 1981; 103: 191-200.  
215. Libby P. Inflammation in atherosclerosis. Nature 2002; 420: 868-874.  
216. Libby P. Inflammation and Atherosclerosis. Circulation 2002; 105: 1135-1143.  
217. Kumar V, Abbas AK, Aster JC. Robbins Basic Pathology, Ninth Edition ed: Elsevier 
Saunders; 2013. 
218. Hansson GK. Inflammation, atherosclerosis, and coronary artery disease. N Engl J 
Med 2005; 352: 1685-1695.  
219. Davies MJ. Stability and instability: two faces of coronary atherosclerosis. The Paul 
Dudley White Lecture 1995. Circulation 1996; 94: 2013-2020.  
220. Libby P. Current concepts of the pathogenesis of the acute coronary syndromes. 
Circulation 2001; 104: 365-372.  
221. Anderson JL, Morrow DA. Acute Myocardial Infarction. N Engl J Med 2017; 376: 2053-
2064.  
222. Almdal T, Scharling H, Jensen JS, et al. The independent effect of type 2 diabetes 
mellitus on ischemic heart disease, stroke, and death: a population-based study of 
13,000 men and women with 20 years of follow-up. Arch Intern Med 2004; 164: 
1422-1426.  
223. Alexander RW. Theodore Cooper Memorial Lecture. Hypertension and the 
pathogenesis of atherosclerosis. Oxidative stress and the mediation of arterial 
inflammatory response: a new perspective. Hypertension 1995; 25: 155-161.  
224. LaRosa JC, Hunninghake D, Bush D, et al. The cholesterol facts. A summary of the 
evidence relating dietary fats, serum cholesterol, and coronary heart disease. A joint 
83 
 
statement by the American Heart Association and the National Heart, Lung, and 
Blood Institute. The Task Force on Cholesterol Issues, American Heart Association. 
Circulation 1990; 81: 1721-1733.  
225. Wilson PWF, D'Agostino RB, Levy D, et al. Prediction of coronary heart disease using 
risk factor categories. Circulation 1998; 97: 1837-1847.  
226. de Lorgeril M, Salen P, Martin JL, et al. Mediterranean diet, traditional risk factors, 
and the rate of cardiovascular complications after myocardial infarction: final report 
of the Lyon Diet Heart Study. Circulation 1999; 99: 779-785.  
227. Must A, Spadano J, Coakley EH, et al. The disease burden associated with overweight 
and obesity. JAMA 1999; 282: 1523-1529.  
228. Anand SS, Islam S, Rosengren A, et al. Risk factors for myocardial infarction in women 
and men: insights from the INTERHEART study. Eur Heart J 2008; 29: 932-940.  
229. Lijfering WM, Flinterman LE, Vandenbroucke JP, et al. Relationship between venous 
and arterial thrombosis: a review of the literature from a causal perspective. Semin 
Thromb Hemost 2011; 37: 885-896.  
230. Prandoni P, Bilora F, Marchiori A, et al. An association between atherosclerosis and 
venous thrombosis. N Engl J Med 2003; 348: 1435-1441.  
231. Warren GW, Alberg AJ, Kraft AS, et al. The 2014 Surgeon General's report: "The 
health consequences of smoking--50 years of progress": a paradigm shift in cancer 
care. Cancer 2014; 120: 1914-1916.  
232. Cheng YJ, Liu ZH, Yao FJ, et al. Current and former smoking and risk for venous 
thromboembolism: a systematic review and meta-analysis. PLoS Med 2013; 10: 
e1001515.  
233. Enga KF, Braekkan SK, Hansen-Krone IJ, et al. Cigarette smoking and the risk of 
venous thromboembolism: the Tromso Study. J Thromb Haemost 2012; 10: 2068-
2074.  
234. Lutsey PL, Virnig BA, Durham SB, et al. Correlates and consequences of venous 
thromboembolism: The Iowa Women's Health Study. Am J Public Health 2010; 100: 
1506-1513.  
235. Mahmoodi BK, Cushman M, Anne Naess I, et al. Association of Traditional 
Cardiovascular Risk Factors With Venous Thromboembolism: An Individual 
Participant Data Meta-Analysis of Prospective Studies. Circulation 2017; 135: 7-16.  
236. Ageno W, Becattini C, Brighton T, et al. Cardiovascular risk factors and venous 
thromboembolism: a meta-analysis. Circulation 2008; 117: 93-102.  
237. Wattanakit K, Lutsey PL, Bell EJ, et al. Association between cardiovascular disease risk 
factors and occurrence of venous thromboembolism. A time-dependent analysis. 
Thromb Haemost 2012; 108: 508-515.  
238. Bai J, Ding X, Du X, et al. Diabetes is associated with increased risk of venous 
thromboembolism: a systematic review and meta-analysis. Thromb Res 2015; 135: 
90-95.  
239. Heit JA, Leibson CL, Ashrani AA, et al. Is diabetes mellitus an independent risk factor 
for venous thromboembolism?: a population-based case-control study. Arterioscler 
Thromb Vasc Biol 2009; 29: 1399-1405.  
240. Lerstad G, Brodin EE, Enga KF, et al. Hyperglycemia, assessed according to HbA1c , 
and future risk of venous thromboembolism: the Tromso study. J Thromb Haemost 
2014; 12: 313-319.  
84 
 
241. Armstrong ME, Green J, Reeves GK, et al. Frequent physical activity may not reduce 
vascular disease risk as much as moderate activity: large prospective study of women 
in the United Kingdom. Circulation 2015; 131: 721-729.  
242. Evensen LH, Isaksen T, Hindberg K, et al. Repeated assessments of physical activity 
and risk of incident venous thromboembolism. Journal of Thrombosis and 
Haemostasis 0.  
243. Borch KH, Hansen-Krone I, Braekkan SK, et al. Physical activity and risk of venous 
thromboembolism. The Tromso study. Haematologica 2010; 95: 2088-2094.  
244. Braekkan SK, Hald EM, Mathiesen EB, et al. Competing risk of atherosclerotic risk 
factors for arterial and venous thrombosis in a general population: the Tromso study. 
Arterioscler Thromb Vasc Biol 2012; 32: 487-491.  
245. Roncaglioni MC, Santoro L, D'Avanzo B, et al. Role of family history in patients with 
myocardial infarction. An Italian case-control study. GISSI-EFRIM Investigators. 
Circulation 1992; 85: 2065-2072.  
246. Braekkan SK, Mathiesen EB, Njolstad I, et al. Family history of myocardial infarction is 
an independent risk factor for venous thromboembolism: the Tromso study. J 
Thromb Haemost 2008; 6: 1851-1857.  
247. Lind C, Enga KF, Mathiesen EB, et al. Family history of myocardial infarction and 
cause-specific risk of myocardial infarction and venous thromboembolism: the 
Tromso Study. Circ Cardiovasc Genet 2014; 7: 684-691.  
248. Mili FD, Hooper WC, Lally C, et al. Family history of myocardial infarction is a risk 
factor for venous thromboembolism among whites but not among blacks. Clin Appl 
Thromb Hemost 2013; 19: 410-417.  
249. Zoller B, Li X, Sundquist J, et al. Venous thromboembolism does not share strong 
familial susceptibility with coronary heart disease: a nationwide family study in 
Sweden. Eur Heart J 2011; 32: 2800-2805.  
250. Hong C, Zhu F, Du D, et al. Coronary artery calcification and risk factors for 
atherosclerosis in patients with venous thromboembolism. Atherosclerosis 2005; 
183: 169-174.  
251. Jezovnik MK, Poredos P, Lusa L. Idiopathic Venous Thrombosis is Associated with 
Preclinical Atherosclerosis. J Atheroscler Thromb 2010; 17: 304-311.  
252. van der Hagen PB, Folsom AR, Jenny NS, et al. Subclinical atherosclerosis and the risk 
of future venous thrombosis in the Cardiovascular Health Study. J Thromb Haemost 
2006; 4: 1903-1908.  
253. Reich LM, Folsom AR, Key NS, et al. Prospective study of subclinical atherosclerosis as 
a risk factor for venous thromboembolism. J Thromb Haemost 2006; 4: 1909-1913.  
254. Prandoni P. Venous thromboembolism and atherosclerosis: is there a link? J Thromb 
Haemost 2007; 5 Suppl 1: 270-275.  
255. Emberson JR, Whincup PH, Morris RW, et al. Extent of regression dilution for 
established and novel coronary risk factors: results from the British Regional Heart 
Study. Eur J Cardiovasc Prev Rehabil 2004; 11: 125-134.  
256. Collins R, MacMahon S, Flather M, et al. Clinical effects of anticoagulant therapy in 
suspected acute myocardial infarction: systematic overview of randomised trials. 
BMJ 1996; 313: 652-659.  
257. Eliasson A, Bergqvist D, Bjorck M, et al. Incidence and risk of venous 
thromboembolism in patients with verified arterial thrombosis: a population study 
based on 23,796 consecutive autopsies. J Thromb Haemost 2006; 4: 1897-1902.  
85 
 
258. Prandoni P, Pesavento R, Sorensen HT, et al. Prevalence of heart diseases in patients 
with pulmonary embolism with and without peripheral venous thrombosis: findings 
from a cross-sectional survey. Eur J Intern Med 2009; 20: 470-473.  
259. Huerta C, Johansson S, Wallander MA, et al. Risk factors and short-term mortality of 
venous thromboembolism diagnosed in the primary care setting in the United 
Kingdom. Arch Intern Med 2007; 167: 935-943.  
260. Sorensen HT, Horvath-Puho E, Sogaard KK, et al. Arterial cardiovascular events, 
statins, low-dose aspirin and subsequent risk of venous thromboembolism: a 
population-based case-control study. J Thromb Haemost 2009; 7: 521-528.  
261. Sorensen HT, Horvath-Puho E, Lash TL, et al. Heart disease may be a risk factor for 
pulmonary embolism without peripheral deep venous thrombosis. Circulation 2011; 
124: 1435-1441.  
262. Barsoum MK, Cohoon KP, Roger VL, et al. Are myocardial infarction and venous 
thromboembolism associated? Population-based case-control and cohort studies. 
Thromb Res 2014; 134: 593-598.  
263. Warlow C, Ogston D, Douglas AS. Venous thrombosis following strokes. Lancet 1972; 
1: 1305-1306.  
264. McCarthy ST, Robertson D, Turner JJ, et al. Low-Dose Heparin as a Prophylaxis against 
Deep-Vein Thrombosis after Acute Stroke. Lancet 1977; 2: 800-801.  
265. McCarthy ST, Turner J. Low-dose subcutaneous heparin in the prevention of deep-
vein thrombosis and pulmonary emboli following acute stroke. Age Ageing 1986; 15: 
84-88.  
266. Oczkowski WJ, Ginsberg JS, Shin A, et al. Venous thromboembolism in patients 
undergoing rehabilitation for stroke. Arch Phys Med Rehabil 1992; 73: 712-716.  
267. Cope C, Reyes TM, Skversky NJ. Phlebographic analysis of the incidence of 
thrombosis in hemiplegia. Radiology 1973; 109: 581-584.  
268. Miyamoto AT, Miller LS. Pulmonary embolism in stroke: prevention by early 
heparinization of venous thrombosis detected by iodine-125 fibrinogen leg scans. 
Arch Phys Med Rehabil 1980; 61: 584-587.  
269. Landi G, D'Angelo A, Boccardi E, et al. Venous thromboembolism in acute stroke. 
Prognostic importance of hypercoagulability. Arch Neurol 1992; 49: 279-283.  
270. Brandstater ME, Roth EJ, Siebens HC. Venous thromboembolism in stroke: literature 
review and implications for clinical practice. Arch Phys Med Rehabil 1992; 73: S379-
391.  
271. Langhorne P, Stott DJ, Robertson L, et al. Medical complications after stroke: a 
multicenter study. Stroke 2000; 31: 1223-1229.  
272. Davenport RJ, Dennis MS, Wellwood I, et al. Complications after acute stroke. Stroke 
1996; 27: 415-420.  
273. Kelly J, Rudd A, Lewis RR, et al. Venous thromboembolism after acute ischemic 
stroke: a prospective study using magnetic resonance direct thrombus imaging. 
Stroke 2004; 35: 2320-2325.  
274. Kamphuisen PW, Agnelli G, Sebastianelli M. Prevention of venous thromboembolism 
after acute ischemic stroke. J Thromb Haemost 2005; 3: 1187-1194.  
275. Sandercock P, Collins R, Counsell C, et al. The International Stroke Trial (IST): A 
randomised trial of aspirin, subcutaneous heparin, both, or neither among 19 435 
patients with acute ischaemic stroke. Lancet 1997; 349: 1569-1581.  
86 
 
276. Kamran SI, Downey D, Ruff RL. Pneumatic sequential compression reduces the risk of 
deep vein thrombosis in stroke patients. Neurology 1998; 50: 1683-1688.  
277. Dennis M, Mordi N, Graham C, et al. The timing, extent, progression and regression 
of deep vein thrombosis in immobile stroke patients: observational data from the 
CLOTS multicenter randomized trials. J Thromb Haemost 2011; 9: 2193-2200.  
278. Amin AN, Lin J, Thompson S, et al. Rate of deep-vein thrombosis and pulmonary 
embolism during the care continuum in patients with acute ischemic stroke in the 
United States. BMC Neurol 2013; 13: 17.  
279. Bembenek JP, Karlinski M, Kobayashi A, et al. Deep venous thrombosis in acute 
stroke patients. Clin Appl Thromb Hemost 2012; 18: 258-264.  
280. Kamphuisen PW, Agnelli G. What is the optimal pharmacological prophylaxis for the 
prevention of deep-vein thrombosis and pulmonary embolism in patients with acute 
ischemic stroke? Thromb Res 2007.  
281. Pongmoragot J, Rabinstein AA, Nilanont Y, et al. Pulmonary embolism in ischemic 
stroke: clinical presentation, risk factors, and outcome. J Am Heart Assoc 2013; 2: 
e000372.  
282. Kumar S, Selim MH, Caplan LR. Medical complications after stroke. Lancet Neurol 
2010; 9: 105-118.  
283. Warlow C, Ogston D, Douglas AS. Deep venous thrombosis of the legs after strokes. 
Part I--incidence and predisposing factors. Br Med J 1976; 1: 1178-1181.  
284. Kelly J, Rudd A, Lewis R, et al. Venous thromboembolism after acute stroke. Stroke 
2001; 32: 262-267.  
285. Bembenek J, Karlinski M, Kobayashi A, et al. Early stroke-related deep venous 
thrombosis: risk factors and influence on outcome. J Thromb Thrombolysis 2011; 32: 
96-102.  
286. Yi X, Lin J, Han Z, et al. The incidence of venous thromboembolism following stroke 
and its risk factors in eastern China. J Thromb Thrombolysis 2012; 34: 269-275.  
287. Bromfield EB, Reding MJ. Relative Risk of Deep Venous Thrombosis or Pulmonary 
Embolism Post-Stroke Based on Ambulatory Status. Neurorehabil Neural Repair 
1988; 2: 51-57.  
288. Wudicks EFM, Scott JP. Pulmonary embolism associated with acute stroke. Mayo 
Clinic Proceedings 1997.  
289. Subbarao J, Smith J. Pulmonary embolism during stroke rehabilitation. IMJ Ill Med J 
1984; 165: 328-332.  
290. Dennis M, Sandercock P, Reid J, et al. Effectiveness of intermittent pneumatic 
compression in reduction of risk of deep vein thrombosis in patients who have had a 
stroke (CLOTS 3): a multicentre randomised controlled trial. Lancet 2013; 382: 516-
524.  
291. Piazza G, Goldhaber SZ, Kroll A, et al. Venous thromboembolism in patients with prior 
stroke. Clin Appl Thromb Hemost 2014; 20: 43-49.  
292. Harvey RL. Prevention of venous thromboembolism after stroke. Top Stroke Rehabil 
2003; 10: 61-69.  
293. Beam DM, Courtney DM, Kabrhel C, et al. Risk of thromboembolism varies, 
depending on category of immobility in outpatients. Ann Emerg Med 2009; 54: 147-
152.  
294. Dennis M, Sandercock P, Reid J, et al. Can clinical features distinguish between 
immobile patients with stroke at high and low risk of deep vein thrombosis? 
87 
 
Statistical modelling based on the CLOTS trials cohorts. J Neurol Neurosurg Psychiatry 
2011; 82: 1067-1073.  
295. Kelly J, Hunt BJ, Lewis RR, et al. Dehydration and venous thromboembolism after 
acute stroke. QJM 2004; 97: 293-296.  
296. Mulley GP. Avoidable complications of stroke. J R Coll Physicians Lond 1982; 16: 94-
97.  
297. Bounds JV, Wiebers DO, Whisnant JP, et al. Mechanisms and timing of deaths from 
cerebral infarction. Stroke 1981; 12: 474-477.  
298. Brown M, Glassenberg M. Mortality factors in patients with acute stroke. JAMA 1973; 
224: 1493-1495.  
299. Viitanen M, Winblad B, Asplund K. Autopsy-verified causes of death after stroke. Acta 
Med Scand 1987; 222: 401-408.  
300. Johnston KC, Li JY, Lyden PD, et al. Medical and neurological complications of 
ischemic stroke: experience from the RANTTAS trial. RANTTAS Investigators. Stroke 
1998; 29: 447-453.  
301. Benson K, Hartz AJ. A comparison of observational studies and randomized, 
controlled trials. N Engl J Med 2000; 342: 1878-1886.  
302. Njolstad I, Mathiesen EB, Schirmer H, et al. The Tromso study 1974-2016: 40 years of 
cardiovascular research. Scand Cardiovasc J 2016; 50: 276-281.  
303. Jacobsen BK, Eggen AE, Mathiesen EB, et al. Cohort profile: the Tromsø Study. Int J 
Epidemiol 2012; 41: 961-967.  
304. UiT The Arctic University of Norway. The Tromsø Study. 
http://tromsoundersokelsen.uit.no/tromso/ Accessed February 20, 2017. 
305. Joakimsen O, Bonaa KH, Stensland-Bugge E. Reproducibility of ultrasound assessment 
of carotid plaque occurrence, thickness, and morphology. The Tromso Study. Stroke 
1997; 28: 2201-2207.  




:0:25,7616:1:0:0:::0:0 Accessed 26 February, 2015. 
307. Stensland-Bugge E, Bonaa KH, Joakimsen O. Reproducibility of Ultrasonographically 
Determined Intima-Media Thickness Is Dependent on Arterial Wall Thickness : The 
Tromso Study. Stroke 1997; 28: 1972-1980.  
308. Johnsen SH, Mathiesen EB, Fosse E, et al. Elevated high-density lipoprotein 
cholesterol levels are protective against plaque progression: a follow-up study of 
1952 persons with carotid atherosclerosis the Tromso study. Circulation 2005; 112: 
498-504.  
309. WHO MONICA Project. MONICA Manual. 
http://www.thl.fi/publications/monica/index.html Accessed 26 February, 2015. 
310. Sacco RL, Kasner SE, Broderick JP, et al. An updated definition of stroke for the 21st 
century: a statement for healthcare professionals from the American Heart 
Association/American Stroke Association. Stroke 2013; 44: 2064-2089.  
311. de Haan HG, Bezemer ID, Doggen CJ, et al. Multiple SNP testing improves risk 
prediction of first venous thrombosis. Blood 2012; 120: 656-663.  
312. Concato J, Shah N, Horwitz RI. Randomized, controlled trials, observational studies, 
and the hierarchy of research designs. N Engl J Med 2000; 342: 1887-1892.  
88 
 
313. Szklo M. Population-based cohort studies. Epidemiol Rev 1998; 20: 81-90.  
314. Szklo M, Nieto FJ. Epidemiology: Beyond the Basics Third Edition: Jones & Bartlett 
Learning; 2014. 
315. Lu CY. Observational studies: a review of study designs, challenges and strategies to 
reduce confounding. Int J Clin Pract 2009; 63: 691-697.  
316. Rochon PA, Gurwitz JH, Sykora K, et al. Reader's guide to critical appraisal of cohort 
studies: 1. Role and design. BMJ 2005; 330: 895-897.  
317. Rothman KJ, Greenland S, Lash TL. Case–Control Studies.  Encyclopedia of 
Quantitative Risk Analysis and Assessment: John Wiley & Sons, Ltd, 2008. 
318. Rothman KJ, Greenland S, Lash TL. Modern epidemiology: Lippincott Williams & 
Wilkins; 2008. 
319. Langholz B. Case–Cohort Study.  Encyclopedia of Biostatistics: John Wiley & Sons, Ltd, 
2005. 
320. Streptomycin Treatment of Pulmonary Tuberculosis - a Medical Research Council 
Investigation. BMJ 1948; 2: 770-&.  
321. Frieden TR. Evidence for Health Decision Making - Beyond Randomized, Controlled 
Trials. N Engl J Med 2017; 377: 465-475.  
322. Sacks H, Chalmers TC, Smith H, Jr. Randomized versus historical controls for clinical 
trials. Am J Med 1982; 72: 233-240.  
323. Sniderman AD, LaChapelle KJ, Rachon NA, et al. The necessity for clinical reasoning in 
the era of evidence-based medicine. Mayo Clin Proc 2013; 88: 1108-1114.  
324. Bothwell LE, Greene JA, Podolsky SH, et al. Assessing the Gold Standard--Lessons 
from the History of RCTs. N Engl J Med 2016; 374: 2175-2181.  
325. Chavez-MacGregor M, Giordano SH. Randomized Clinical Trials and Observational 
Studies: Is There a Battle? J Clin Oncol 2016; 34: 772-773.  
326. Rothwell PM. External validity of randomised controlled trials: "to whom do the 
results of this trial apply?". Lancet 2005; 365: 82-93.  
327. Kulathinal S, Karvanen J, Saarela O, et al. Case-cohort design in practice–experiences 
from the MORGAM Project. Epidemiologic Perspectives & Innovations 2007; 4: 15.  
328. Cologne J, Preston DL, Imai K, et al. Conventional case-cohort design and analysis for 
studies of interaction. Int J Epidemiol 2012; 41: 1174-1186.  
329. Rothman KJ, Greenland S. Causation and causal inference in epidemiology. Am J 
Public Health 2005; 95 Suppl 1: S144-150.  
330. Hill AB. The Environment and Disease: Association or Causation? Proc R Soc Med 
1965; 58: 295-300.  
331. Kundi M. Causality and the interpretation of epidemiologic evidence. Environ Health 
Perspect 2006; 114: 969-974.  
332. Thygesen LC, Andersen GS, Andersen H. A philosophical analysis of the Hill criteria. J 
Epidemiol Community Health 2005; 59: 512-516.  
333. Hofler M. The Bradford Hill considerations on causality: a counterfactual perspective. 
Emerg Themes Epidemiol 2005; 2: 11.  
334. Katan MB. Commentary: Mendelian Randomization, 18 years on. Int J Epidemiol 
2004; 33: 10-11.  
335. Roetker NS, Armasu SM, Pankow JS, et al. Taller height as a risk factor for venous 
thromboembolism: a Mendelian randomization meta-analysis. J Thromb Haemost 
2017; 15: 1334-1343.  
89 
 
336. Maino A, Rosendaal FR, Algra A, et al. Hypercoagulability Is a Stronger Risk Factor for 
Ischaemic Stroke than for Myocardial Infarction: A Systematic Review. PLoS One 
2015; 10: e0133523.  
337. Krokstad S, Langhammer A, Hveem K, et al. Cohort Profile: the HUNT Study, Norway. 
Int J Epidemiol 2013; 42: 968-977.  
338. Tjonneland A, Olsen A, Boll K, et al. Study design, exposure variables, and 
socioeconomic determinants of participation in Diet, Cancer and Health: a 
population-based prospective cohort study of 57,053 men and women in Denmark. 
Scand J Public Health 2007; 35: 432-441.  
339. Kypri K, Samaranayaka A, Connor J, et al. Non-response bias in a web-based health 
behaviour survey of New Zealand tertiary students. Prev Med 2011; 53: 274-277.  
340. Eggen AE, Mathiesen EB, Wilsgaard T, et al. The sixth survey of the Tromso Study 
(Tromso 6) in 2007-08: collaborative research in the interface between clinical 
medicine and epidemiology: study objectives, design, data collection procedures, and 
attendance in a multipurpose population-based health survey. Scand J Public Health 
2013; 41: 65-80.  
341. Barbujani G, Colonna V. Human genome diversity: frequently asked questions. Trends 
Genet 2010; 26: 285-295.  
342. Mamdani M, Sykora K, Li P, et al. Reader's guide to critical appraisal of cohort studies: 
2. Assessing potential for confounding. BMJ 2005; 330: 960-962.  
343. Greenland S, Morgenstern H. Confounding in health research. Annu Rev Public Health 
2001; 22: 189-212.  
344. Normand SL, Sykora K, Li P, et al. Readers guide to critical appraisal of cohort studies: 
3. Analytical strategies to reduce confounding. BMJ 2005; 330: 1021-1023.  
345. Delgado-Rodriguez M, Llorca J. Bias. J Epidemiol Community Health 2004; 58: 635-
641.  
346. Schwarz PE, Muylle F, Valensi P, et al. The European perspective of diabetes 
prevention. Horm Metab Res 2008; 40: 511-514.  
347. Steffensen FH, Lauritzen T, Sorensen HT. Validity of self-reported smoking habits. 
Scand J Prim Health Care 1995; 13: 236-237.  
348. Bowling A. Mode of questionnaire administration can have serious effects on data 
quality. Journal of Public Health 2005; 27: 281-291.  
349. Hutcheon JA, Chiolero A, Hanley JA. Random measurement error and regression 
dilution bias. BMJ 2010; 340.  
350. MacMahon S, Peto R, Cutler J, et al. Blood pressure, stroke, and coronary heart 
disease. Part 1, Prolonged differences in blood pressure: prospective observational 
studies corrected for the regression dilution bias. Lancet 1990; 335: 765-774.  
351. Clarke R, Shipley M, Lewington S, et al. Underestimation of risk associations due to 
regression dilution in long-term follow-up of prospective studies. Am J Epidemiol 
1999; 150: 341-353.  
352. Smabrekke B, Rinde LB, Hindberg K, et al. Atherosclerotic Risk Factors and Risk of 
Myocardial Infarction and Venous Thromboembolism; Time-Fixed versus Time-
Varying Analyses. The Tromso Study. PLoS One 2016; 11: e0163242.  
353. Hald EM, Lijfering WM, Mathiesen EB, et al. Carotid atherosclerosis predicts future 
myocardial infarction but not venous thromboembolism: the Tromso study. 
Arterioscler Thromb Vasc Biol 2014; 34: 226-230.  
90 
 
354. Braekkan SK, Borch KH, Mathiesen EB, et al. HDL-cholesterol and future risk of 
venous thromboembolism: the Tromso Study. J Thromb Haemost 2009; 7: 1428-
1430.  
355. Altman DG, Bland JM. Missing data. BMJ 2007; 334: 424.  
356. Sterne JA, White IR, Carlin JB, et al. Multiple imputation for missing data in 
epidemiological and clinical research: potential and pitfalls. BMJ 2009; 338: b2393.  
357. Buhi ER, Goodson P, Neilands TB. Out of sight, not out of mind: strategies for 
handling missing data. Am J Health Behav 2008; 32: 83-92.  
358. Graham JW. Missing data analysis: making it work in the real world. Annu Rev 
Psychol 2009; 60: 549-576.  
359. Quist-Paulsen P, Naess IA, Cannegieter SC, et al. Arterial cardiovascular risk factors 
and venous thrombosis: results from a population-based, prospective study (the 
HUNT 2).  2010; 95: 119-125.  
360. Corraini P, Ording AG, Henderson VW, et al. Cancer, other comorbidity, and risk of 
venous thromboembolism after stroke: a population-based cohort study. Thromb Res 
2016; 147: 88-93.  
361. Ibanez B, James S, Agewall S, et al. 2017 ESC Guidelines for the management of acute 
myocardial infarction in patients presenting with ST-segment elevation: The Task 
Force for the management of acute myocardial infarction in patients presenting with 
ST-segment elevation of the European Society of Cardiology (ESC). Eur Heart J 2018; 
39: 119-177.  
362. Cavallari I, Morrow DA, Creager MA, et al. Frequency, Predictors and Impact of 
Combined Antiplatelet Therapy on Venous Thromboembolism in Patients with 
Symptomatic Atherosclerosis. Circulation 2017.  
363. Prevention of pulmonary embolism and deep vein thrombosis with low dose aspirin: 
Pulmonary Embolism Prevention (PEP) trial. Lancet 2000; 355: 1295-1302.  
364. Kunutsor SK, Seidu S, Khunti K. Statins and primary prevention of venous 
thromboembolism: a systematic review and meta-analysis. Lancet Haematol 2017; 4: 
e83-e93.  
365. Becattini C, Agnelli G, Schenone A, et al. Aspirin for preventing the recurrence of 
venous thromboembolism. N Engl J Med 2012; 366: 1959-1967.  
366. Braekkan SK, Caram-Deelder C, Siegerink B, et al. Statin use and risk of recurrent 
venous thrombosis: results from the MEGA follow-up study. Res Pract Thromb 
Haemost 2017; 1: 112-119.  
367. Biedermann JS, Kruip M, van der Meer FJ, et al. Rosuvastatin use improves measures 
of coagulation in patients with venous thrombosis. Eur Heart J 2018; 39: 1740-1747.  
368. Grady D, Wenger NK, Herrington D, et al. Postmenopausal hormone therapy 
increases risk for venous thromboembolic disease. The Heart and Estrogen/progestin 
Replacement Study. Ann Intern Med 2000; 132: 689-696.  
369. van Langevelde K, Šrámek A, Vincken PWJ, et al. Finding the origin of pulmonary 
emboli with a total-body magnetic resonance direct thrombus imaging technique. 
Haematologica 2013; 98: 309-315.  
370. Jons C, Jacobsen UG, Joergensen RM, et al. The incidence and prognostic significance 
of new-onset atrial fibrillation in patients with acute myocardial infarction and left 




371. Zusman O, Amit G, Gilutz H, et al. The significance of new onset atrial fibrillation 
complicating acute myocardial infarction. Clin Res Cardiol 2012; 101: 17-22.  
372. Ogren M, Bergqvist D, Eriksson H, et al. Prevalence and risk of pulmonary embolism 
in patients with intracardiac thrombosis: a population-based study of 23 796 
consecutive autopsies. Eur Heart J 2005; 26: 1108-1114.  
373. Mutin M, Canavy I, Blann A, et al. Direct evidence of endothelial injury in acute 
myocardial infarction and unstable angina by demonstration of circulating 
endothelial cells. Blood 1999; 93: 2951-2958.  
374. Merlini PA, Bauer KA, Oltrona L, et al. Persistent activation of coagulation mechanism 
in unstable angina and myocardial infarction. Circulation 1994; 90: 61-68.  
375. Ardissino D, Merlini PA, Bauer KA, et al. Coagulation activation and long-term 
outcome in acute coronary syndromes. Blood 2003; 102: 2731-2735.  
376. Collaboration CT, Dennis M, Sandercock PA, et al. Effectiveness of thigh-length 
graduated compression stockings to reduce the risk of deep vein thrombosis after 
stroke (CLOTS trial 1): a multicentre, randomised controlled trial. Lancet 2009; 373: 
1958-1965.  
377. Jorgensen HS, Nakayama H, Raaschou HO, et al. Recovery of walking function in 
stroke patients: the Copenhagen Stroke Study. Arch Phys Med Rehabil 1995; 76: 27-
32.  
378. Jorgensen HS, Nakayama H, Raaschou HO, et al. Outcome and time course of 
recovery in stroke. Part II: Time course of recovery. The Copenhagen Stroke Study. 
Arch Phys Med Rehabil 1995; 76: 406-412.  
379. Westendorp WF, Nederkoorn PJ, Vermeij JD, et al. Post-stroke infection: a systematic 
review and meta-analysis. BMC Neurol 2011; 11: 110.  
380. Takano K, Yamaguchi T, Kato H, et al. Activation of coagulation in acute 
cardioembolic stroke. Stroke 1991; 22: 12-16.  
381. Fisher M, Francis R. Altered coagulation in cerebral ischemia. Platelet, thrombin, and 
plasmin activity. Arch Neurol 1990; 47: 1075-1079.  
382. Berge E, Friis P, Sandset PM. Hemostatic activation in acute ischemic stroke. Thromb 
Res 2001; 101: 13-21.  
383. Feinberg WM, Erickson LP, Bruck D, et al. Hemostatic markers in acute ischemic 
stroke. Association with stroke type, severity, and outcome. Stroke 1996; 27: 1296-
1300.  
384. Jin R, Yang G, Li G. Inflammatory mechanisms in ischemic stroke: role of 
inflammatory cells. J Leukoc Biol 2010; 87: 779-789.  
385. Lansberg MG, O'Donnell MJ, Khatri P, et al. Antithrombotic and thrombolytic therapy 
for ischemic stroke: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: 
American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. 
Chest 2012; 141: e601S-e636S.  
386. Helsedirektoratet. National Guidelines of Treatment and Rehabilitation after 
Ischemic Stroke, 2010. Oslo, Norway. 
387. Turpie AG, Hull RD, Schellong SM, et al. Venous thromboembolism risk in ischemic 
stroke patients receiving extended-duration enoxaparin prophylaxis: results from the 
EXCLAIM study. Stroke 2013; 44: 249-251.  
388. Jiang B, Ryan KA, Hamedani A, et al. Prothrombin G20210A mutation is associated 
with young-onset stroke: the genetics of early-onset stroke study and meta-analysis. 
Stroke 2014; 45: 961-967.  
92 
 
389. Hamedani AG, Cole JW, Mitchell BD, et al. Meta-analysis of factor V Leiden and 
ischemic stroke in young adults: the importance of case ascertainment. Stroke 2010; 
41: 1599-1603.  
390. Siegerink B, Maino A, Algra A, et al. Hypercoagulability and the risk of myocardial 
infarction and ischemic stroke in young women. J Thromb Haemost 2015; 13: 1568-
1575.  
391. Herm J, Hoppe B, Siegerink B, et al. A Prothrombotic Score Based on Genetic 
Polymorphisms of the Hemostatic System Differs in Patients with Ischemic Stroke, 
Myocardial Infarction, or Peripheral Arterial Occlusive Disease. Frontiers in 
Cardiovascular Medicine 2017; 4.  
392. Haapaniemi E, Helenius J, Jakovljevic D, et al. Ischaemic stroke patients with 
heterozygous factor V Leiden present with multiple brain infarctions and widespread 
atherothrombotic disease. Thromb Haemost 2009; 101: 145-150.  
393. Hanson E, Nilsson S, Jood K, et al. Genetic variants of coagulation factor XI show 
association with ischemic stroke up to 70 years of age. PLoS One 2013; 8: e75286.  
394. Yeh P-S, Lin H-J, Li Y-H, et al. Prognosis of young ischemic stroke in Taiwan: impact of 
prothrombotic genetic polymorphisms. Thromb Haemost 2004; 92: 583-589.  
395. van Adrichem RA, Debeij J, Nelissen RG, et al. Below-knee cast immobilization and 
the risk of venous thrombosis: results from a large population-based case-control 
study. J Thromb Haemost 2014; 12: 1461-1469.  
396. Bruzelius M, Bottai M, Sabater-Lleal M, et al. Predicting venous thrombosis in women 
using a combination of genetic markers and clinical risk factors. J Thromb Haemost 
2015; 13: 219-227.  
397. Bergmann JF, Cohen AT, Tapson VF, et al. Venous thromboembolism risk and 
prophylaxis in hospitalised medically ill patients. The ENDORSE Global Survey. 
Thromb Haemost 2010; 103: 736-748.  
398. Tapson VF, Decousus H, Pini M, et al. Venous thromboembolism prophylaxis in 
acutely ill hospitalized medical patients: findings from the International Medical 
Prevention Registry on Venous Thromboembolism. Chest 2007; 132: 936-945.  
399. Barbar S, Noventa F, Rossetto V, et al. A risk assessment model for the identification 
of hospitalized medical patients at risk for venous thromboembolism: the Padua 
Prediction Score. J Thromb Haemost 2010; 8: 2450-2457.  
400. Nendaz M, Spirk D, Kucher N, et al. Multicentre validation of the Geneva Risk Score 
for hospitalised medical patients at risk of venous thromboembolism. Explicit 
ASsessment of Thromboembolic RIsk and Prophylaxis for Medical PATients in 
SwitzErland (ESTIMATE). Thromb Haemost 2014; 111: 531-538.  
401. Spyropoulos AC, Anderson FA, Jr., FitzGerald G, et al. Predictive and associative 
models to identify hospitalized medical patients at risk for VTE. Chest 2011; 140: 706-
714.  
402. Stuck AK, Spirk D, Schaudt J, et al. Risk assessment models for venous 
thromboembolism in acutely ill medical patients. A systematic review. Thromb 
Haemost 2017; 117: 801-808.  
403. Amin AN, Varker H, Princic N, et al. Duration of venous thromboembolism risk across 





Repeated measurements of carotid atherosclerosis and future
risk of venous thromboembolism: the Tromsø Study
B . SMABREKKE ,* L . B . R INDE ,* E . M. HALD ,*† I . N JØLSTAD,*‡ E . B . MATHIESEN ,*§¶
S . H . JOHNSEN ,§¶ J . - B . HANSEN ,*† S . K . BRÆKKAN*† and W. M. L I J FER ING**
*K. G. Jebsen Thrombosis Research and Expertise Center (TREC), Department of Clinical Medicine, UiT The Arctic University of Norway;
†Division of Internal Medicine, University Hospital of North Norway; ‡Epidemiology of Chronic Diseases Research Group, Department of
Community Medicine, UiT The Arctic University of Norway; §Brain and Circulation Research Group, Department of Clinical Medicine, UiT
The Arctic University of Norway; ¶Department of Neurology, University Hospital of North Norway; and **Department of Clinical
Epidemiology, Leiden University Medical Center, the Netherlands
To cite this article: Smabrekke B, Rinde LB, Hald EM, Njølstad I, Mathiesen EB, Johnsen SH, Hansen J-B, Brækkan SK, Lijfering WM. Repeated
measurements of carotid atherosclerosis and future risk of venous thromboembolism: the Tromsø Study. J Thromb Haemost 2017; 15:
2344–51.
Essentials
 The relationship between atherosclerosis and venous
thromboembolism (VTE) is controversial.
 In total, 10 426 participants recruited from the general
population were included.
 Carotid intima media thickness and total plaque area
was not associated with VTE.
 There was no association between plaque initiation or
plaque progression and subsequent VTE.
Summary. Background: Whether a relationship between
atherosclerosis and subsequent venous thromboembolism
(VTE) exists is controversial. Objective: To investigate the
association between carotid atherosclerosis and VTE by
using repeated measurements of intima media thickness
(IMT) and total plaque area (TPA) in participants
recruited from the general population. Methods: Partici-
pants were recruited from the fourth (1994–1995), fifth
(2001–2002) and sixth (2007–2008) surveys of the Tromsø
Study. In total, 10 426 participants attended, for whom
measurements of carotid IMT and TPA and potential
confounders were updated at each available survey. Time-
varying Cox regression models were used to calculate haz-
ard ratios (HRs) of VTE across various levels of IMT
and TPA adjusted for age, sex, and body mass
index. Results: There were 368 incident VTE events dur-
ing a median follow-up of 10.8 years. Participants with
increasing IMT were, on average, older and had a less
favorable cardiovascular risk profile. There was no associ-
ation between tertiles of increasing TPA and the risk of
VTE in the time-varying model, and increasing IMT was
not associated with an increased risk of VTE (HR 0.96,
95% confidence interval [CI] 0.86–1.07). Neither plaque
formation nor plaque progression was associated with the
risk of VTE (respectively: HR 1.00, 95% CI 0.98–1.02;
and HR 0.96, 95% CI 0.84–1.11). Conclusion: Carotid
IMT and TPA were not associated with an increased risk
of VTE in time-varying analyses. Furthermore, there was
no association between plaque initiation or plaque pro-
gression and subsequent VTE.
Keywords: atherosclerosis; cohort studies; repeated
measurements; risk factors; venous thromboembolism.
Introduction
Although medical textbooks consider venous thromboem-
bolism (VTE) and arterial cardiovascular disease as differ-
ent disease entities [1], Virchow’s triad (1856) postulates
that the pathophysiology of thrombosis, either venous or
arterial, is an interplay between: (i) stasis of the blood;
(ii) hypercoagulability; and (iii) vessel wall injury [2]. The
vascular component of Virchow’s triad has been much
less studied in the etiology of VTE than in that of arterial
cardiovascular disease, for which vessel wall injury is an
established precursor of disease.
Interestingly, recent studies have shown that arterial
cardiovascular diseases, such as myocardial infarction and
ischemic stroke, are associated with an increased risk of
VTE [3–5]. In addition, in a landmark study from 2003,
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Prandoni et al. reported that atherosclerosis, measured
according to total plaque area (TPA), was twice as preva-
lent in patients with unprovoked venous thrombosis as in
age-matched and sex-matched controls [6]. These findings
suggested that atherosclerosis could be a shared risk fac-
tor for arterial cardiovascular disease and VTE. Although
the association between atherosclerosis and arterial car-
diovascular disease is well established [7–9], the associa-
tion between atherosclerosis and VTE remains
controversial. For instance, case–control studies are not
designed to reveal the direction of the association, and do
not enable interpretations on causality, owing to the
undetermined temporal sequence between exposure and
outcome. Furthermore, the association between
atherosclerosis and VTE might be explained by the pres-
ence of confounding risk factors, such as increasing age
and obesity [10].
Previous cohort studies did not show any association
between atherosclerosis and subsequent VTE [11–13].
However, these cohorts were based on a single measure-
ment of TPA and carotid intima media thickness (IMT)
obtained at the beginning of a follow-up period that
lasted for > 10 years. Because atherosclerosis may
develop over time, a long follow-up with several years
between the baseline measurement and the event could
introduce regression dilution bias, and thereby lead to
underestimation of the true association [14,15]. Therefore,
a small effect of atherosclerosis on VTE risk could be
masked in traditional cohort studies with single measure-
ments and long-term follow-up. The potential problem of
regression dilution could be overcome by utilizing
repeated assessments of the atherosclerosis status within
the same individuals during follow-up. This will provide a
more accurate estimation of the risk status at the time
before the outcome occurs.
We therefore aimed to investigate the association
between the presence, formation and progression of caro-
tid atherosclerosis and VTE by using a large prospective
cohort with repeated measurements of IMT and TPA, in
participants recruited from the general population.
Methods
Study population
Participants were recruited from the fourth, fifth and sixth
surveys of the Tromsø Study, conducted in 1994–1995,
2001–2002, and 2007–2008, respectively. In the fourth
study, all inhabitants aged 55–74 years and a random 5–
10% sample in the other age groups > 24 years, were
invited to a second, more extensive examination, including
ultrasonography of the carotid artery [16]. Subjects who
attended the second visit of Tromsø 4, in addition to ran-
dom samples within different age groups, were eligible for
the second visit of Tromsø 5 and for Tromsø 6. A detailed
description of the Tromsø Study has been published else-
where [17]. Participants with a previous history of VTE
were excluded. In addition, participants attending for the
ultrasound examination, but with missing information on
the measures of carotid atherosclerosis, were excluded. In
total, 10 426 participants attended for ultrasound exami-
nation of the right carotid artery in Tromsø 4, 5, and/or 6
(Fig. 1). The study was approved by the regional commit-
tee for research ethics in North Norway, and all partici-
pants gave their informed, written consent.
Atherosclerotic risk factors and assessment of atherosclerosis
Information on atherosclerotic risk factors was collected
by physical examination, blood sampling, and self-admi-
nistered questionnaires, and the collection was repeated at
each survey. Height, weight, blood pressure and non-fast-
ing serum lipids were measured as previously described in
detail [18]. Body mass index (BMI) was calculated as
weight in kilograms divided by the square of height in
meters (kg m2). Questionnaires were used to obtain infor-
mation on the use of lipid-lowering drugs, current smok-
ing, diabetes mellitus, physical activity, and education.
Ultrasound examination of the right carotid artery was
performed for assessment of IMT and TPA. A thorough
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Fig. 1. Study population. The study population was recruited from the second visits at the fourth, fifth and sixth surveys of the Tromsø Study,
conducted in 1994–1995, 2001–2002, and 2007–2008, respectively.
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published previously [16, 19–21]. In brief, high-resolution
B-mode ultrasonography of the right carotid artery was
performed by experienced examiners, with the use of an
ultrasound scanner (Acuson Xp10 128 ART [Mountain
View, CA, USA] equipped with a 7.5-MHz linear-array
transducer in Tromsø 4 and 5; and a GE Vivid 7 [GE
Vingmed Ultrasound, Horten, Norway] with a linear 12-
MHz transducer in Tromsø 6). The right carotid artery
was scanned longitudinally from the level of the clavicle,
through the carotid bulb (bifurcation segment) and the
proximal internal carotid segment (ICA) as far down-
stream as possible. A plaque was defined as a localized
protrusion of the vessel wall into the lumen of at least
50% as compared with the adjacent IMT. Still images
were reported for each plaque, and digitized with the
Matrox Meteor II frame grabber card and Matrox INTEL-
LICAM (Matrox Imaging, Montreal, QC, Canada). With
the use of ADOBE PHOTOSHOP 7.0, measurements of plaque
area were made by outlining the perimeter of the plaque,
and the plaque area was calculated as pixel values. For
the resolution used in the present study, a plaque area of
167 pixels corresponded to 1 mm2. In each subject, a
maximum of six plaques were registered in the near and
far walls of the distal part of the common carotid artery
(CCA), bifurcation, and ICA, respectively. TPA was cal-
culated as the sum of all plaques. IMT was defined as the
average of the mean IMT values of the near and far walls
of the CCA and the far wall of the bifurcation. To mini-
mize variability in IMT during the cardiac cycle, image
capture was standardized by recording images at the top
of the R-wave in an electrocardiogram (ECG) signal. Pla-
que initiation was defined as the development of new pla-
ques at follow-up in vessels without plaques at the
previous examination, and plaque progression was defined
as the difference in TPA between two measurements. Par-
ticipants with negative progression were included in the
no-progression group [16,22].
Identification and validation of VTE
All incident VTE events during follow-up were identified
by searching the hospital discharge diagnosis registry, the
autopsy registry and the radiology procedure registry at
the University Hospital of North Norway. The University
Hospital of North Norway is the only hospital in the
region, and all diagnostic radiology and hospital care is
provided exclusively by this hospital. The medical record
for each potential case of VTE was reviewed by trained
personnel, and a VTE event was considered to be adjudi-
cated when the presence of clinical signs and symptoms
of deep vein thrombosis (DVT) or pulmonary embolism
was combined with objective confirmation tests (by com-
pression ultrasonography, venography, spiral computed
tomography, perfusion–ventilation scan, pulmonary
angiography, and autopsy), and resulted in a VTE diag-
nosis that required treatment, as previously described in
detail [23]. DVTs were recorded in the upper and lower
extremities, including the inferior vena cava, and at unu-
sual sites (the mesenteric veins, portal veins, and in the
venous sinuses). VTE cases from the autopsy registry
were recorded when the death certificate indicated VTE
as the cause of death or as a significant condition con-
tributing to death.
Statistical analysis
Statistical analyses were performed with STATA version 14.0
(Stata Corporation, College Station, TX, USA). As the dis-
tribution of TPA was skewed to the right, TPA was square
root transformed to approximate a normal distribution for
the analyses in which TPA was used as a continuous vari-
able. Cox proportional hazard regression models were used
to assess the association between atherosclerosis (i.e. IMT
and TPA) and VTE in a time-varying analysis. In these
analyses, all participants contributed with one or more
observation periods, each lasting from one measurement
until the next, or until a censoring event (i.e. migration,
death, or end of study period) occurred. The follow-up
ended on 31 December 2012. Atherosclerosis measure-
ments and other risk factors were updated at every survey,
when available, and used as time-varying covariates. Of the
10 426 participants included in the study, 5154 participants
attended two or three surveys, which resulted in a total
number of 18 154 observation periods for the time-varying
analyses. For participants attending only one survey, mea-
surements were valid from baseline to the first censoring
event. Age was used as the time-scale, with the participants’
age at study enrolment being defined as entry time, and age
at the censoring event being defined as exit time. Hazard
ratios (HRs) with 95% confidence intervals (CIs) were cal-
culated, and all analyses were adjusted for age (as time-
scale), sex, and BMI. The proportional hazards assumption
was confirmed with Schoenfeld’s global test. Statistical
interactions between the covariates and the main exposures
were tested by including the cross-product terms in the pro-
portional hazard model, and no interactions were found.
We performed two sensitivity analyses. In the first sen-
sitivity analysis, we censored participants at the next sur-
vey that they did not attend. This analysis was performed
to ensure that the carry-on of measurements in partici-
pants who attended only one survey did not dilute the
effect in the original analyses. Statin use may potentially
confound the association between atherosclerosis and
VTE. As we did not have sufficient information on statin
use among the Tromsø 4 participants, the second sensitiv-
ity analysis was restricted to participants who did not use
lipid-lowering drugs in Tromsø 5 or Tromsø 6.
Results
During a median follow-up of 10.8 years, 368 participants
experienced an incident VTE event. The baseline
© 2017 International Society on Thrombosis and Haemostasis
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characteristics of traditional atherosclerotic risk factors
and TPA across quartiles of carotid IMT are shown in
Table 1. In general, all traditional atherosclerotic risk fac-
tors changed for the worse across increasing quartiles of
IMT. Participants in the fourth quartile had higher blood
pressure, BMI, triglyceride levels, and total cholesterol
levels, and lower HDL cholesterol levels, than partici-
pants in the first quartile. Among participants in the high-
est quartile, there were also higher proportions of males
and of participants with hypertension and self-reported
diabetes, and a lower proportion of physically active and
highly educated participants. The quartiles of IMT con-
tained approximately the same proportions of current
smokers.
HRs for VTE with TPA and IMT as continuous and
categorical variables are shown in Table 2. There was no
association between TPA as a continuous variable and
VTE (HR per standard deviation [SD] increase of 0.99,
95% CI 0.90–1.11), and no linear trend of increased risk
of VTE across increasing tertiles of TPA when no plaque
was set as the reference group (P for trend = 0.9). IMT
was not associated with risk of VTE (HR per SD increase
of 0.96, 95% CI 0.86–1.07), and the P for trend across
increasing quartiles of IMT was 0.7. Additional adjust-
ment for total cholesterol, HDL cholesterol, smoking,
diabetes mellitus and diastolic blood pressure had a negli-
gible effect on the risk estimates (HRs per SD increase
for TPA and IMT were 0.98 [95% CI 0.88–1.09] and 0.96
[95% CI 0.86–1.07], respectively). Similar results were
obtained when the participants were censored at the first
survey that they did not attend (Table S1) and when the
analyses were restricted to participants not using lipid-
lowering drugs in Tromsø 5 or 6 (Table S2).
HRs for VTE according to the formation and progres-
sion of carotid plaques are shownd in Table 3. There was
no association between plaque formation and future risk
of VTE (HR 1.00, 95% CI 0.98–1.02). Progression of car-
otid plaque size was not associated with VTE (HR 0.96,
95% CI 0.84–1.11), and there was no linear trend of VTE
risk across tertiles of plaque progression in TPA (P for
trend = 0.5). The multivariable-adjusted model showed
similar results for both plaque formation and plaque
progression.
Discussion
Previous case–control studies have reported an associa-
tion between carotid plaques and VTE [6,24], whereas
later cohort studies [11–13] have not shown any associa-
tion between carotid atherosclerosis and future risk of
VTE. A potential limitation of cohorts with long follow-
up is that changes in atherosclerosis over time could lead
to an underestimation of the true association between
atherosclerosis and VTE [14,15]. To investigate whether
the apparent discrepancy in results in case–control and
cohort studies could be explained by regression dilution
bias, we conducted a study with repeated measurements
of carotid atherosclerosis within the same individuals
Table 1 Baseline characteristics of traditional atherosclerotic risk factors across quartiles of carotid intima media thickness (IMT); in total,










Number of participants 2612 2618 2590 2606
VTE events, n 69 92 79 128
Age (years), mean  SD 53.2  10.4 59.1  6.7 61.5  6.6 64.2  6.7
Male sex, % (n) 31.9 (832) 39.5 (1034) 51.1 (1323) 59.2 (1542)
Systolic BP (mmHg), mean  SD 131  19 139  21 144  22 152  23
Diastolic BP (mmHg), mean  SD 78  11 81  12 83  12 85  13
Hypertension, % (n)* 34.0 (887) 50.9 (1331) 62.9 (1626) 75.1 (1956)
BMI (kg m2), mean  SD 25.2  3.7 26.4  4.1 26.8  4.0 27.2  4.2
Triglycerides (mmol L1), mean  SD 1.47  0.98 1.61  0.99 1.67  1.01 1.80  1.02
Total cholesterol (mmol L1), mean  SD 6.19  1.23 6.40  1.26 6.43  1.27 6.61  1.35
HDL cholesterol (mmol L1), mean  SD 1.61  0.45 1.59  0.44 1.53  0.42 1.46  0.43
Self-reported diabetes, % (n) 1.6 (42) 2.8 (72) 3.7 (95) 6.0 (155)
Smoking, % (n) 31.6 (823) 26.9 (703) 27.0 (699) 29.2 (761)
Physical activity, % (n)† 32.8 (817) 33.9 (844) 31.6 (776) 25.6 (632)
Education % (n)‡ 26.1 (653) 23.8 (584) 21.7 (522) 17.4 (426)
Total plaque area (mm2), mean  SD 0.55  1.29 1.18  1.79 1.98  2.23 3.97  2.68
No plaque, % (n) 82.8 (2163) 65.9 (1725) 50.5 (1307) 21.9 (570)
First tertile, % (n) 10.7 (280) 18.2 (476) 18.1 (468) 12.7 (330)
Second tertile, % (n) 4.8 (126) 10.8 (282) 18.8 (488) 25.2 (658)
Third tertile, % (n) 1.7 (43) 5.1 (135) 12.6 (327) 40.2 (1048)
BP, blood pressure; BMI, body mass index; SD, standard deviation; VTE, venous thromboembolism. *Hypertension: systolic BP of
≥ 140 mmHg, or diastolic BP of ≥ 90 mmHg, or the use of antihypertensive medicine. †Hard physical activity for ≥ 1 h every week. ‡Fifteen
or more years of education (corresponding to 3 years in a university or academy).
© 2017 International Society on Thrombosis and Haemostasis
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during follow-up. We found that measures of carotid
atherosclerosis were not associated with future risk of
VTE. Our findings suggest that atherosclerosis as measured
with carotid ultrasonography is not an intermediate for the
association between arterial and venous thrombosis.
Our results are in accordance with those of previous
cohort studies on the association between atherosclerosis
and VTE using time-fixed analyses [11–13]. The
Atherosclerosis Risk in Communities study, which
included 13 000 subjects aged 45–64 years with a median
follow-up time of 12.5 years, found no association
between increased carotid IMT or the presence of carotid
plaques and VTE risk [11]. The Cardiovascular Health
Study study followed 4100 subjects aged ≥ 65 years for a
period of 12 years, and measured subclinical atherosclero-
sis according to IMT, the presence of carotid plaques,
ankle brachial index, and ECG abnormalities. In this
study, subclinical atherosclerosis was not associated
with an increased risk of overall or unprovoked VTE.
Unexpectedly, they found an inverse relationship between
high-risk carotid plaques and VTE [12]. Furthermore, a
previous study from the Tromsø cohort with 15.4 years
of follow-up, including > 6200 participants, found that
single measurements of IMT and TPA at baseline were
associated with future myocardial infarction, but not
VTE [13].
The finding of no association between atherosclerosis
and VTE in cohort studies is in contrast to the results
from two previous case–control studies [6,24]. Prandoni
et al. reported a higher frequency of carotid plaques in
153 patients with unprovoked VTE than in 146 patients
with provoked VTE and 150 hospitalized controls. In this
study, plaques were defined as a protrusion into the vessel
lumen of at least 2 mm [6]. In a study including 89 cases
of unprovoked VTE and 89 controls, Hong et al.
reported an association between coronary artery calcifica-
tion and VTE [22]. Several factors may explain the diver-
gent results between cohort and case–control studies
conducted on this topic. Recruitment of controls that are
not fully representative of the source population from
which the cases were derived may result in overestimation
of the true effect in case–control studies. This problem is
more likely to occur when the size of the control group is
small. Moreover, the exposure is measured after the out-
come in case–control studies, and therefore the temporal
sequence of the events cannot be determined. In conven-
tional cohorts, exposure may change over time, and this
may lead to underestimation of the true effect. However,
with repeated measurements, it was possible to update an
individual’s risk status over time, and consequently obtain
a better estimation of an individual’s atherosclerotic
status in the period before the VTE diagnosis. Using this
approach, we did not find any association between caro-
tid atherosclerosis measures and VTE risk.
Although some studies have reported associations
between atherosclerotic risk factors, such as diabetes,
hypertension, and dyslipidemia, and the risk of VTE [25–
27], the only atherosclerotic risk factors that have consis-
tently been shown to increase the risk of VTE are age
and obesity [18,28,29]. A recent meta-analysis of nine
cohorts, including almost 250 000 participants and 5000
VTEs, found no association between traditional, modifi-
able atherosclerotic risk factors and VTE, using tradi-
tional time-fixed Cox regression models adjusted for age,
sex, and BMI [30]. The only exception was cigarette
smoking, which was associated with an increased risk of
provoked VTE, an association that was possibly mediated
through other conditions such as cancer. Furthermore, in
a previous report from the Tromsø Study, based on
repeated measurements of atherosclerotic risk factors, we
showed that BMI, but not blood pressure, serum lipid
levels, diabetes, or smoking, was associated with an
increased risk of VTE [31].
Major strengths of our study include the prospective
design with repeated exposure measurements and long
follow-up, the large number of participants recruited from
the general population, and the thorough validation and
adjudication of VTE. The repeated measurements of
atherosclerosis and potential confounders made it possible
to update risk status over time, and thereby to reduce the
chance of regression dilution bias. The study has some
limitations. Unfortunately, we did not have verified base-
line information on previous history of VTE among all of
the study subjects. We started to identify VTE cases in
January 1994, and those who were registered with a
recurrent event in the study period (1994–2012), and
those who had a VTE shortly before inclusion, were iden-
tified and excluded from the analyses because of previous
VTE. Subjects who had a VTE before 1994 and did not
experience a recurrence in the study period would not be
detected, and, consequently, these would be treated as
healthy participants during follow-up. As the prevalence
of VTE in the general population is relatively low, this
would lead to only a small change in the overall number
of person-years at risk, and thus would presumably have
a negligible influence on the risk estimates. Carotid ultra-
sonography is operator-dependent and prone to measure-
ment errors. However, a previous study found the overall
reproducibility of TPA to be good, with small interob-
server mean arithmetic and mean absolute differences
[16]. Although the measurement errors in carotid ultra-
sonography are too large to allow study of the progres-
sion of atherosclerosis at an individual level, carotid
ultrasonography at a population level gives enough power
to overcome the measurement variability, and makes it
possible to detect even weak associations [16]. Examina-
tion of only one carotid artery may potentially introduce
misclassification. However, studies comparing ultrasound
IMT measurements of the left and right common carotid
artery found no significant difference between the sides in
the normal population [32,33]. Furthermore, studies have
shown that carotid atherosclerosis correlates well with the
© 2017 International Society on Thrombosis and Haemostasis
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general extent of atherosclerotic disease in an individual
[34,35]. Statins have been shown to reduce the risk of
VTE in some [36–38], but not all, studies [39,40]. Statin
use reduces carotid plaque development and lowers pla-
que progression [41,42], and lack of adjustment for statin
use could result in underestimation of the association
between atherosclerosis and VTE. However, sensitivity
analysis restricted to participants who did not use statins
showed no association between carotid atherosclerosis
and VTE. Aspirin is often prescribed to subjects at risk
of cardiovascular disease, but may also prevent venous
thrombosis. However, although aspirin use has been asso-
ciated with a decreased risk of recurrent VTE [43,44], it
has not been associated with a reduced risk of incident
VTE in population-based studies [37,45].
In conclusion, we found that the formation and pro-
gression of carotid atherosclerosis, as measured with
ultrasonography, was not associated with future risk of
VTE in time-varying analyses. Our findings suggest that
atherosclerosis is not an intermediate for the association
between arterial cardiovascular diseases and VTE.
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Supplementary table S1. Hazard ratios (HR) with 95% confidence intervals (CI) of venous 
thromboembolism (VTE) according to total plaque area and intima media thickness using a 
time-varying Cox regression model. Participants were censored at the next survey they did not 
attend, the date of an incident VTE event, the date they died or moved from the municipality 
of Tromsø or at the end of follow-up, whichever came first. The Tromsø Study 1994-2012. 
Risk factors Events Person-years HR (95% CI) † 
Total Plaque Area* 301  0.98 (0.87-1.10) 
No plaque 117 50283 Ref. 
1st tertile (1.018-3.506 mm2) 54 17712 1.00 (0.72-1.39) 
2nd tertile (3.506-5.031 mm2) 67 17337 1.13 (0.83-1.54) 
3rd tertile (5.031-15.696 mm2) 63 16889 0.92 (0.67-1.28) 
P for trend   0.9 
Intima Media Thickness* 301  0.94 (0.83-1.06) 
1st quartile (0.358-0.743 mm) 48 26683 Ref. 
2nd quartile (0.744-0.849 mm) 63 25754 0.90 (0.62-1.32) 
3rd quartile (0.849-0.970 mm) 87 25075 1.06 (0.73-1.53) 
4th quartile (0.971-2.748 mm) 103 24708 1.05 (0.72-1.53) 
P for trend   0.5 
* Per standard deviation (SD) increase; 1 SD TPA = 2.60 mm2; 1 SD IMT = 0.19 mm 
† Adjusted for age (as time scale), sex and BMI 
 
 
Supplementary table S2. Hazard ratios (HR) with 95% confidence intervals (CI) of venous 
thromboembolism (VTE) according to total plaque area and intima media thickness using a 
time-varying Cox regression model. Participants with previous or current use of lipid-
lowering drugs were excluded. The Tromsø Study 1994-2012. 
Risk factors Events Person-years HR (95% CI) † 
Total Plaque Area* 296  0.99 (0.90-1.11) 
No plaque 118 45122 Ref. 
1st tertile (1.183-3.506 mm2) 52 15168 0.94 (0.67-1.31) 
2nd tertile (3.506-5.031 mm2) 62 13818 1.09 (0.79-1.49) 
3rd tertile (5.033-15.696 mm2) 64 12244 1.05 (0.76-1.45) 
P for trend   0.6 
Intima Media Thickness* 296  0.98 (0.87-1.11) 
1st quartile (0.358-0.743 mm) 49 24993 Ref. 
2nd quartile (0.744-0.849 mm) 69 22306 0.99 (0.68-1.44) 
3rd quartile (0.849-0.970 mm) 80 20496 1.00 (0.69-1.45) 
4th quartile (0.971-2.748 mm) 98 18557 1.09 (0.75-1.59) 
P for trend   0.6 
* Per standard deviation (SD) increase; 1 SD TPA = 2.60 mm2; 1 SD IMT = 0.19 mm 
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Essentials
• Registry-based studies indicate a link between arterial-
and venous thromboembolism (VTE).
• We studied this association in a cohort with confounder
information and validated outcomes.
• Myocardial infarction (MI) was associated with a 4.8-
fold increased short-term risk of VTE.
• MI was associated with a transient increased risk of
VTE, and pulmonary embolism in particular.
Summary. Background: Recent studies have demonstrated
an association between venous thromboembolism (VTE)
and arterial thrombotic diseases. Objectives: To study the
association between incident myocardial infarction (MI)
and VTE in a prospective population-based
cohort. Methods: Study participants (n = 29 506) were
recruited from three surveys of the Tromsø Study (con-
ducted in 1994–1995, 2001–2002, and 2007–2008) and fol-
lowed up to 2010. All incident MI and VTE events
during follow-up were recorded. Cox regression models
with age as the time scale and MI as a time-dependent
variable were used to calculate hazard ratios (HRs) of
VTE adjusted for sex, body mass index, blood pressure,
diabetes mellitus, HDL cholesterol, smoking, physical
activity, and education level. Results: During a median
follow-up of 15.7 years, 1853 participants experienced an
MI and 699 experienced a VTE. MI was associated with
a 51% increased risk of VTE (HR 1.51; 95% confidence
interval [CI] 1.08–2.10) and a 72% increased risk of pul-
monary embolism (PE) (HR 1.72; 95% CI 1.07–2.75),
but not significantly associated with the risk of deep vein
thrombosis (DVT) (HR 1.36; 95% CI 0.86–2.15). The
highest risk estimates for PE were observed during the
first 6 months after the MI (HR 8.49; 95% CI
4.00–18.77). MI explained 6.2% of the PEs in the popula-
tion (population attributable risk) and 78.5% of the PE
risk in MI patients (attributable risk). Conclusions: Our
findings indicate that MI is associated with a transient
increased VTE risk, independently of traditional
atherosclerotic risk factors. The risk estimates were par-
ticularly high for PE.
Keywords: epidemiology; myocardial infarction;
pulmonary embolism; risk factors; venous
thromboembolism.
Introduction
Despite definite differences in pathology and treatment
strategies, growing evidence suggests a bidirectional rela-
tionship between venous thromboembolism (VTE) (deep
vein thrombosis [DVT] and pulmonary embolism [PE])
and arterial thromboembolic diseases (ATDs) (myocar-
dial infarction [MI] and ischemic stroke) [1–4]. The rela-
tionship between ATD and VTE could be attributable
to shared risk factors, such as obesity, smoking, or a
family history of MI, indirect causal factors, such as
hospitalizations accompanied by periods of immobiliza-
tion, or a direct causal relationship, such as a transient
prothrombotic response secondary to sudden tissue dam-
age, and venous stasis following heart failure [5].
The results from prospective cohorts, applying cause-
specific regression models, have revealed that, among the
traditional atherosclerotic risk factors, only age, obesity
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and a familial predisposition for MI are shared risk fac-
tors for ATD and VTE [6–9]. In a case–control study,
patients with unprovoked VTE were reported to have a
higher frequency of carotid plaques than control partici-
pants [2]. Conversely, subsequent large population-based
cohort studies have failed to confirm an association
between carotid atherosclerosis and VTE [10–12], indicat-
ing that atherosclerosis is not a shared risk factor for
ATD and VTE.
Population-based registry studies have shown that
patients with a history of MI are at increased short-term
risk of subsequent VTE [13,14]. However, results from
registry-based linkage studies should be interpreted with
caution, as they often lack information about con-
founders and have limited validation of exposure and out-
comes. For instance, an evaluation of the Danish
National Patient Registry revealed that the positive pre-
dictive values for VTE diagnoses from emergency depart-
ments and hospitals were only 44% and 67–77%,
respectively [15]. Moreover, the lack of important clinical
information, such as body mass index (BMI), has limited
our ability to adjust for confounding in previous registry-
based studies [13,14].
We therefore aimed to investigate the association
between MI and the future risk of VTE in a population-
based cohort with validated information on exposure
(MI), the endpoint (VTE), and potential confounders.
Materials and methods
Study population
The Tromsø Study is a single-center, prospective, popula-
tion-based study, with repeated health surveys of the
inhabitants of Tromsø, Norway. Study participants were
recruited from the fourth, fifth and sixth surveys of the
Tromsø Study, conducted in 1994–1995, 2001–2002, and
2007–2008, respectively. The overall attendance rates were
high: 77% in the fourth survey, 78% in the fifth survey,
and 66% in the sixth survey. A detailed description of the
Tromsø Study has been published elsewhere [16]. In total,
30 586 unique participants aged 25–97 years participated
in at least one of the surveys, and, of these, 21 529 partic-
ipants participated in two or all three surveys. Partici-
pants who did not consent to medical research (n = 225),
participants not officially registered as inhabitants of the
municipality of Tromsø at the date of study enrollment
(n = 48) and participants with a previous history of VTE
(n = 78) or MI (n = 729) before baseline were excluded.
Consequently, 29 506 participants were included in the
study, and followed from the date of enrollment to
the end of follow-up, i.e. 31 December 2010 (Fig. 1). The
regional committee for medical and health research ethics
in North Norway approved the study, and all participants
gave their informed written consent.
Baseline measurements
Information about study participants was collected by
physical examination, from blood samples and from self-
administrated questionnaires at each survey. Systolic and
diastolic blood pressures were measured three times at 1-
min intervals with an automatic device (Dinamap Vital
Signs Monitor, 1846; Critikon, Tampa, FL, USA), with
the participant in a sitting position after 2 min of rest,
and defined as the mean of the last two readings. Non-
fasting blood samples were collected from an antecubital
vein; serum was prepared by centrifugation with
3000 9 g in 10 min after 1 hour in open air at room tem-
perature, and analyzed at the Department of Clinical
Chemistry, University Hospital of North Norway (UNN),
Tromsø, Norway. Serum total cholesterol was analyzed
by use of an enzymatic colorimetric method with a com-
mercially available kit (CHOD-PAP; Boehringer-Man-
nheim, Mannheim, Germany). Serum HDL cholesterol
was measured after the precipitation of lower-density
lipoproteins with heparin and manganese chloride. Height
and weight were measured with participants wearing light
clothes and no shoes. BMI was calculated as weight in
kilograms divided by the square of height in meters
(kg m2). Obesity (BMI of ≥ 30 kg m2) was classified
according to the World Health Organization (WHO) defi-
nition [17]. Hypertension was classified as a mean systolic
blood pressure of ≥ 140 mmHg, a mean diastolic blood
Tromsø 4
n = 26 169
Tromsø 5
Total n = 7749
Remeasured n = 6904
New n = 845
Tromsø 6
Total n = 12 726
Remeasured from Tromsø 4
and Tromsø 5 n = 10 234
New n = 2492






n = 29 506
Fig. 1. Inclusion of study participants from the fourth (1994–1995), fifth (2001–2002) and sixth (2007–2008) surveys of the Tromso Study.
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pressure of ≥ 90 mmHg, or self-reported use of blood
pressure-lowering drugs. Hypercholesterolemia was classi-
fied as a total serum cholesterol level of ≥ 6.5 mmol L1
or self-reported use of lipid-lowering drugs. Information
on family history of MI, diabetes mellitus, physical activ-
ity and education level was collected from a self-adminis-
tered questionnaire.
Assessment of MI
Adjudication of hospitalized and out-of-hospital MI events
was performed by an independent endpoint committee, and
based on data from hospital and out-of-hospital medical
records, autopsy records, and death certificates. The
national 11-digit identification number allowed linkage to
national and local diagnosis registries. Cases of incident MI
were identified by linkage to the hospital discharge diagno-
sis registry at the UNN, by searching for ICD-9 codes
410-414 and 430-438 in the time period 1994–1998, and
thereafter ICD-10 codes I20-I25 and I60-I69. The hospital
medical records were retrieved for case validation. Modi-
fied WHO MONICA/MORGAM criteria for MI [18] were
used, and included clinical symptoms and signs, findings in
electrocardiograms, values of cardiac biomarkers, and
autopsy reports when applicable. Furthermore, linkage to
the National Causes of Death Registry at Statistics Norway
allowed the identification of fatal incident MI cases that
occurred as out-of-hospital deaths, including deaths that
occurred outside of Tromsø. The death certificates were
used to collect relevant information on the MI events from
additional sources, such as autopsy reports and records
from nursing homes, ambulance services, and general
practitioners.
Registry of VTE
All incident VTE events during follow-up were identified
by searching the hospital discharge diagnosis registry,
the autopsy registry and the radiology procedure registry
at the UNN, as previously described [19]. The UNN is
the only hospital in the region, and all diagnostic radiol-
ogy and hospital care is provided exclusively by this
hospital. The medical record for each potential VTE
case was reviewed by trained personnel, and a VTE
event was considered to be verified and recorded when
the presence of clinical signs and symptoms of DVT or
PE were combined with objective confirmatory tests
(i.e. compression ultrasonography, venography, spiral
computed tomography, perfusion–ventilation scan, pul-
monary angiography, or autopsy), and resulted in a
VTE diagnosis that required treatment, as previously
described in detail [19]. VTE cases from the autopsy reg-
istry were recorded when the death certificate indicated
VTE as the cause of death or as a significant condition
associated with death. The VTE events were classified as
provoked or unprovoked according to the presence of
provoking factors at the time of diagnosis. Provoking
factors included recent surgery or trauma within the
previous 8 weeks, acute medical conditions (i.e. acute
MI, ischemic stroke, or major infectious diseases), active
cancer, immobilization (i.e. bed rest for > 3 days, wheel-
chair use, or long-distance travel exceeding 4 h within
the 14 days prior to the event), or any other factor
described by a physician in the medical record
(e.g. intravascular catheter).
Statistical analysis
Participants who developed MI during the study period
contributed with non-exposed person-time from the inclu-
sion date to the date of a diagnosis of MI, and then with
exposed person-time from the date of MI onwards. For
each participant, non-exposed and exposed person-years
were counted from the date of enrollment to the date of
an incident diagnosis of VTE or to the date on which the
participant died or moved from Tromsø, or until the end
of the study period, i.e. 31 December 2010, whichever
came first. Participants who died or moved from the
municipality during follow-up were censored at the date
of death or migration.
Statistical analyses were performed with STATA ver-
sion 14.0 (Stata Corporation, College Station, TX, USA).
Crude incidence rates (IRs) of VTE were calculated, and
expressed as number of events per 1000 person-years at
risk. Cox proportional hazards regression models were
used to calculate hazard ratios (HRs) with 95% confi-
dence intervals (CIs) of VTE, DVT and PE after MI. Age
was used as the time scale in the Cox model, with the age
of the participants at study enrollment being defined as
entry time, and the age at the time of the VTE event or
censoring event (i.e. death, migration, or the date of study
end) being defined as exit time. MI was included as a
time-dependent covariate in the Cox model. Therefore,
participants who developed MI during follow-up con-
tributed with person-years in both the unexposed and
exposed group. For those who participated in several sur-
veys, information on possible potential confounders was
updated at each survey. We estimated HRs with three dif-
ferent models. The first model was adjusted for age (as
time scale) and sex, and the second model was addition-
ally adjusted for BMI. The third model was adjusted for
age (as time scale), sex, BMI, diabetes mellitus, smoking,
systolic blood pressure, HDL cholesterol, physical activ-
ity, and education.
The proportional hazards assumption was tested by the
use of Schoenfeld residuals, and found to be not violated.
Statistical interactions between MI and sex were tested by
including cross-product terms in the proportional hazards
models, and no interactions were found.
Attributable risk (AR), i.e. the proportion of events among
the exposed participants that could be explained by the expo-
sure, was calculated from IRs of VTE in the MI (Ie) and non-
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MI (Io) populations, and expressed as a percentage
(AR = 100 9 [Ie – Io]/Ie). Population AR (PAR), i.e. the
proportion of events in the population that could be attribu-
ted to the exposure, was calculated on the basis of IRs of VTE
in the total population (Ip) and in the non-exposed population
(Io), and expressed as a percentage (PAR = 100 9 [Ip – Io]/
Ip). GRAPHPAD PRISM version 6.0 (GraphPad Software, San
Diego, CA, USA) was used to generate a figure showing the
change in VTE risk over time (Fig. 2).
Results
There were 1892 (6.4%) participants who developed a first-
time MI, and 699 (2.4%) participants who developed a
first-time VTE, during a median of 15.7 years of follow-up.
The baseline characteristics of the study participants with
and without MI are shown in Table 1. Participants with
MI had a higher mean age and a higher BMI, and included
a higher proportion of men, smokers and participants with
hypertension than those without MI (Table 1).
The characteristics of the VTE events are shown in
Table 2. Among the 699 VTE events, 405 (57.9%) were
DVTs and 294 (42.1%) were PEs. Moreover, 358 events
(51.2%) were classified as provoked, and 341 events
(48.8%) were classified as unprovoked. The most frequent
provoking factors were active cancer, immobilization, and
surgery (Table 2). The proportion of PEs was higher
among the VTE events that occurred after an MI (53%
versus 41%) than among the VTE events that appeared
in the absence of a previous MI. Furthermore, surgery
was a more frequent provoking factor for VTE in partici-
pants with prior MI (27%) than in those without MI
(15%) (data not shown).
IRs and HRs of VTE and subtypes of VTE according
to MI are shown in Table 3. In participants without




















































Fig. 2. Changes in crude incidence rates per 1000 person-years for
venous thromboembolism (VTE) and pulmonary embolism (PE) in
the periods 0–6 months, 6–12 months, 1–3 years, 3–5 years and more
than 5 years after myocardial infarction (MI).
Table 1 Baseline characteristics of participants without and with






Age (years), mean  SD 45  14 62  13
Sex (male), % (n) 45.9 (12675) 61.0 (1154)
BMI (kg m2), mean  SD 25.2  3.9 26.6  4.1
Total cholesterol (mmol L1),
mean  SD
5.90  1.27 6.92  1.28
HDL (mmol L1), mean  SD 1.50  0.41 1.41  0.40
Triglycerides (mmol L1),
mean  SD
1.51  1.02 1.95  1.18
Systolic blood pressure (mmHg),
mean  SD
132  19 152  24
Diastolic blood pressure (mmHg),
mean  SD
77  12 87  14
Hypertension*, % (n) 31.5 (8700) 70.7 (1337)
Hypercholesterolemia†, % (n) 30.5 (8429) 63.0 (1192)
Smoking‡, % (n) 35.6 (9803) 41.2 (780)
Physical activity§, % (n) 33.4 (9210) 20.0 (380)
Education¶, % (n) 34.1 (9406) 12.2 (231)
Self-reported diabetes mellitus, %
(n)
1.5 (401) 6.3 (120)
BMI, body mass index; SD, standard deviation. *Mean systolic/dias-
tolic blood pressure of ≥ 140/≥ 90 mmHg, use of antihypertensives,
or self-reported hypertension. †Total cholesterol level of
≥ 6.5 mmol L1, use of lipid-lowering drugs, or self-reported hyper-
cholesterolemia. ‡Self-reported daily smoking; yes/no. §One or more
hours of moderate or hard physical activity per week; yes/no. ¶More
than 10 years of education.
Table 2 Characteristics of venous thromboembolism events
(n = 699); the Tromsø Study 1994–2010
% (n)
Clinical characteristics
Deep vein thrombosis 57.9 (405)













*Only women were included in the analysis. †Current or previous
use of hormone replacement therapy or oral contraceptives.
‡Myocardial infarction in a first-degree relative before age 60 years.
§Bed rest for > 3 days, journeys of > 4 h by car, boat, train or air
within the last 14 days, or other types of immobilization. ¶Other
provoking factor described by a physician in the medical record (e.g.
intravascular catheter).
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person-years of follow-up (IR of 1.8 per 1000 person-
years), whereas there were 47 VTE events during
7062 person-years of follow-up in participants exposed
to MI (IR of 6.7 per 1000 person-years). Overall, partic-
ipants with a previous MI had a 51% (HR 1.51;
95% CI 1.09–2.11) higher VTE risk than participants
without a previous MI in a multivariable model adjusted
for traditional atherosclerotic risk factors, including sex,
BMI, systolic blood pressure, diabetes mellitus, HDL
cholesterol, smoking, physical activity, and education
level (Table 3). In a subgroup of participants with avail-
able data on family history of MI (n = 21 096), the
addition of a family history of MI to the multivariable
model did not change the risk estimates for the associa-
tion between MI and VTE (Table S1). In separate analy-
ses of PE and DVT after MI, PE showed higher risk
estimates than DVT. The multivariable HRs were 1.72
(95% CI 1.07–2.79) for PE and 1.36 (95% CI 0.86–2.15)
for DVT (Table 3).
In analyses stratified by the presence of provoking fac-
tors, MI was associated with increased risks of provoked
VTE (multivariable adjusted HR 1.83; 95% CI 1.21–2.79)
and provoked PE (multivariable adjusted HR 2.29;
95% CI 1.20–4.37), but not with provoked DVT or any
unprovoked events (Table 4). Among MI patients, 72.4%
of the VTEs could be attributed to the MI (AR), and
4.7% of the VTE events in the entire study population
could be attributed to the MI (PAR). For PE, the num-
bers attributable to MI were higher; the AR was 78.5%,
and the PAR was 6.2%.
IRs and HRs of VTE were high immediately after the
MI, and declined rapidly thereafter (Table 5; Fig. 2). The
IR of VTE was 18 per 1000 person-years, and the HR of
VTE was five-fold higher in participants with MI than in
Table 3 Incidence rates (IRs) and hazard ratios (HRs) of venous thromboembolism (VTE), deep vein thrombosis (DVT) and pulmonary embo-
lism (PE) according to myocardial infarction (MI) exposure; the Tromsø Study 1994–2010
Person-years VTE events Crude IR (95% CI)* Model 1†, HR (95% CI) Model 2‡, HR (95% CI) Model 3§, HR (95% CI)
Total VTE
No MI 354 865 652 1.8 (1.7–2.0) Reference Reference Reference
MI 7062 47 6.7 (5.0–8.9) 1.49 (1.10–2.01) 1.41 (1.04–1.92) 1.51 (1.09–2.11)
DVT
No MI 354 865 383 1.1 (1.0–1.2) Reference Reference Reference
MI 7062 22 3.1 (2.1–4.7) 1.25 (0.81–1.93) 1.17 (0.75–1.83) 1.36 (0.86–2.15)
PE
No MI 354 865 269 0.8 (0.7–0.9) Reference Reference Reference
MI 7062 25 3.5 (2.4–5.2) 1.80 (1.18–2.73) 1.71 (1.12–2.60) 1.72 (1.07–2.79)
CI, confidence interval. *Per 1000 person-years. †Model 1: age as time scale, adjusted for sex. ‡Model 2: model 1 + body mass index.
§Model 3: model 2 + systolic blood pressure, diabetes mellitus, HDL cholesterol, smoking, physical activity, and education level.
Table 4 Incidence rates (IRs) and hazard ratios (HRs) for venous thromboembolism (VTE), deep vein thrombosis (DVT) and pulmonary
embolism (PE) according to myocardial infarction (MI) exposure by the presence of predisposing factors; the Tromsø Study 1994–2010
Person-years VTE events Crude IR (95% CI)* Model 1†, HR (95% CI) Model 2‡, HR (95% CI) Model 3§, HR (95% CI)
Provoked VTE
No MI 354 865 331 0.9 (0.8–1.0) Reference Reference Reference
MI 7062 27 3.8 (2.6–5.6) 1.65 (1.11–2.46) 1.63 (1.09–2.42) 1.83 (1.21–2.79)
Unprovoked VTE
No MI 354 865 321 0.9 (0.8–1.0) Reference Reference Reference
MI 7062 20 2.8 (1.8–4.4) 1.32 (0.83–2.09) 1.19 (0.75–1.91) 1.16 (0.67–2.00)
Provoked DVT
No MI 354 865 216 0.6 (0.5–0.7) Reference Reference Reference
MI 7062 15 2.1 (1.3–3.5) 1.44 (0.85–2.47) 1.45 (0.85–2.48) 1.59 (0.91–2.76)
Unprovoked DVT
No MI 354 865 167 0.5 (0.4–0.5) Reference Reference Reference
MI 7062 7 1.0 (0.5–2.1) 0.96 (0.44–2.07) 0.79 (0.35–1.80) 1.02 (0.45–2.34)
Provoked PE
No MI 354 865 115 0.3 (0.3–0.4) Reference Reference Reference
MI 7062 12 1.7 (1.0–3.0) 2.00 (1.09–3.67) 1.91 (1.04–3.50) 2.29 (1.20–4.37)
Unprovoked PE
No MI 354 865 154 0.4 (0.4–0.5) Reference Reference Reference
MI 7062 13 1.8 (1.1–3.2) 1.65 (0.92–2.94) 1.56 (0.88–2.79) 1.29 (0.62–2.67)
CI, confidence interval. *Per 1000 person-years. †Model 1: age as time scale, adjusted for sex. ‡Model 2: model 1 + body mass index.
§Model 3: model 2 + systolic blood pressure, diabetes mellitus, HDL cholesterol, smoking, physical activity, and education level.
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those without MI during the first 6 months after the inci-
dent MI diagnosis (adjusted HR 4.86; 95% CI 2.57–9.05).
Following the initial 6 months after the MI, the VTE risk
was not significantly increased (Table 5). Separate analysis
of PE showed a similar, although augmented, risk pattern.
The multivariable HR for PE during the first 6 months
after MI was 8.49 (95% CI 4.00–18.17). The PE risk
remained almost four-fold higher from 6 months to 1 year
after the MI than the risk in those without MI (adjusted
HR 3.78; 95% CI 1.20–11.89), but the association disap-
peared when the observation period was extended beyond
1 year (Table 5).
Discussion
In our population-based cohort, participants with MI had
a higher risk of subsequent VTE, and PE in particular,
than participants without MI in analyses adjusted for tra-
ditional atherosclerotic risk factors. The risk estimates for
PE were highest during the first 6 months after the MI,
and declined rapidly thereafter. We found that 78.5% of
the PE events among MI patients could be attributed to
the MI, whereas 6.2% of the PEs in the population could
be attributed to MI.
Previous studies have indicated an association between
MI and an increased risk of future VTE. In a meta-analysis
of placebo-controlled trials evaluating the effect of
antithrombotic drugs, 4% of patients with MI had a
symptomatic PE during the first 2 weeks after the MI
event [20]. A relationship between MI and PE was further
supported by a cross-sectional study, in which an associa-
tion between coronary heart disease and PE was found in
patients aged ≥ 60 years [21]. In agreement with our find-
ings, Sørensen et al. found that the risk of VTE, and of
PE in particular, was higher in the first months immedi-
ately after an MI than the VTE risk in population-based
controls in two registry-based case–control studies [13,14].
The explanations for the observed association between
MI and the future VTE risk are not yet known. Potential
mechanisms include shared risk factors, indirect factors,
or a direct causal relationship [5]. If the association
between MI and VTE is attributable to shared cardiovas-
cular risk factors, the cardiovascular risk factors work as
confounding factors by increasing the risks of both MI
and VTE. In agreement with this, cohort studies conduct-
ing cause-specific analyses have revealed age, obesity and
a family history of MI as shared risk factors for MI and
VTE [6–9]. Conversely, our findings argue against a
strong impact of shared risk factors on the association
between MI and the future VTE risk. First, shared risk
factors would mediate a permanent and not a transient
VTE risk, as observed in our study. Second, adjustments
for atherosclerotic risk factors, such as obesity and a fam-
ily history of MI, would substantially attenuate the asso-
ciation between MI and subsequent VTE if the risk
factors were actual confounders. In our study, adjust-
ments for atherosclerotic risk factors had a marginal
impact on the risk estimates for the association between
Table 5 Incidence rates (IRs) and hazard ratios (HRs) for venous thromboembolism (VTE), deep vein thrombosis (DVT) and pulmonary
embolism (PE) according to time after myocardial infarction (MI); the Tromsø Study 1994–2010








No MI 354 865 652 1.8 (1.7–2.0) Reference Reference Reference
< 6 months 601 11 18.3 (10.1–33.0) 4.38 (2.41–7.98) 4.26 (2.34–7.75) 4.82 (2.57–9.05)
0.5–1 year 556 4 7.2 (2.7–19.2) 1.72 (0.64–4.61) 1.68 (0.63–4.49) 2.10 (0.78–5.62)
1–3 years 1880 9 4.8 (2.5–9.2) 1.14 (0.59–2.20) 1.10 (0.57–2.13) 1.20 (0.60–2.42)
3–5 years 1428 9 6.3 (3.3–12.1) 1.45 (0.75–2.81) 1.40 (0.72–2.71) 1.56 (0.77–3.14)
>5 years 2598 14 5.4 (3.2–9.1) 1.11 (0.65–1.89) 1.00 (0.58–1.74) 0.90 (0.46–1.74)
DVT
No MI 354 865 383 1.1 (1.0–1.2) Reference Reference Reference
< 6 months 601 3 5.0 (1.6–15.5) 2.08 (0.67–6.52) 2.05 (0.66–6.42) 2.41 (0.77–7.54)
0.5–1 year 556 1 1.8 (0.3–12.8) 0.76 (0.11–5.43) 0.75 (0.11–5.37) 0.89 (0.13–6.38)
1–3 years 1880 4 2.1 (0.8–5.7) 0.89 (0.33–2.39) 0.88 (0.33–2.36) 1.03 (0.38–2.77)
3–5 years 1428 7 4.9 (2.3–10.3) 2.04 (0.96–4.32) 1.99 (0.94–4.23) 1.14 (1.14–5.15)
> 5 years 2598 7 2.7 (1.3–5.7) 1.00 (0.47–2.13) 0.85 (0.38–1.90) 0.89 (0.37–2.16)
PE
No MI 354 865 269 0.8 (0.7–0.9) Reference Reference Reference
< 6 months 601 8 13.3 (6.7–26.6) 7.46 (3.67–15.17) 7.13 (3.51–14.48) 8.49 (4.00–18.17)
0.5–1 year 556 3 5.4 (1.7–16.7) 2.98 (0.95–9.32) 2.83 (0.90–8.85) 3.78 (1.20–11.89)
1–3 years 1880 5 2.7 (1.1–6.4) 1.46 (0.60–3.54) 1.38 (0.57–3.35) 1.45 (0.53–3.91)
3–5 years 1428 2 1.4 (0.4–5.6) 0.72 (0.18–2.92) 0.68 (0.17–2.76) 0.44 (0.06–3.18)
> 5 years 2598 7 2.7 (1.3–5.7) 1.24 (0.58–2.64) 1.18 (0.56–2.52) 0.90 (0.33–2.45)
CI, confidence interval. *Per 1000 person-years. †Model 1: age as time scale, adjusted for sex. ‡Model 2: model 1 + body mass index.
§Model 3: model 2 + systolic blood pressure, diabetes mellitus, HDL cholesterol, smoking, physical activity, and education level.
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MI and VTE. However, our findings do not exclude the
possibility of joint effects between shared inherited pro-
thrombotic risk factors that would augment the VTE risk
under circumstances of high thrombosis risk related to
the MI itself (e.g. hospitalizations accompanied by peri-
ods of immobilization, a transient prothrombotic
response secondary to sudden tissue damage, and venous
stasis following heart failure) [22,23]. Furthermore, sev-
eral other risk factors for VTE, including high levels of
coagulation factors VIII, IX, and XI, plasminogen activa-
tor inhibitor-1, and von Willebrand factor, have also been
shown to be risk factors for arterial cardiovascular dis-
ease [24,25]; the levels of these increase immediately after
MI, and may therefore mediate the transient VTE risk
after MI observed in our study.
The transient increase in the VTE risk after MI points
towards causal mechanisms related to the MI itself.
Patients with MI are hospitalized and temporarily immo-
bilized, both of which are strong predisposing factors for
VTE [26]. Previous studies have suggested that hospital-
ization after MI partly explains the observed association
between MI and subsequent VTE [13,27]. This suggestion
was supported by the short-term nature of the risk [13]
and the attenuation of risk estimates after adjustment for
hospitalization for surgery or acute medical illness, as well
as nursing home confinement [27]. Accordingly, we
observed a transient short-term VTE risk after MI, and
stratified analyses revealed higher risk estimates for pro-
voked than for unprovoked events. In agreement with
previous observations [13,14,27], our findings support the
notion that indirect causal factors, such as hospitalization
and subsequent immobilization, as well as coronary artery
bypass surgery or endovascular procedures after MI, may
contribute substantially to the observed association
between MI and VTE.
A direct causal relationship between MI and VTE may
also contribute to the VTE risk in MI patients. Local dis-
turbances in the cardiopulmonary circulation after MI
may predispose to thrombus formation by stasis in the pul-
monary circulation, owing to backward failure secondary
to left ventricular dysfunction [28,29], by injury to the vas-
cular endothelium [30], or by activation of the coagulation
system during the acute phase of MI [31]. Atrial fibrillation
is a frequent complication after MI [32]. Recently, we
reported that atrial fibrillation was associated with an
increased risk of VTE, and of PE in particular [33].
According to the transient nature of the VTE risk and the
particularly high PE risk observed in our study, it is likely
that direct causal mechanism(s) secondary to local distur-
bances in the cardiopulmonary circulation or electrome-
chanical activity (e.g. atrial fibrillation) may be responsible
for some of the VTE risk after MI. Previous studies have
shown that DVT can be identified in only 50% of patients
with PE [34], which supports the concept that pulmonary
thrombi may form de novo in the lungs or originate from
other sources of emboli. Alternatively, the high PE rather
than DVT risk after MI may be explained by detection
bias, as patients with previous MI are more likely to
undergo examinations for chest pain.
Our findings may have some clinical implications. In
our population-based cohort, 6.2% of PE events could be
attributed to MI exposure, and 78% of the VTE events
among the MI patients were attributable to the MI itself.
These numbers may actually be underestimates, owing to
the concomitant use of drugs (aspirin, heparins, and sta-
tins) in MI, which is known to reduce the VTE risk. The
high amount of PE explained by exposure to MI may
suggest that anticoagulant treatment of MI patients
would prevent several subsequent PE events. Randomized
clinical trials have shown that prolonged oral anticoagu-
lant treatment with vitamin K antagonists (VKAs) is
equal to (Waris II trial) [35] or superior to (ASPECT II
trial) [36] antiplatelet treatment for recurrent MI. Unfor-
tunately, none of these studies has reported VTE as a
secondary endpoint. Furthermore, VKAs and non-
vitamin K oral anticoagulants (NOACs) have been shown
to reduce the incidence of recurrent VTE by ~ 90%.
However, the impact of anticoagulant treatment together
with antiplatelet treatment for prevention of PE in MI
patients needs to be weighed against the expected bleed-
ing risk resulting from combined treatment [35,37–39].
Alternatively, the transient nature of the VTE risk after
MI suggests that MI patients may benefit more from
extended thromboprophylaxis with low molecular weight
heparins or NOACs, with an expected efficacy of 50–70%
prevention of VTEs over the first 3–6 months [40,41].
Major strengths of our study include the prospective
design, the large number of participants recruited from a
general population, the long-term follow-up, the wide age
distribution, the updated confounder information, and
the validated VTE and MI events. As many cardiovascu-
lar risk factors are modifiable, some participants’ individ-
ual risk profiles may change during follow-up, leading to
regression dilution bias and an underestimation of the
associations. However, an advantage of our study is the
repeated measurements of participant characteristics dur-
ing follow-up. Because of this, we can explore the real
effect of cardiovascular risk factors on the outcomes dur-
ing follow-up to a greater extent, resulting in more reli-
able risk estimates than in a traditional cohort study.
However, our study has some potential limitations. In a
cohort study, non-response bias is a possible limitation.
Those who participate in cohort studies tend to be health-
ier and more interested in their health than the general
population. Our estimated incidence may therefore be
lower than the true incidence. Furthermore, the low num-
bers of both exposure and outcome events in the present
cohort may lead to low statistical power for assessing the
potential impact of MI on the VTE risk, particularly in
subgroup analyses.
In conclusion, the present cohort study implies that
first-lifetime MI is associated with an increased risk of
© 2016 International Society on Thrombosis and Haemostasis
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VTE, and particularly of PE. The transient nature of the
VTE risk after MI suggests that direct or indirect causal
mechanisms related to the MI event itself are primarily
responsible for the observed association. We found that
6.2% of the VTE events in the population could be
attributed to MI.
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Supplemental Tables 
 
Supplementary Table I for Online Data Supplement. Incidence Rates and Hazard Ratios for VTE, DVT and PE after AMI including only 
subject with data on family history (n=21 096) 
 Person-years VTE-
events 
Crude IR (95% 
CI)* 
HR (95% CI)† HR (95% CI)†!‡ HR (95% CI)†!‡ 
Total VTE        
   No AMI 279152 472 1.7 (1.5-1.9) Reference Reference Reference 
   AMI 5381 30 5.6 (3.9-8.0) 1.24 (0.85-1.81) 1.26 (0.83-1.92) 1.25 (0.82-1.90) 
DVT       
   No AMI 279152 277 1.0 (0.9-1.1) Reference Reference Reference 
   AMI 5381 12 2.2 (1.3-3.9) 0.90 (0.50-1.62) 1.01 (0.55-1.86) 0.99 (0.54-1.83) 
PE       
   No AMI 279152 195 0.7 (0.6-0.8) Reference Reference Reference 
   AMI 5381 18 3.5 (2.1-5.3) 1.66 (1.02-2.72) 1.60 (0.90-2.86) 1.59 (0.89-2.84) 
AMI indicates acute myocardial infarction; CI, confidence interval; DVT, deep vein thrombosis; HR, hazard ratio; IR, incidence rate; PE, 
pulmonary embolism; and VTE, venous thromboembolism. 
*Per 1000 persons-years 
†Adjusted for age (as time scale) and sex-adjusted 
!Adjusted for body mass index 
‡Adjusted for systolic blood pressure, diabetes mellitus, HDL, smoking, physical activity, education level, and family history of myocardial 
infarction. 
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